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SUMMARY  
Complement lectins are pathogen recognition receptors (PRRs) that bind to pathogen 
associated molecular patterns (PAMPs) of various microbes. The circulating serum 
levels and functional genetic variants of four such innate immune recognition elements, 
namely the human mannose-binding lectin (MBL), ficolin-2 (FCN2), collectin 11 (CL-K1), 
mannose-binding associated serine protease-2 (MASP2) were studied in intracellular 
(visceral leishmaniasis) and extracellular (urinary schistosomiasis) parasitic diseases. In 
extracellular Schistosoma haematobium infection, MBL, MASP2, and collectin-11 (CL-
K1) and their functional variants were associated with relative protection. In intra-cellular 
Leishmania donovani infection, MBL, ficolin-2 and their functional variants were 
observed to be a susceptible host factor. IL-6 was observed to regulate the lectin 
expression during distinct parasitic infections. In conclusion, this dissertation provides 
probable evidence on the differential role of lectins in intra and extracellular infections.  
ZUSAMMENFASSUNG  
Komplement-Lektine sind sogenannte “pathogen recognition receptors” (PRRs), welche 
Pathogen-assoziierte molekulare Muster (“pathogen associated molecular patterns”, 
PAMPs) diverser Krankheitserreger erkennen. Ich untersuchte zirkulierenden 
Serumlevel und funktionelle genetische Varianten von vier solcher PRRs in einer 
intrazellulären (viszerale Leishmaniose) und einer extrazellulären (urogenitale 
Schistosomiase) Krankheit: Mannose-bindendes Lektin (MBL), Ficolin 2 (FCN2), 
Collektin 11 (CL-K1), und MBL assoziierte Serinprotease 2 (MASP2). In der 
extrazellulären Schistosoma haematobium Infektion waren MBL, MASP2, und Collektin 
11, sowie deren funktionelle Varianten mit einem relativen Schutz gegen die Krankheit 
assoziiert. In der intrazellulären Leishmania donovani Infektion waren MBL, Ficolin 2, 
und deren funktionelle Varianten Suszeptibilitätsfaktoren. Während distinkter 
parasitischer Infektionen regulierte IL-6 die Lektinexpression. Zusammenfassend 
erbringt diese Dissertation diverse Beweise für die differentielle Rolle von Lektinen in 
intra- und extrazellulären parasitischen Infektionen. 
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GENERAL INTRODUCTION 
1. Human Immune System and Infection  
A host can evolve two types of defense mechanisms to ensure its survival when 
challenged by a pathogen: resistance and tolerance [1]. The human immune system 
resists the invading pathogens. The immune system is broadly divided into innate and 
adaptive immunity, but, both are interconnected and aid in elimination of pathogens [2]. 
The adaptive immune system consists of T and B lymphocytes, which functions as 
antigen-specific recognition to identify and eliminate the pathogen and ensures a long-
lived immunological memory against reinfections [3].  
1.1 Innate Immunity  
Innate immunity is a first line of the host’s defense against infections. It provides robust, 
immediate and non-specific immune responses to invading pathogens. Innate immunity 
is further divided into evolutionarily primitive humoral and cellular components. [4]. 
Innate immune system consists of anatomical barriers, complement system and natural 
killer cells, phagocytes, pattern recognition receptors (PRRs), toll-like receptors (TLRs) 
that play a vital role in the protection of the host from pathogenic challenges [5]. 
1.2 Complement System  
The complement system was first identified as a heat-sensitive factor in fresh serum for 
its ability to ‘complement’ the antibacterial properties of antibody [6]. The complement 
system can be activated through three major pathways: classical, lectin, and alternative. 
The complement system consists of 30-40 plasma and cell membrane proteins and 
functions between the innate and adaptive immune systems. It plays a vital role in host 
defenses against infections. Activation of the complement leads to robust and efficient 
proteolytic cascades to eliminate pathogens by inducing chemotaxis (attraction of 
leukocytes), opsonophagocytosis, and direct destruction of the microorganisms by 
enabling membrane attack complexes (MAC) in the cell wall [7].  
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2. Lectin Complement Pathway  
The lectin complement pathway plays a key role in innate immunity by recognizing 
invading pathogens [8]. The lectin pathway is initiated by the binding of mannose-
binding lectin (MBL) and other c-type lectins to sugar moieties exhibited on cell surfaces 
of several microbes and activates the esterase activity of MBL-associated serine 
proteases (MASP-1,2 and 3). Once activated, MASPs cleave and activate C4 and C2 
thus generating the C3 convertase (C4bC2a). C3 convertase binds and cleave C3, 
generating C3b and C3a. The C3a fragment has anaphylatoxic and proinflammatory 
activity where as C3b has opsonic activity. C3b is also involved in C5 convertase 
(C4b2a3b) generation and cleaves C5, C6, C7, C8, and C9 proteins, resulting in the 
assembly of membrane attack complexes (C5b-9) on the target pathogen [9]. Unlike the 
classical pathway, the activation of the lectin pathway is independent of a specific 
antibody response. The early activation of the complement system during pathogen 
invasion occurs mainly by lectin pathway with a rapid response, since it is independent 
of specific antibody response. The lectin pathway also triggers the activation of the 
alternative pathway by generating C3b, which results in synergistic activation of the 
complement system [10]. Due to its essential role in innate immunity, the lectin pathway 
has been preserved throughout animal and hominoid evolution [11]. Lectin deficiency is 
associated with susceptibility to infections [12]. 
 
 
 
 
 
Figure 1: Overview of the lectin pathway of complement activation. MBL, CL-K1 or ficolins 
interact with pathogen’s glycoproteins and initiate the complement cascade that result in 
pathogen lysis. Figure courtesy to Dr. Velavan. 
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Mannose-Binding Lectin (MBL) 
MBL was the first lectin protein described to initiate the lectin pathway. It is synthesized 
in the liver and acts as an acute-phase plasma protein (APP) during infections. MBL is 
an oligomer consisting of three polypeptide chains, each containing a collagen-like 
domain and a carbohydrate recognition domain (CRD) similar to C1q to recognize 
pathogens [13]. MBL deficiency (low serum level) affects around 30% of the human 
population and is associated with disease susceptibility [14]. MBL encoded by the MBL2 
gene on human chromosome 10q11.2-10q21 [15]. MBL2 gene polymorphisms are 
associated with circulating MBL serum level and functional activity. In specific, three 
promoter variants localized at positions − 550(H/L), − 221(X/Y) and + 4(P/Q) modulate 
the MBL transcription. In addition, three non-synonymous variants in exon-1 at codons 
52 (MBL2*D), 54 (MBL2*B) and 57 (MBL2*C) disrupt the sequence of Gly-Xaa-Yaa 
tandem repeats in collagen-like domain and results in impaired oligomerization of the 
MBL protein [16, 17]. Garred et al., reviewed that MBL deficient alleles have been found 
in different frequencies in different populations [18]. For example, in Quechua 
Amerindians from Peru, the MBL2*B allele has the frequency of 0.80 and almost 
replaced the wild type MBL2*A allele whereas MBL2*C allele is almost exclusively 
present in the African population at the frequency of 0.24 [19]. 
  Due to the same chromosomal location, the combination these promoter and 
exon-1 variants resulted in seven common ‘secretor haplotypes’. Among them the 
haplotypes MBL2*HYPA, LYPA and LYQA are associated with high expression of MBL, 
while the haplotypes MBL2*LYQC, LXPA, HYPD and LYPB are associated with low 
expression of MBL [17, 20]. Apart from these seven common secretor haplotypes, 
specific haplotypes have been found in few ethnic groups such as LYPD in Czech, 
HXPA in Morocco and LYQB in Cameroon [14]. MBL has been shown to bind to a wide 
range of microbes and activate the complement cascade [21]. The impact of MBL 
deficiency towards the susceptibility of various bacterial, viral, fungal and parasitic 
infections were described [22, 23]. Epidemiological studies have suggested that lower 
MBL serum level and MBL deficient alleles correlate with increased susceptibility to 
various infectious diseases [24].  
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Ficolins (FCN) 
Ficolins are a group of oligomeric lectins and has a similar function that of MBL. In 
humans, three types of ficolins (Ficolin-1, Ficolin-2 and Ficolin-3) exist with similar 
structures, but differential tissue expression and functional roles [25]. Ficolin-1 (M-
ficolin) is expressed in lung, spleen, monocytes and present in serum. Ficolin-2 (L-
ficolin) synthesized in the liver and is present in serum whereas Ficolin-3 (H-ficolin) is 
expressed in liver and lung [26]. The Ficolin-1, -2 and -3 proteins are encoded by the 
FCN1, FCN2 and FCN3 genes respectively. The FCN1 and FCN2 genes are located in 
a tail-to-tail orientation on chromosome 9q34 whereas FCN3 gene is located on 
chromosome 1p35. FCN consists of a collagen-like tail region and functional fibrinogen-
like domain that recognizes the acetylated compounds of invading pathogens. Ficolin-1 
and -2 bind to cellular components such as lipoteichoic acid and sialic acid that found in 
bacteria and activate complement cascade through MASP-2 [27].  
Genetic variants in ficolin coding genes and their serum abnormalities have been 
investigated against many infectious diseases and has been established as a key 
component of innate immunity [28]. Number of polymorphisms that affect the expression 
and function of ficolins were listed in their corresponding coding genes. Though several 
polymorphisms have been identified in the FCN1 and FCN3 genes, the important 
functional variants have been reported in the FCN2 gene. Three promoter variants in 
the FCN2 gene at positions −986G>A, −602G>A, and −4A>G have been associated 
with reduced ficolin-2 serum levels. Two structural variants in exon-8 at positions 
+6359C>T (Thr236Met) and +6424G>T (Ala258Ser) were observed to show differential 
binding properties to acetylated compounds [23]. Similar to MBL, ficolins activate the 
complement cascade and induce opsonophagocytosis and stimulates the 
proinflammatory cytokines. Many investigations have been reported the role of ficolins 
in various infectious and autoimmune diseases [28]. Ficolin-2 deficiency has been 
associated with recurrent infections and low birth weight in neonates [29]. Trypanosoma 
cruzi calreticulin (TcCRT), a chaperone molecule protein inhibit the lectin complement 
cascade by interacting with ficolins-2 [30] signifies the importance of this lectin. 
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Collectin Kidney-1 (CL-K1) 
CL-K1 (Collectin-11) is a recently discovered lectin pathway initiating protein and is 
ubiquitously expressed in many tissues, including the kidney, liver and adrenal glands 
[31]. Similar to MBL, CL-K1 has a collagen like domain and a Carbohydrate Recognition 
Domain (CRD) that binds to various bacteria, fungi and viruses [32]. The CL-K1 is 
encoded by COLEC11 gene and is located on human chromosome 2p25.3. Structural 
genetic variants in COLEC11 were associated with individuals affected with Carnevale, 
Mingarelli, Malpuech and Michels syndrome (also known as 3MC or Malpuech facial 
clefting syndrome), a congenital disorder characterized by facial clefting, a caudal 
appendage, growth deficiency and cognitive disabilities [33]. CL-K1 was observed to 
interact with MASP-2 in the presence of mannan and deposits C4b through complement 
activation [34]. Unlike MBL and ficolins, genetic association studies on CL-K1 with 
infectious diseases are inadequate. 
MBL-associated serine protease-2 (MASP-2)  
Upon recognition of carbohydrate structures on pathogens by lectins such as MBL, FCN 
and CL-K1, MASPs are activated to cleave the down-stream complement component 
C2 and C4 subsequently activates the lectin complement cascade [35]. MASP-2 is 
composed of six domains including a serine protease domain that exhibits the esterase 
activity. In humans MASP-1 (encoded by MASP1 gene located on chromosome 3q27-8) 
and MASP-2 (encoded by MASP2 gene located on chromosome 1p31.23-31) exist with 
similar structure and function. However, alternative splicing of the MASP1 gene 
produces MASP-3. Among these, MASP-2 is the vital serine protease in the lectin 
complement activation that majorly expressed in liver [36]. Various naturally occurring 
polymorphisms including p.D120G and p.P126L in MASP2 gene modulate the 
circulating MASP-2 levels, protease activity and binding affinity to MBL [37].  The 
MASP-2 serum levels and MASP2 deficient alleles were observed to be diverse among 
different ethnicities [38]. MASP-2 deficiency is reported among Caucasians [39]. MASP-
2 serum levels and their functional genetic variants were associated with several 
infectious diseases [40]. 
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2.1 Dual role of lectins in distinct infections  
Complement lectins deficiency per se increases the susceptibility to many 
infections. It was observed that lectins, in specific MBL play a dual role during intra and 
extra-cellular infections. MBL is a highly investigated serum lectin and considered as a 
“double-edged sword”, as low MBL serum levels and MBL deficient alleles increases the 
susceptibility towards severe or recurrent infections caused by extracellular pathogens 
[41-43]. On the other hand, low MBL serum levels and MBL deficient alleles were 
shown to associate with protection against intracellular pathogens like Mycobacterium 
spp. and Leishmania spp. [44-46]. The hypothesis is that MBL deficiency may be 
protective against intracellular pathogens, as it enhances the uptake into macrophages, 
the milieu preferred by these pathogens for their survival. However, one meta-analysis 
of MBL with tuberculosis in different ethnicities and different Mycobacterium species 
have disproved the hypothesis [47].  
Ficolins are other important lectin that analogous to MBL and expected to 
function similar to MBL against Mycobacterium spp. infection. In contrary, during 
Mycobacterium tuberculosis infection, the ficolin-2 serum levels were reduced in TB 
patients compared to healthy controls [48]. Moreover, low MBL and low M-ficolin levels 
have been found to be protective factor while low MASP2 (MBL associated serine 
protease-2) was observed to be susceptible factor against M.leprae infection [49]. 
Conflicting observations from earlier investigations resulted in unclear understanding of 
lectins in intra and extracellular pathogenic infections. Till date, no simultaneous 
investigations have been conducted to elucidate the possible role of lectins in intra and 
extracellular infections. We focused our investigations on parasitic diseases as the 
knowledge of lectins in parasitic diseases was limited and it is ambiguous whether 
lectins are of factual importance to human host during parasitic infections [50].  
3. Parasitic Diseases 
A diverse range of parasites can infect humans, from unicellular protozoan to 
multicellular metazoan organisms, such as worms. The major human parasitic diseases 
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are malaria, schistosomiasis, African trypansomiasis, leishmaniasis, Chagas’ disease, 
lymphatic filariasis and onchocerciasis [51]. Parasitic diseases are a significant threat to 
global health and causes more than a million deaths every year [52]. It is also 
associated with significant morbidity in terms of DALYs (Daily Adjusted Life Years) and 
has a large economic impact in tropical and subtropical regions of the world including 
Africa, South America and Asia [53]. Parasite diseases are directly associated with 
poverty and affects largely the poor people with low income [54].  
3.1 Complement Lectin pathway activation and Parasite Immune Evasion 
Parasites, upon successfully crossing an anatomical barrier of the host, immediately 
face the complement attack by lectins due to its rapid immune response [10]. The 
activated lectin pathway directs many immune effector functions, that ultimately result in 
destruction of invading parasites via effector molecules, such as the anaphylatoxins 
(C3a and C5a), opsonins (C3b/iC3b) and the lytic terminal complement complex (TCC) 
[55]. Many parasites including Leishmania spp., Plasmodium spp., Trypanosoma cruzi, 
Schistosoma mansoni were observed to bind to the lectin pathway initiating molecules 
such as MBL and ficolins and activates the lectin pathway [56-59]. However, parasites 
have evolved numerous immune evasion strategies to escape from complement attack. 
For example, T.cruzi expresses specific complement receptors (complement C2 
receptor inhibiting trispanning-CRIT, calreticulin, Gp58/68) that inhibit the complement 
cascade [10]. On the other hand, in Leishmania spp., enhance the complement activity 
by the conversion of active C3b into inactive C3b (iC3b) through glycoprotein 63 
(Gp63), a C3b acceptor that induce parasite phagocytosis by macrophages. In addition, 
amastigotes enhance their cellular uptake by targeting complement receptor 3 (CR3) 
[60]. Schistosoma mansoni inhibit complement attack by expressing its constitutive 
components such as schistosoma complement inhibitory protein-SCIP, C3 receptor, 
ectoproteases and CRIT. Plasmodium falciparum infection needs balance between the 
activation and regulation of the complement system to determine the severity and 
outcome of malaria. Recent findings demonstrated that C5a modulated in placental and 
cerebral malaria [61, 62].  
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4. Extra cellular parasitic infection-Schistosomiasis 
Schistosomiasis (Bilharziasis), a chronic parasitic disease caused by Schistosoma 
trematode worms. The disease is largely categorized into two forms viz. intestinal 
schistosomiasis and urogenital schistosomiasis based on the site of infection in human 
host. S. mansoni, S. japonicum, S. mekongi and S. intercalatum are the four species 
that causes intestinal schistosomiasis. Urogenital schistosomiasis is caused by S. 
haematobium [63]. Schistosomiasis is a poverty associated neglected tropical disease 
and occurs largely in parts of Africa, South America, and Asia [64]. Globally there are 
over 207 million people infected with the disease and an estimated of 779 million people 
are at risk of schistosomiasis [65]. Approximately 93% of the world’s schistosomiasis 
cases occur solely in sub-Saharan Africa [66] and is considered as the second most 
socio-economically devastating tropical parasitic disease next to malaria [67].  
4.1 Urogenital schistosomiasis 
Urogenital schistosomiasis is endemic in many parts of sub-Saharan Africa (SSA). 
Nearly two-thirds of the cases of schistosomiasis in SSA result from urinary tract 
infections caused by the multicellular trematode parasite S. haematobium [68]. Adult 
worms reside in the veins of the urinary bladder plexus of the pelvic region where they 
lay eggs daily. These eggs subsequently penetrate the vessels and move towards the 
genital tract. The encountered eggs are sequestered by the human immune system and 
cause granuloma formations in the urinary bladder, lower ureters, cervix, vagina, 
prostate gland, and seminal vesicles [69]. The clinical manifestations of schistosomiasis 
include anemia, hematuria, hydronephrosis, upper urinary tract lesions and 
granulomatous inflammation in the genital tract [70, 71]. Chronic inflammation pathology 
in the affected organs leads to pelvic pain, post-coital bleeding and ulcerations of 
genitalia in women where as ejaculatory pain, hematospermia and leukocytospermia in 
men.  
          Epidemiologically, S. haematobium and HIV prevalence geographically overlap in 
Africa due to the damaging effects of urogenital schistosomiasis in the genital tracts 
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[72]. The epithelial ulcers caused by S. haematobium infection have been suggested to 
ease viral entry and observed to be a potential risk factor for acquisition of HIV [73]. 
However, strong gender bias was observed where women are more likely to get HIV 
infection due to urogenital schistosomiasis (Female genital schistosomiasis-FGS) than 
men. The disease is also linked to horizontal transmission of HIV as the sandy patches 
of FGS increases the susceptibility and Th2 directed CD4+ cells provide the shelter for 
HIV viral entry and replication. Therefore it may represent one of Africa's most important 
cofactors for the AIDS epidemic [74]. Bladder cancer is another severe complication of 
urogenital schistosomiasis. Individuals with urogenital schistosomiasis may develop 
bladder cancer much earlier than uninfected people. The severity of the disease is 
associated with intensity of infection, worm burden and tissue egg burden, and the 
duration of infection [75]. S. haematobium is classified as a Group 1 carcinogen by the 
World Health Organization (WHO) because it deposits eggs in the urinary bladder of 
infected people that leads to bladder cancer [76, 77]. The standard diagnostic test for 
active urogenital schistosomiasis is microscopical examination of viable eggs in urine 
and praziquantel is the standard drug of treatment. The limited supply of praziquantel, 
treatment gaps and rapid reinfections increases the disease burden [78]. 
4.2 Life cycle of Schistosoma haematobium 
The life cycle of S. haematobium (Figure 2) begins once humans contact freshwater-
harbouring cercariae. The infectious cercariae penetrate the human skin by their 
glandular secretions to reach the blood vessels and migrate to heart, lung, and liver and 
finally ends in the venous plexus of the bladder. The incubation period takes about 5-7 
weeks; during the period schistosomula larvae mature into female and male adult 
worms and live as a permanently embraced couple. Adult female worms produce 300 -
3000 of eggs per day and shed them into the environment via urine. On contact with 
fresh water, the egg releases the miracidium, which searches for their intermediate snail 
host (Biomphalaria and Bulinus).  
 
13	  
	  
 
 
 
 
 
 
 
Figure 2: The life cycle of Schistosoma haematobium (source: www.cdc.gov). Freshwater snails 
serve as intermediate host. Cercariae (infective form) released by snail penetrate human skin 
and undergo structural changes and migrate to venous plexus of the bladder and further pair 
and produce eggs. 
Once inside the snail, the parasites undergo asexual replication (sporocysts) and 
produce thousands of infectious cercariae that are ready to infect a new host [78]. 
Several factors including snail populations, cercarial density and patterns of human 
contact were observed to result in a focal distribution of the infection within countries, 
regions, and villages [70]. Children in early adolescence are at higher risk as they 
constantly come into contact with cercariae-infected water during their daily activities 
[79]. Additionally, certain occupational groups (fisherman, irrigation farmers) and women 
who need to access fresh water for their daily activities also possess greater risk of 
infection [78]. 
4.3 Lectins and schistosomiasis 
Schistosomes surface is covered by fucosylated tegument that consist of various 
glycoconjugates and carbohydrate-binding proteins in all life stages [80]. The tegument 
of schistosomes has been characterized by lectin-binding studies [81, 82]. MBL 
recognized the S. mansoni adult and cercariae worms and activated the complement 
14	  
	  
system in vitro in C1q deficient serum [59]. In addition, ficolin-2 serum levels and FCN2 
gene polymorphisms were observed to confer relative protection against urogenital 
schistosomiasis [83]. These observations signify the role of the lectins in 
schistosomiasis.  
5. Intra cellular parasitic infection-Leishmaniasis 
Leishmaniasis, a vector-borne neglected tropical disease, is caused by caused by 
obligate intra-macrophage protozoa parasites from over 20 Leishmania spp. [84]. The 
disease is transmitted to human hosts by the bite of a blood sucking female 
phlebotomine sand fly. The disease is characterized by four distinct clinical 
manifestations viz. Cutaneous Leishmaniasis, Muco-cutaneous Leishmaniasis, Visceral 
Leishmaniasis (kala-azar) and Post Kala-azar Dermal Leishmaniasis (PKDL) [85]. 
Leishmaniasis has strong links with poverty and is associated with malnutrition, lack of 
resources to pay diagnosis and treatment, lack of bed nets, more prone to vector bites 
[86]. The disease is endemic in areas of the tropics, subtropics, southern Europe and 
temperate regions of some 88 countries [84]. According to World Health Organization 
(WHO) report, an estimated of 1.3 million new cases and 20 000 to 30 000 deaths occur 
annually due to leishmaniasis. An estimated of 310 million people are at risk of 
Leishmaniasis [87]. 
5.1 Visceral Leishmaniasis 
Visceral Leishmaniasis (VL) is the most severe form of leishmaniasis and 100% fatal if 
left untreated. As the name denotes, the disease affects visceral organs including 
spleen, liver and lymph nodes [88]. VL is caused by Leishmania donovani (family: 
Trypanosomatidae, Order: Kinetoplastida) in East Africa and in the Indian subcontinent, 
whereas Leishmania infantum is the causative agent in North Africa, Latin America and 
Mediterranean regions of Europe. However, L. infantum infects mostly children and 
immunosuppressed individuals, whereas L. donovani infects all age groups [85, 89]. 
The common symptoms for VL are splenomegaly, hepatomegaly, anemia and weight 
loss. However, splenomegaly is often a typical symptom for VL [90].  
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VL ranks second in mortality next to malaria among tropical diseases with an 
estimation of 50,000 deaths per annum [91] and accounts for more than 2 million 
disability adjusted life years (DALYs) lost [92]. PKDL is a chronic, dermal sequel of VL 
that occurs in some patients who are cured from VL and limited mainly to Indian sub-
continent and Africa. Though low mortality rates are reported, PKDL plays a major role 
in inter-epidemic transmission of VL due to the rich parasite density in dermal lesions 
[93]. Although VL is prevalent worldwide, the majority (≥90%) of cases occur in the 
following six countries viz. Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil [85]. 
VL is considered as a major health problem in Indian sub continent (India, Nepal and 
Bangladesh) with an estimation of 150 million people living at risk and shares 67% of 
the global disease burden. 
 In India, VL is endemic in Central-East India (Bihar, West Bengal and Eastern 
part of Uttar Pradesh) and accounts for more than 90% of all Indian VL. The Bihar state 
of India shares almost 50% of the global VL burden and is observed to be a “hot spot” of 
visceral leishmaniasis [85, 94-96]. Microscopical visualization of amastigotes in splenic 
aspirates is the standard diagnostic method for VL. However, rK39 rapid diagnostic test 
(RDT) strip can substitute invasive splenic aspirates in Indian VL. Antimonial treatments 
are the drug of choice to cure VL except in Bihar where antimony treatment was 
ineffective and replaced with Amphotericin B [97]. Changes in vector control practices 
and therapeutic modalities were responsible for increased incidence of VL and related 
mortality in India [98]. 
5.2 Life cycle of Leishmania donovani 
The life cycle of L. donovani (Figure 3) exists in two different developmental stages: the 
extracellular promastigotes in the invertebrate host (sand fly), and the intracellular 
amastigotes in the vertebrate (mammals) host. Female phlebotomine sandflies transmit 
the disease during their blood meal, by inoculating metacyclic promastigotes into the 
skin of the human host. 
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Figure 3: The life cycle of Leishmania donovani adapted from Ref. [85]. The female 
phlebotomine sandflies transmits the promastigotes into human host and parasites were 
phagocytosed by macrophages. Inside the cells they transform into amastigotes and 
replicates.  
The parasites are phagocytosed by macrophages, monocytes, and langerhans cells 
where they differentiate into amastigotes [85, 99]. Upon their internalization by 
macrophages and other cells, promastigotes inhibit phagolysosome biogenesis and 
multiply inside the cell rather than getting lysed [100]. In the host, infected macrophages 
migrate from skin to visceral organs like the spleen, the liver and give rise to pathologies 
associated with VL. During the blood meal sandflies pick up amastigotes and releases 
them into their midgut where parasites differentiate into procyclic promastigotes and 
followed by metacyclic promastigotes. Finally differentiated metacyclic forms are ready 
for the transmission to the next vertebrate host by sand-fly bite [99].  
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5.3 Lectins and Visceral Leishmaniasis 
Leishmania spp., is enveloped with mannose-containing lipophosphoglycan (LPG) and 
mannose glycoinositol-phospholipids [58]. These glycoconjugates are recognized by the 
lectins such as the mannose-binding lectin.  Earlier study reported that MBL binds to L. 
braziliensis mediated by a specific carbohydrate on the surface of parasites [101]. MBL 
was observed to enhance the susceptibility to VL [102-104]. However, these studies 
were focused on the South America and Africa with infections caused by L. chagasi and 
L. infantum with limited sample size. No investigations were reported on the role of 
lectins (MBL and ficolins) in VL caused by L. donovani that responsible for more VL 
cases. 
6. Interleukin-6 regulates acute phase response of lectins in infections  
IL-6 is an important cytokine that regulates a various immunological functions during 
distinct infections [105]. IL-6 stimulates the expression of acute phase proteins in 
hepatocytes by binding to IL-6-responsive elements in the promoter region of the 
respective genes [106]. MBL is such an acute-phase plasma protein (APP), and is 
regulated tightly by IL-6 [107]. MBL is a serum lectin that initiates the complement 
activation. Moreover, MBL deficiency is associated with a variety of diseases [14, 108-
110]. The MBL2 promoter region consists of type 1 and type 2 IL-6-responsive 
sequences [24]. Therefore, it is anticipated that IL-6 regulates the MBL in infections and 
inflammation. In a patent infection, schistosomes induce strong Th2 immune response 
through increased production of IL-6 that down-regulate Th1 immune response [111]. In 
addition, the cercariae are recognized by host macrophages that induce the secretion of 
IL-6 [112]. IL-6 was observed to be protective factor against Schistosoma-induced 
pulmonary hypertension in vivo [113].  
          Leishmania donovani is the causative agent of VL in India with the predominance 
of Th2 immune response in active infections whereas protection is associated with Th1 
immune response [114]. IL-6 levels were consistently elevated in active VL cases and 
appear to play a central role in pathogenesis of VL [108, 115, 116]. IL-6 was observed 
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to favor parasite survival in human macrophages as it down modulates the cytokine-
enhanced anti-leishmanial activity [117].  The functional role of IL-6 and MBL has been 
addressed in schistosomiasis and VL independently. However, the role of IL-6 in 
regulation of MBL expression in these diseases was not investigated. Therefore, we 
studied the role of IL-6 and its relation with MBL regulation in urinary schistosomiasis 
and visceral leishmaniasis. As ficolins and Collectin-Kidney-1 (CL-K1) share similarities 
in both their structure and function with MBL [28], we also studied the impact of IL-6 in 
the expression of these proteins in the investigated diseases. 
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OBJECTIVES 
The role of the lectins in parasite infections is controversial and is context dependent. 
The investigated studies aimed to analyze the functional role of lectins in intra and 
extracellular parasitic infections. The objectives are, 
1. In the first part of the thesis, we aim to investigate the possible genetic and 
phenotypic associations of the lectins mannose-binding lectin (MBL), collectin- 
kidney 1 (CL-K1), and the downstream cleaving enzyme MBL associated serine 
protease 2 (MASP-2) with urinary schistosomiasis in a Nigerian study group. 
2. In the second part of the thesis, we aim to study the possible genetic and 
phenotypic associations of the lectins MBL, ficolin-2 with visceral leishmaniasis in 
an Indian study group. 
3. In addition, we aim to investigate the induction of acute phase responses by IL-6 
in lectins expression during urinary schistosomiasis and visceral leishmaniasis.	  
STUDY GROUP 
Urinary schistosomiasis: To represent extracellular parasitic infection we utilized a 
Nigerian study group consisting of Schistosoma haematobium infected patients 
(schistosoma egg positive in urine, SEP; n=168) and two control groups of individuals 
who previously exposed (schistosoma ELISA positive, SELP; n=123) and never 
exposed (schistosoma ELISA negative, SELN; n=69).  
Visceral leishmaniasis: To represent intracellular parasitic infection we used an Indian 
study group consisting of Leishmania donovani infected individuals (n=218) and healthy 
subjects (n=225). 
METHODS  
All the functional genetic variants in investigated lectin encoding genes were genotyped 
by direct sequencing and corresponding serum levels were measured by ELISA. 
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RESULTS 
Manuscript 1: Mannose-binding lectin and susceptibility to schistosomiasis. 
Antony JS et al. Mannose-binding lectin and susceptibility to schistosomiasis. J Infect 
Dis 2013, 207(11):1675-1683. 
The serum MBL levels were higher in control groups (SELP+SELN) when compared to 
schistosomiasis positive (SEP) cases (P<0.0001). The serum MBL levels of the 
reconstructed MBL2*HYPA haplotype in SEP cases was observed to be lower when 
compared to SELP control group (P<0.0001) as well as with pooled controls 
(SELP+SELN) (P<0.0001). All the analyzed functional MBL2 SNPs in investigated 
groups were in Hardy-Weinberg equilibrium. Linkage disequilibrium pattern revealed 
that the 6-bp (-338 to -332) deletion in the promoter region was in linkage disequilibrium 
with the promoter variant +4C/T (P/Q) in all studied sub groups. The homozygous 
variant LL (-550CC) genotype was observed more frequent in SEP case group in 
comparison to controls (SEP vs. SELP+SELN: OR=2.1, 95%CI=1.06-4.59, P=0.03) 
inferring an increased risk to S. haematobium infection. The heterozygous genotype HL 
(-550GC) was observed less frequent in SEP case group compared to both control 
groups (SEP vs. SELP+SELN: OR =0.44, 95%CI=0.20-0.91, P=0.03) contributing 
towards a protective factor to S. haematobium infection. The minor allele -550H was 
observed more in control group (SEP vs. SELP+SELN: OR=0.5, 95%CI=0.24-0.98, 
P=0.03) suggesting a shielding factor against urinary schistosomiasis.  
In exon1, heterozygous genotype PQ (+4CT) was observed more frequent in SEP case 
group in comparison to SELN control (SEP vs. SELN: OR=2.27, 95%CI=1.2-4.31, 
P=0.02). The homozygous genotypes PP (+4CC) were observed less in the SEP cases 
group compared to SELN (OR=0.4, 95%CI=0.2-0.9, P=0.02). The heterozygous 6-bp 
deletion was observed to be more in SEP cases when compared to SELN (OR=2.15, 
95%CI=1.1-4.09, P=0.01). The reconstructed MBL2*HYPA haplotypes was associated 
with protection (SEP vs. SEP vs. SELP+SELN:  OR=0.5, 95%CI=0.25-98, P=0.03).  
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Manuscript 2: Lectin complement protein Collectin 11 (CL-K1) and susceptibility 
to urinary schistosomiasis.  
Antony JS et al. Lectin complement protein Collectin 11 (CL-K1) and susceptibility to 
urinary schistosomiasis. PLoS Negl Trop Dis 2015, 9(3):e0003647.  
The mean circulating CL-K1 serum levels among healthy Nigerian individuals were 
246±155 ng/mL. The circulating CL-K1 serum levels were differentially distributed 
between the investigated groups (SEP=175 ng/mL vs. SELN 246ng/ml, P=0.0004; SEP 
175 ng/mL vs. SELP+SELN 198 ng/mL, P=0.039). The COLEC11 non-synonymous 
variant (rs7567833-AA, p.216H) in exon8 was found to be higher in SELN healthy 
controls (OR=0.2, 95%CI=0.08-0.9,Pcorr=0.01) conferring a decreased risk for urinary 
schistosomiasis. Similar contributions were also observed in different genetic models 
[(Allelic model: OR=0.44, 95%CI=0.22-0.72, Pcorr=0.0004); (Dominant model: OR=0.42, 
95%CI=0.22-0.79, Pcorr=0.0048); (Recessive model: OR=0.2, 95%CI=0.08-0.9, 
Pcorr=0.01)]. The other variants in the promoter region were not significantly associated. 
The distribution of reconstructed COLEC11*TCCG haplotype (with all major alleles) was 
observed more frequent in SEP cases than in SELN healthy controls (OR=1.76, 
95%CI=1.15-2.70, Pcorr=0.007).  
The COLEC11*TCCA haplotype with p.R216H substitution was observed more 
frequently in SELN controls [SEP vs. SELN: OR=0.38, 95%CI=0.23-0.63, Pcorr=0.0001; 
SEP cases vs. SELP+SELN controls: OR=0.66, 95%CI=0.43-0.99, Pcorr=0.04)]. The 
minor allele of exon 8 variant rs7567833A (p.216H) was significantly associated with 
increased CL-K1 serum levels. A gene dose dependent effect on the distribution 
of serum CL-K1 levels was observed. The COLEC11*TCCA haplotype contributed to 
low serum CL-K1 levels in the SEP cases (P<0.0001). Furthermore, individuals with 
COLEC11*TCCG haplotype was observed to have lower CL-K1 serum levels when 
compared to other haplotypes in investigated control groups but not in SEP cases. 
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Manuscript 3: Correlation of Interleukin-6 levels and lectins during Schistosoma 
haematobium infection. 
Antony JS et al. Correlation of Interleukin-6 levels and lectins during Schistosoma 
haematobium infection.  Cytokine 2015. doi:10.1016/j.cyto.2015.04.019 
IL-6 serum levels among combined (SELP+SELN) controls varied from 0.2 to 18.9 
pg/ml with a median of 1.8 pg/mL. IL-6 serum levels were elevated in S. haematobium 
egg-positive (SEP) cases (mean 8.7 pg/ml) when compared to the both control 
subgroups separated or merged. (SELP: mean 4.9 pg/ml, SELN: mean 5.9 pg/ml, 
SELP+SELN: mean 5.3 pg/ml: P < 0.0001). We further correlated IL-6 serum levels with 
those of the previously reported lectins (MBL, ficolin-2, CL-K1) in both SEP cases and 
control subgroups. IL-6 serum levels were positively correlated with MBL (Spearman’s 
rho coefficient: ρ=0.189, P=0.01), ficolin-2 (ρ=0.192, P=0.01) and CL-K1 (ρ=0.292, 
P=0.0002) in cases. Notably, IL-6 was inversely correlated with MBL (ρ=-0.239, 
P=0.001) and ficolin-2 (ρ=-0.239, P=0.001) in the pooled control subgroups. CL-K1 did 
not show any significant correlation with IL-6 in controls. A similar correlation was 
observed when the control subgroups were analyzed separately.  
 To validate the association of IL-6 with lectins production, similar investigation 
was performed in visceral leishmaniasis, an intracellular parasitic disease.  IL-6 levels 
were measured in VL cases (n=58) and controls (n=30) with the similar experimental 
settings and correlated with lectins MBL and ficolin-2 levels. IL-6 levels were elevated in 
VL cases (mean 7.07 pg/mL) compared to controls (mean 3.1 pg/mL) (P = 0.003). In VL 
cases, the MBL levels were positively correlated with IL-6 (Spearman’s rho coefficient: 
ρ=0.3, P=0.01) while ficolin-2 did not show any significant correlation with IL-6. No 
correlation was observed between IL-6 and lectins in control subjects.  
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Manuscript 4: Association of Ficolin-2 serum levels and FCN2 genetic variants 
with Indian visceral leishmaniasis  
Mishra A and Antony JS et al. Association of Ficolin-2 serum levels and FCN2 genetic 
variants with Indian visceral leishmaniasis. PLoS One 2015, 10(5):e0125940.  
Ficolin-2 serum levels were elevated in VL cases (mean 2.77 µg/ml) when compared to 
healthy controls (mean 1.94µg/ml) (adjusted P<0.0001; corrected for age, sex and 
ethnicity). All investigated variants (-986G/A, -602 A>G, -4 A>G and +6359 C>T) in VL 
patients and controls were in Hardy-Weinberg equilibrium (P<0.05) except for one 
studied +6424 G>T (rs7851696) variant in VL cases and excluded for further analyses. 
Both in genotype and allele distributed with significant differences between VL cases 
and controls for the non-synonymous variant +6359C>T (p.T236M). The homozygous 
genotype +6359-TT occurred more frequently among VL cases compared to controls 
after adjusting for age, sex and ethnicity (OR=2.2, 95%CI=1.23-7.25, P=0.008), 
indicating that this variant was associated with susceptibility with VL. The similar effect 
was observed with different genetic models [Allelic: OR=1.4, 95%CI=1.02-1.94, P=0.03; 
Recessive: OR=2.2, 95%CI=1.23-7.25, P=0.008]. However, +6359 C>T was observed 
to be in strong LD with -986 G/A, and -4 A>G but not with -602 A>G. Other investigated 
FCN2 variants were not significantly associated with visceral leishmaniasis. The 
distribution of reconstructed haplotype FCN2*AAAC was found more frequently in 
healthy controls compared to VL cases (OR=0.59, 95%CI=0.37-0.94, P=0.023). 
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Manuscript 5: Low MBL-associated serine protease 2 (MASP-2) levels correlate 
with urogenital schistosomiasis in Nigerian children. 
Ojurongbe O and Antony JS et al. Low MBL-associated serine protease 2 (MASP-2) 
levels correlate with urogenital schistosomiasis in Nigerian children. Trop Med Int Health 
2015. 20(10):1311-1319.  
All investigated functional MASP-2 variants in each subgroup were in Hardy-Weinberg 
equilibrium, except for the variant rs2273346 (p.V377A) in SEP cases, which was 
excluded from further analyses. No significant contribution of genotypes or alleles was 
observed. The exon 3 variant rs72550870 (p.D120G) was monomorphic in the 
population under study. A total of twelve haplotypes were observed at a frequency >2% 
in our study population. However, the frequencies of the observed secretor haplotypes 
did not differ between subgroups (SEP cases vs. SELP, SELN controls; SEP cases vs. 
SELP+SELN controls). 
 The MASP-2 serum levels varied from 1.8 to 1073 ng/mL with a median of 106.9 
ng/mL. The serum levels were not differentially distributed among our study subgroups 
(P>0.05). The multivariate analysis, however, revealed a confounding effect of age to 
MASP-2 serum levels (P=0.0001). We, therefore, grouped our study participants 
according to age and to the rationale that younger children might be rather at risk, as 
they have frequent contact with water infested by the infectious form of schistosomae, 
the cercariae. Based on an average puberty age of 12 years in the population studied, 
the subjects were separated into the groups of ≤12 years and >12 years of age. We 
observed that MASP-2 serum levels were lower in children ≤12 years with a patent 
infection (SEP) compared to those with previous infections (SELP) (P=0.0074). MASP-2 
serum levels were higher in infected (SEP) older children and adults (>12 years) 
compared to those who were exposed previously (SELP) (P=0.032). The correlation 
analyses were performed for the MBL and ficolin-2 serum levels described previously 
for the same study group with the circulating MASP-2 serum levels assessed here. We 
noticed that only MBL serum levels were positively correlated with MASP-2 serum 
levels (r=0.39, P=0.01).  
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Manuscript 6: Mannose-Binding Lectin (MBL) as a susceptible host factor 
influencing Indian visceral leishmaniasis. 
Mishra A and Antony JS et al. Mannose-binding lectin as a susceptible factor 
influencing Indian visceral leishmaniasis. Parasitol Int 2015, 64(6):591-596.   
Mean circulating MBL serum levels among Indian healthy individuals were 109.6±143 
ng/ml. The MBL2 serum levels in the study group varied from 0.44 to 911 ng/ml with a 
median of 122.5 ng/mL. Circulating MBL serum levels were heterogeneously distributed 
between visceral leishmaniasis (VL) cases and healthy controls (median VL 
cases=155.1 ng/mL vs Controls =78.64 ng/mL, P=0.007 after adjusted for age, sex and 
ethnicity). Both genotype and allele frequencies for all of the studied MBL2 variants in 
each subgroup were in Hardy-Weinberg equilibrium except for variant rs10556764 (-338 
to -332 6bp deletion) in VL cases and subsequently excluded for further analysis. The 
promoter variants -78C/T and +4P/Q are in strong LD with each other in both VL cases 
and controls. The frequency of MBL2 minor alleles in the promoter region -78T was 
observed higher in healthy controls compared to VL cases after adjusted for age, sex 
and ethnicity (OR=0.7, 95%CI=0.5-0.96, adjusted P=0.026). In addition, the distribution 
of another promoter variant +4Q in the transcription start site was observed higher in the 
healthy controls compared to VL cases after adjusted for age, sex and ethnicity 
(OR=0.66, 95%CI=0.48-0.9, adjusted P=0.012). Both observations were consistently 
significant with the dominant genetic model.  
The MBL2*LYQA haplotype was observed more frequently in healthy controls than in 
cases (OR=0.69, 95%CI=0.5-0.97, adjusted P=0.034). Serum MBL levels were 
associated with functional MBL2 genotypes. The minor alleles rs11003123T, 
rs7095891T (+4Q) and rs4647964A contribute to significantly increased MBL serum 
levels, whereas the major alleles rs11003123C, rs7095891C (+4P) and rs4647964G 
contribute to a significantly decreased MBL serum levels in healthy controls. Serum 
MBL levels were in accordance with their respective diplotypes in VL patients 
(P<0.0001).  
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DISCUSSION 
Human resistance to pathogenic infections is mediated by humoral and cellular effector 
systems of innate immunity. The complement system is an essential component of the 
innate immunity and leads to the generation of opsonic, chemotactic, and lytic functions 
against invading pathogens. The complement proteins deficiency leads to disease 
susceptibility and to recurrent infections [118]. The success in infecting the host by 
pathogens is dependent on their capacity to resist the complement attack, either by 
inhibiting the complement cascade or by escaping its activation [119]. Complement 
system consists of more than 40 circulating serum proteins including group of pattern 
recognition molecules, cleaving proteases enzymes, complement components, 
receptors and regulators [120]. These components interact in a complex cascade of 
events including enzymatic cleavage of molecules and dramatic conformational 
changes generating biologically active molecules. Upon recognition of pathogens, the 
complement system is activated via one or more of the following three pathways namely 
classical, lectin and alternative pathway. Though the complement lectin pathway 
uncovered later, it is shown to be crucial in recognition and clearance of parasites 
compared to classical and alternative complement pathways [10].  
Though the lectin deficiency associated with increased susceptibility to several 
infections [41-43], it is also reported to be a protective factor in intracellular infections 
[44-46]. However, conflicting observations were reported among functionally similar 
lectins in intracellular infections and warranted further investigations [48]. The impact of 
lectin deficiency on parasitic infections is limited. Therefore, in this thesis, we studied 
the interactions host lectins in intra and extra cellular parasitic infections.  
1. Lectins in extracellular S. haematobium infection 
Schistosomiasis is a multifactorial disease which depends on environmental, behavioral, 
parasitic, vector and host factors [121]. Furthermore, individuals from certain families 
possess the highest infection levels and are more susceptible to severe reinfections 
suggesting that host genetic factors may play a possible role in resistance to 
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Schistosoma infections [122, 123]. Human genome scans in 11 Brazilian families have 
identified an SM1 locus responsible for controlling S. mansoni infection intensity on 
chromosome 5q31–q33 [124] and subsequently were reconfirmed in the Senegalese 
population [125]. Many immune response genes, including several Th2 specific 
cytokines (interleukin (IL)- 3, IL-4, IL-5, IL-9, IL-13), interferon regulatory factor 1, 
colony-stimulating factor 1 (CSF-1), CSF-2 and the IL-12/IL-23 p40 subunit were 
mapped in this region and observed to be a major genetic susceptible loci for 
schistosomiasis [126]. In light of these earlier observations, it is evident that the host 
genetic make up is a crucial factor to resist schistosoma infections.  
 Earlier observations documented that lectins recognize the Schistosoma 
tegument surface and initiate complement mediated innate immune response [59]. 
Therefore, in the current study we evaluated lectins serum levels and respective 
functional variants against urinary schistosomiasis in a Nigerian study group. A previous 
study on ficolin-2 using the same study group revealed that FCN2 gene polymorphisms 
and ficolin-2 levels influence the S.haematobium infection [83]. In the present study we 
extended our investigations to other important lectins such as Mannose-binding Lectin 
(MBL), Collectin-kidney 1 (CL-K1) and MBL Associated Serine Protease 2 (MASP-2) in 
order to study their functional role in urinary schistosomiasis.  
 In our study, the influence of MBL serum levels and MBL2 functional 
polymorphisms to urinary schistosomiasis susceptibility was assessed. Data revealed 
that MBL serum levels were higher in the control groups compared to the infected 
individuals indicating a protective role of MBL against S. haematobium infection. Our 
results are in line with previous observations where MBL was reviewed as a key 
component of the innate immune system by protecting persons against a broad range of 
infectious diseases caused by bacteria, fungi, viruses, and parasites [22]. Our genotype 
results showed that three variants in MBL2 gene (-550G/C, +4C/T and 6bp deletion at -
338 to-332) play a role in influencing susceptibility to schistosomiasis. The major allele -
550L contributed towards increased susceptibility whereas -550H minor allele in the 
studied population decreased the risk of Schistosoma infection. The distributions of 
heterozygous genotypes (+4CT and wt/6bp-del) were higher in the cases in comparison 
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to controls revealing a higher risk of getting schistosomiasis. MBL2 haplotype analysis 
showed that the MBL2*HYPA haplotype occurred less frequently in the cases group 
than in controls elucidating the protective effect of this high MBL secreting haplotype 
towards schistosomiasis. Similar results on the influence of MBL2*HYPA haplotypes 
have been demonstrated on pediatric patients with common infectious diseases and 
reduced risk of infection following allogeneic hematopoietic stem cell transplantation 
[127, 128]. 
 We extended our investigations to evaluate the association of Collectin-kidney 1 
(CL-K1) with urinary schistosomiasis as Schistosome teguments are fucosylated and 
CL-K1 has higher binding affinity to fucose [129, 130]. This is a primary study that 
examined the role of CL-K1 in an infectious disease context. The current study 
demonstrated that CL-K1 serum level was higher in the control group compared with 
infected individuals, showing that high levels of CL-K1 contributes protective effect to S. 
haematobium infection. The result was in line with previous observation on MBL and 
ficolin-2 using the same study group. Genotype association analysis revealed that the 
non-synonymous substitution in the exon8 (p.R216H) contributes to reduced 
schistosomiasis susceptibility. In specific, the minor allelic variant (p.216H) reduces the 
infection risk and the result was consistent with different genetic models employed. In 
addition, allele p.216H was associated with higher CL-K1 serum levels in healthy 
individuals. Of interest, rs7567833G/A (p.R216H) variant was reported to be under 
selective pressure and is differentially distributed in world populations [131, 132]. Other 
observed polymorphisms in the promoter and coding regions did not contributed to the 
disease susceptibility. COLEC11 haplotypes revealed that COLEC11*TCCA haplotype 
confers a shielding effect to S. haematobium infection. In light of these findings, it is 
evident that higher CL-K1 serum levels and the p.216H allele confer a protective effect 
to the host against urinary schistosomiasis.  
 Further, we investigated MBL-associated serine protease 2 (MASP-2) utilizing 
the same study group, as it is a direct downstream protein of MBL and ficolins in lectin 
complement pathway [133]. We hypothesized that the MASP-2 complement protein is 
as equally important as MBL, CL-K1 and ficolin-2 to resist against S. haematobium 
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infections and thus MASP-2 serum levels and MASP2 variants were evaluated. No 
significant contributions of investigated MASP2 variants to schistosomiasis susceptibility 
were observed. The MASP-2 serum levels were not differentially distributed in 
investigated groups, but age was observed to be a confounding factor influencing 
MASP-2 serum levels, hence the data was segregated based on the mean puberty age 
(12 years) in the study population [134]. An age related pattern was observed in the 
distribution of MASP-2 levels in patent S. haematobium infected individuals. Infected 
children (<12 years) had lower serum MASP-2 levels compared to unaffected children. 
On the other hand, infected older children and adults had higher serum MASP-2 levels 
compared to control subjects with similar age. Similar age-related patterns in urinary 
schistosomiasis have also been identified in studies on other immune components such 
as myeloid dendritic cells (mDCs) and distinct cytokines [135-137]. The experimental 
infection of S. mansoni in mice either before or after puberty showed that pre-
puberty infected mice had a higher number of adult worms and higher mortality rates as 
compared to post-puberty infected mice [138]. A clear association of age and intensity 
of infection is predicted in the field. In endemic areas, children below puberty age are 
more likely to get an S. haematobium infection than adults due to the lack of acquired 
protective immunity [139]. Based on our observations on MASP-2 and its relation with 
puberty age, we agree with the hypothesis of ‘Puberty and Resistance to 
Schistosomiasis’ proposed by Fulford et al., as it suggests that host age needs to be 
considered to achieve elimination of schistosomiasis [140].  
 Overall, our findings support the notion that lectins MBL, CL-K1 and their 
functional variants may be protective host factors in urinary schistosomiasis. We also 
observed that MASP-2 serum levels were associated with age and relative protection 
from urinary schistosomiasis in Nigerian children. 
2. Lectins in intracellular L. donovani infection 
Visceral Leishmaniasis (VL) is a complex disease phenotype determined by multiple 
factors such as the environment, the insect vector, and the parasite and host genetics. 
The contributing host genetics involves multiple immune genes towards disease 
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susceptibility [141]. Notably, 80–90% of human L. donovani infections are sub-clinical or 
asymptomatic, usually associated with host immunity. Additional to other factors, 
genetic risk factors determine why two people with the same exposure to infection differ 
in susceptibility [142]. Recent genome-wide association studies (GWAS) from Brazil and 
India with larger sample size have identified a strong association HLA-DRB1–HLA-
DQA1 locus in both populations irrespective of the geographical distance and different 
causative parasite species [143]. The role of host genetics in VL susceptibility reviewed 
by Sakthianandeswaren et al., by exploring published literatures and concluded that 
many GWAS and candidate gene association studies demonstrated to the contribution 
of host genetics to resist against L. donovani infection [144].   
 Complement system has long been acknowledged as an important component of 
host defense to extra-cellular pathogens. However, their role in intra-cellular pathogens 
favors progression of the infection, as in Leishmania. As soon as the Leishmania 
promastigotes are injected by phlebotomine sandflies into the skin, the parasite has to 
face two of the most ancient yet effective immune mechanisms: (1) lysis by 
complement; and (2) destruction by phagocytes. Leishmania not only evades 
destruction by complement and phagocytes, but exploits the opsonic properties of 
complement to enhance its interaction with phagocytes, the host cells in which it 
replicates [145]. Leishmania spp., activates the lectin-complement pathway suggesting 
the active participation of lectins in VL [58, 101]. In current study, we investigated the 
possible contributions of MBL2, FCN2 functional variants and circulating MBL, ficolin-2 
levels in VL cases and controls from endemic region of Bihar, India. 
 The influence of MBL serum levels and MBL2 functional polymorphisms to VL 
was assessed. Data revealed that MBL serum levels were higher in the VL cases 
compared to the controls indicating a susceptible role of MBL against L. donovani 
infection. Our observation is in line with earlier studies from Brazil that MBL level was 
increased in individuals with VL caused by L. chagasi compared to asymptomatic and 
uninfected individuals [44, 102]. Genotype analysis showed that two variants in 
promoter region of MBL2 gene (-78C/T and +4C/T) were associated with decreased 
susceptibility to VL. The contribution of the variant -78C/T (rs11003123) to circulating 
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MBL level or associations in other diseases are limited. Reconstructed MBL2 
haplotypes revealed that the MBL2*LYQA haplotypes were distributed more frequently 
in healthy controls compared to VL patients, conferring a protective effect. The 
MBL2*LYQA haplotype is related to higher expression of serum MBL levels and 
associated with reduced risk in severe malaria patients from the Indian population [110]. 
 In addition, we investigated ficolin-2 serum levels and FCN2 variants to L. 
donovani infection in the same study group, as ficolin-2 is a functional analogue to MBL 
[146].  We observed that ficolin-2 serum levels were higher in VL cases compared to 
healthy controls conferring the susceptible role ficolin-2 to L. donovani infections similar 
to MBL. However, our observation was outlined with an earlier report where ficolin-2 
levels were decreased in individuals with chronic Chagas disease caused by 
Trypanosoma cruzi, an intracellular parasite phlyogentically related to L. donovani [147]. 
Our results strongly suggest that high concentrations of ficolin-2 may enhance the 
uptake of L. donovani to host phagocytes/macrophages, the milieu preferred by these 
pathogens for their survival and replication. Genetic association analysis of FCN2 
variants with VL showed that the structural variant +6359 C>T (rs17549193, p.T236M) 
in fibrinogen like domain of FCN2 gene was observed to increase the predisposition to 
visceral leishmaniasis. The computational prediction revealed that p.T236M substitution 
has major impact on the physiochemical property of the ficolin-2 and related to a 
significantly higher ficolin-2 serum level [148, 149]. Our FCN2 haplotypes revealed that 
the FCN2*AAAC haplotype frequency was higher among controls than in VL cases, 
indicating that individuals with this haplotype had a diminished probability to develop VL.  
 Overall, we observed a high serum MBL and ficolin-2 levels in patients with VL 
inferring an active involvement of lectin pathway in visceral leishmaniasis. We also 
demonstrated that MBL2, FCN2 variants are significantly associated with VL in the 
studied Indian study group. 
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3. IL-6 regulates lectins expression in parasitic infections 
The pathogenesis of parasitic diseases is complex. Parasites, appear to initiate the 
acute phase plasma response during their migration and localized inflammation that is 
regulated by cytokines and hepatocyte-stimulating factors [150]. Cytokines are released 
in response to infection and are involved in many pathophysiological events. IL-6 is a 
pleiotropic cytokine and has the capacity to induce the expression of APP [107]. In 
pediatric patients with community acquired infections and bacteremia, the acute phase 
C-reactive protein was strongly correlated with IL-6 [151]. As MBL is a known APP 
[152], we hypothesized that IL-6 might exert synergistic effects with MBL and other 
lectins during S. haematobium and L. donovani infection [153]. Therefore, we studied 
the role of IL-6 in urogenital schistosomiasis and VL.  
 Our data indicate that IL-6 serum levels were higher among S. haematobium 
infected individuals compared to the S. haematobium sero-positive and sero-negative 
control subgroups. This observation is in line with earlier reports of natural and 
experimental Schistosoma infections [111, 154]. IL-6 serum levels have previously been 
shown to be also elevated in patients with S. haematobium induced bladder cancer and, 
correlated with advanced tumor grade and exhibited as a disease modifier [155]. 
Moreover, IL-6 was observed to interact with monocytes and platelets in killing of S. 
mansoni parasites [156]. Our findings emphasize the potential role of IL-6 in the 
pathogenesis of urinary schistosomiasis. Schistosomiasis is a strong inducer of a Th2 
response with IL-6 expression.  
 We noticed a positive correlation of the lectins MBL, Ficolin-2 and CL-K1 with IL-
6 in urinary schistosomiasis. Similar positive correlation was observed between IL-6 and 
the C-reactive protein (CRP) in HIV patients with the immune reconstitution 
inflammatory syndrome (IRIS) [157]. It is evident that MBL and other functional 
analogues may be modulated by IL-6 stimuli and essentially up-regulates the acute 
phase response proteins (APP) encoding genes [158]. However, in spite of the up-
regulation by IL-6 of APP genes, we observed reduced MBL, Ficolin-2 and CL-K1 
serum levels in S. haematobium infected individuals. We postulate that the schistosoma 
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parasite factors contribute to lower circulating serum levels of MBL, Ficolin-2 and CL-K1 
by complement consumption. Related observation of MBL and IL-6 has been described 
in meningococcal infection [159]. In a cystic fibrosis patient who infused with 
recombinant MBL, MBL was observed to modulate the inflammatory reaction as IL-6 
and CRP levels were inversely correlated with MBL serum levels [160]. Of interest, we 
noticed an inverse correlation of IL-6 with MBL and ficolin-2, but not with CL-K1 serum 
levels, both in seropositive and sero-negative controls as they did not exposed to 
inflammatory stimuli. 
 The observation of IL-6 and lectin expression in VL is similar to the 
schistosomiasis. IL-6 levels were elevated in VL cases compared to controls similar to 
earlier reports [108, 115, 116]. IL-6 seems to be a central cytokine in VL as it is 
associated with mortality, liver damage, and the regulation of other vital cytokines [108]. 
IL-6 was also observed to reduce the anti-leishmanial activity in human macrophages 
[117]. A positive correlation was observed between MBL and IL-6 in VL cases. The 
similar positive correlation of IL-6 and APP–CRP was observed in VL cases [108]. It is 
clear that likewise with CRP, MBL may be modulated by IL-6 stimuli in L. donovani 
infections. Moreover, the circulating serum levels of MBL were elevated in the same 
investigated samples. However, no association between ficolin-2 and IL-6 was observed 
in VL cases. No correlation of lectins with IL-6 was noticed in control subjects. We 
speculate that a larger sample size would corroborate the understanding of the 
contribution IL-6 in regulation of ficolin-2 expression in L. donovani infection as we 
measured the IL-6 in less number of samples. We have shown that IL-6 levels are 
elevated in infected individuals and that IL-6 levels regulate the production of lectins 
during the infection.  
4. Are lectins friend or foe in parasitic infections? 
Often, parasites exhibit very strong immune evasion strategies to escape from 
complement attack and to achieve the infections. Earlier studies investigated that, the 
complement system fails to kill the parasite, due to immune evasion or subversion (i.e., 
abusing the complement components to facilitate the infections) [50]. The 
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glycoconjugates presented by parasites are involved in the stimulation of non-specific 
innate immune response and recognized by host carbohydrate binding protein family of 
receptors including lectins in a calcium dependent manner. The lectin complement 
system is a primary part of the innate immunity that encounters parasites immediately 
upon invasion into the human host [10]. However, lectins deficiency is an essential host 
factor contributing to the infection susceptibility. The objective 1 and 2 presented in this 
thesis explored the role of the lectin pathway components in distinct parasitic infections.   
4.1 MBL and parasitic diseases 
The mannose-binding lectin (MBL) is a key recognition element involved in binding 
oligosaccharide structures exposed on parasites. MBL is a circulating serum protein 
constitutively present in the blood and act very immediate against the invaded parasites 
[10]. Schistosoma, an extra-cellular blood fluke trematode worms and are constantly 
exposed to MBL. In addition, MBL was shown to adhere to the surface glycoproteins of 
cercariae and adult worms [59]. Therefore, we investigated the effect of MBL in urinary 
schistosomiasis. The clinical relevance of our findings is that higher circulating MBL 
levels and high MBL expression genotype led to increased protection to S. 
haematobium infection in the investigated Nigerian study group. In contrast, a recent 
study reported that higher plasma MBL levels increase the susceptibility to S. 
haematobium infections in Zimbabwean study group [161]. The mechanisms behind 
these contrasting findings towards a role of MBL levels in urinary schistosomiasis are 
not clearly understood as both populations have African ethnicity and similar sample 
size. However, the authors justified that due to the numerous intracellular infections 
occurring in African population, might have exerted selection pressure to low MBL2 
expression genotypes and thus reduced MBL plasma levels [162]. Moreover, 
experimental Schistosoma infection in MBL knockout (MBL-A–/–) mice revealed that the 
course of infection was not altered, raising questions about biological relevance of MBL 
against schistosomiasis [163]. Nevertheless, we strongly rely on observations of MBL 
against schistosomiasis as we noticed a similar effect with other functional analogues 
such as ficolin-2 and CL-K1 in the same study group [83]. 
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 The extra-cellular living filarial worms Wuchereria bancrofti, Brugia malayi, 
and Brugia timori are the causative agents for lymphatic filariasis. Their cell wall is rich 
in carbohydrate sugars that expresses D-mannose, N-acetyl-D-glucosamine and L-
fucose that can ably be recognize by MBL [164]. The low MBL expression genotype of 
the host was observed to increase the susceptibility to W. bancrofti infection in 
Tanzanian [165] and south-Indian [43] population. Moreover, the experimental infection 
of Brugia malayi, in Mannose-binding lectin A-deficient (MBL-A–/–) mice have increased 
susceptibility to a nematode infection [164]. MBL has also been shown to interact with 
Trichinella spiralis glycoproteins and trigger the complement activation [166]. However, 
no genetic and/or phenotypic association studies were reported that relate MBL with 
Trichinosis. The rapid binding of MBL detected to the surface of Giardia intestinalis 
causing Giardiasis and the serum depleted with MBL failed to kill parasites in vitro [167]. 
Together, in line with our observations on S. haematobium, the higher MBL levels and 
genotype conferring high expression ensures the protection against the extra-cellular 
parasitic infections. 
 Leishmania donovani, an intra-cellular (macrophage) parasitic protozoan 
responsible for visceral leishmaniasis. Earlier reports documented that high MBL 
producing genotypes, alleles and high serum MBL levels were associated with active VL 
cases [44, 102, 104, 168]. As previous studies demonstrated, we also observed higher 
serum MBL levels in patients with VL. These results suggest that the high MBL levels 
favor the development of L. donovani infection and act as disease modifier in VL. 
Conversely, in our study the high MBL producing allele +4Q was observed to be a 
protective factor against VL. The similar discordant result was noticed in our association 
study of MBL2 variants with urinary schistosomiasis where the heterozygous genotype 
(+4PQ) was observed to be a risk factor. Moreover, in contrary to previous 
observations, the susceptible effect −221X/Y and codon 57C was reported with 
cutaneous leishmaniasis caused by Leishmania guyanensis [169]. These contradicting 
observations on the impact of various MBL2 variants need to be further explored.  
 Trypanosoma cruzi, an intra-cellular (fibroblast, macrophages and epithelial cells) 
protozoan parasite responsible for Chagas’ disease (CD).  MBL bound to the sugar 
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moieties of T. cruzi trypomastigotes and found to enhance the invasion process into the 
host cell [170]. High MBL levels were observed to associated with the risk of severe 
cardiomyopathy in chronic CD [171]. However, the low MBL producer MBL2*B genotype 
were present more frequently in CD patients than non-infected individuals [172]. Similar 
to VL, high MBL levels enhance the CD clinical outcome. 
Plasmodium spp., are intra-erythrocyte living protozoan parasites responsible for 
malaria. The red blood cells infected with P. falciparum were recognized by MBL in vitro 
but not inhibited the parasite growth [173]. Low serum MBL levels and low MBL 
producing genotypes were associated with severe malarial anemia and parasitemia in 
Gabonese population [41, 174, 175]. The MBL variants were also associated of with 
severe malaria in Ghanian children [176] and placental malaria in primiparous Ghanian 
women [177]. Nevertheless, another study reported that, the MBL haplotype was 
associated with low-birth-weight babies, but not with placental malaria in Cameroonian 
women [178]. Low MBL producing variants were strongly associated with malaria in 
Indian population [110]. Together, MBL deficiency increases the susceptibility to 
malarial infections.  
The role of MBL in distinct parasitic infections is controversial. The MBL 
deficiency and low MBL producing variants were shown to be associated with increased 
susceptibility to extracellular parasitic infections.  However, MBL deficiency and low 
MBL producing variants were observed to confer protection against certain intracellular 
parasites such as Trypanosoma spp. and Leishmania spp. We observed a similar role 
of MBL in our investigated L. donovani infection. The widely accepted hypothesis for 
this differential role of MBL is that, intra cellular parasites use MBL as an opsonin to 
enhance their uptake into the phagocytes. This additional uptake mechanism helps the 
intra-cellular parasites to escape from complement mediated lysis [179]. In line, the high 
MBL levels was observed to enhance phagocytosis in other intracellular pathogens 
such as Mycobacterium spp., [180]. Though, Plasmodium spp., are intra-cellular 
parasites, they live inside of erythrocytes. Therefore, it is likely to explain that lectins do 
not enhance their invasion as noticed in Leishmania spp. and Trypanosoma spp. The 
investigations on the effect of lectins in hepatic invasion of sporozoites are limited. But, 
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a study reported that MBL does not alter the hepatic invasion of P. yoelii in MBL-A 
deficient mice [181]. However, the role of other lectins in enhancing the invasion of 
Plasmodium spp., sporozoites in hepatic cells need to be further explored. 
4.2 Ficolins and parasitic diseases 
Ficolins are poorly investigated. In case of extra-cellular parasitic infections, the earlier 
study with our study samples reported that high ficolin-2 levels and high ficolin-2 
producing variants were associated with protection against urinary schistosomiasis [83]. 
The ficolins were able to bind to the surface of G. intestinalis and kill parasites in vitro 
[167]. In case of intra-cellular parasitic infections, decreased ficolin-2 levels were 
observed in Chagas’ disease. The results contradicts their previous observation on MBL 
in same patients [147]. However, the authors failed to justify this contrary results. The T. 
cruzi calreticulin molecule was observed to inhibit lectin pathway by direct interaction 
with ficolin-2 signify this lectin [30]. Nevertheless, in our investigations on VL, we 
noticed that high ficolin-2 levels and high ficolin-2 producing variants increase the 
occurrence of L. donovani infection. In addition, the association of FCN2 haplotype with 
cutaneous leishmaniasis was reported in Syrian Arab population [182]. Ficolin-A was 
reported to increase the survival rate of Plasmodium berghei infected mice [183]. Due to 
the strong acute disease on admission, the ficolin-2 levels were found to be higher in 
severe malaria cases compared to mild malaria [184]. Based on our results, ficolins also 
a play a differential role in intra and extra cellular parasitic infections.  
4.3 CL-K1 and parasitic diseases 
No previous studies have investigated the role of CL-K1 with any infectious diseases. 
Though CL-K1 was reported to recognize several bacteria, fungi and viruses [31, 32], 
the binding to schistosomes was not demonstrated. However, we investigated CL-K1 
due to fact that CL-K1 binds to the fucose rich tegument of the Schistosomes [129]. We 
observed that p.R216H was associated with high CL-K1 expression and 
schistosomiasis. Another recent study demonstrated that, three naturally occurring 
mutations were associated with 3MC syndrome and prevents secretion of CL-K1 from 
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mammalian cells and affects the normal developmental processes [185]. In agreement 
with MBL and ficolin-2, CL-K1 and their functional variants may be associated with 
protection against schistosomiasis. 
4.4 MASPs and parasitic diseases 
Relatively very few studies investigated MASP-2 deficiency in parasitic infections. 
Earlier study showed that low MASP-2 producing genotypes occurred at a higher 
frequency in patients with cardiomyopathy in chronic Chagas disease [186, 187]. 
However, experimental infection of T. cruzi in MASP-2-deficient mice did not confer 
higher susceptibility [188]. In our investigations, we noticed that high MASP-2 serum 
levels confer relative protection to schistosomiasis in Nigerian children. The MASP2 
p.439H variant  responsible for dysfunctional MASP-2 protein was earlier reported to 
protect Ghanian women from placental malaria [177]. 
 Together, we observed the differential role of lectins that depends on the 
parasites habitant nature either intra or extra cellular living. In addition, IL-6 was 
observed to regulate the lectins expression in S. haematobium and L. donovani 
infection. Our study observations strongly support the notion that lectins are acute 
phase plasma proteins [152]. In the light of our results we proposed a model (Figure 4) 
that illustrate the relevance of lectins in investigated parasitic diseases. In parasitic 
diseases caused by extra-cellular pathogens, IL-6 mediated acute-phase response of 
lectins may be activated. However, in spite of the up-regulation by IL-6 of APP genes, 
we noticed that S. haematobium parasite factors contribute to lower the circulating 
serum levels of MBL, ficolin-2 and CL-K1 by complement consumption (Figure 4A). In 
parasitic diseases caused by intra-cellular pathogens, IL-6 mediated acute-phase 
response of lectins may be activated. In turn, this favors the phagocytosis of the 
parasite into the phagosomes, a milieu that assists persistence of the parasite (Figure 
4B). Though overlapping endemicity of schistosomiasis and visceral leishmaniasis was 
observed in Sudan, no data available on co-infection. 
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Figure 4: The model illustrates the relevance of lectins in parasitic diseases. (A) In 
parasitic diseases caused by extra-cellular pathogens, IL-6 mediated acute-phase 
response of lectins may be activated. However, reduced lectins serum levels noticed 
due to the complement consumption of the parasite. (B) In parasitic diseases caused by 
intra-cellular pathogens, IL-6 mediated acute-phase response of lectins may be 
activated. In turn, this favors the phagocytosis of the parasite into the phagosomes, a 
milieu that assists persistence of the parasite.  
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However, it is observed that S. mansoni delays the healing of cutaneous lesions caused 
by L. major in co-infected mice [189]. The intestinal helminth infections was observed to 
influence clinical outcome of cutaneous leishmaniasis in patients [190]. Our 
observations warrant further experimental and clinical investigations of lectins on co-
infection of intra and extracellular parasitic infections. 
Conclusion 
The impact of lectins deficiency and its association to parasitic diseases has been 
previously investigated. However, the scenario is highly debated as the studies suggest 
a positive or negative impact of lectins deficiency on susceptibility to parasitic infections 
based on their cellular habitants. In this thesis, we investigated the interaction of lectins 
with intra and extra cellular parasites, as it is important to understand the host-pathogen 
interactions to eradicate the disease. Our findings support the observation that in extra 
cellular S. haematobium infection, MBL, Collectin-11 (CL-K1), MASP-2 and their 
functional variants were associated with relative protection in a Nigerian study group. 
Dissimilar, in intra-cellular L. donovani infection, MBL, ficolin-2 and their functional 
variants were observed to be a susceptible host factor. Here we conclude based on the 
observations that lectins play a differential role during intra and extra-cellular parasitic 
infections and serve as a ‚double-edged sword’. Our findings suggest that parasite 
cellular habitat determines the role of lectins. We also observed that the lectins 
expression was regulated by IL-6 in investigated parasitic infections. Taken together, 
these investigations lay a basis to understand the role of lectins in intra and extracellular 
parasitic infections. 
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M A J O R A R T I C L E
Mannose-Binding Lectin and Susceptibility to
Schistosomiasis
Justin S. Antony,1,a Olusola Ojurongbe,1,2,a Hoang van Tong,1 Eman Abou Ouf,1 Thomas Engleitner,1 Akeem A. Akindele,2
Olawumi R. Sina-Agbaje,3 Adegboyega O. Adeyeba,2 Peter G. Kremsner,1 and Thirumalaisamy P. Velavan1
1Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany; and 2Ladoke Akintola University of Technology, Ogbomoso, and 3Ogun State
Hospital, Ijaye Abeokuta, Nigeria
Background. Human ﬁcolin 2 (encoded by FCN2) and mannose-binding lectin (encoded by MBL2) bind to
speciﬁc pathogen-associated molecular patterns, activate the complement lectin cascade in a similar manner, and
are associated with several infectious diseases. Our recently published study established certain FCN2 promoter vari-
ants and ﬁcolin-2 serum levels as protective factors against schistosomiasis.
Methods. We used the Nigerian cohort from our recently published study, which included 163 Schistosoma
haematobium–infected individuals and 183 matched healthy subjects, and investigated whether MBL deﬁciency and
MBL2 polymorphisms are associated with schistosomiasis.
Results. MBL serum levels were signiﬁcantly higher in controls and were associated with protection (P < .0001).
The −550H minor allele was signiﬁcantly associated with protection (P = .03), and the heterozygous genotypes
−550HL were observed to confer protection (P = .03). The MBL2*HYPA haplotype was signiﬁcantly associated with
protection (P = .03), with signiﬁcantly higher serum MBL levels in controls (P = .00073). The heterozygous 6-bp de-
letion in the promoter was observed to be a susceptibility factor in schistosomiasis (P = .03).
Conclusions. In agreement with ﬁndings from our recently published study, the ﬁndings reported here support
the observation that MBL is also associated with protection in schistosomiasis.
Keywords. MBL2; genotypes; haplotypes; serum level; Schistosomiasis.
Schistosomiasis is one of the neglected tropical diseases
targeted for elimination by the World Health Organiza-
tion and is caused by different species of the trematode
genus Schistosoma. Of the 207 million estimated cases of
schistosomiasis worldwide, 93% (192 million) occur in
sub-Saharan Africa, with Nigeria recording the highest
number of cases (29 million), followed by the United
Republic of Tanzania (19 million) and the Democratic
Republic of the Congo and Ghana (15 million each) [1].
Although various species cause schistosomiasis, Schisto-
soma haematobium is themost ubiquitous species in sub-
Saharan Africa, contributes to urogenital schistosomiasis,
and is associatedwith severe pathological conditions, such
as hematuria, bladder cancer, and hydronephrosis [2–4].
S. haematobium infection represents a massive public
health problem in Nigeria. It is endemic in many states
of the federation, causing immense morbidity, as mea-
sured by disability-adjusted life-years, and represents a
massive public health problem in Nigeria. The most-
affected age group is school-aged children who are con-
stantly in contact with cercariae-infected water [5]. Rapid
reinfection [6], a limited supply of praziquantel, and the
failure of the host immune system to mount parasite-
speciﬁc immune responses add to the disease burden [7].
The prevalence of schistosomiasis within communities
of endemicity may be inﬂuenced by several exposure-
related factors, such as local environment and behavior,
and by genetic factors related to individual susceptibil-
ity [8]. In schistosomiasis, studies have documented
that recurrent infections in certain communities are
subject to individual variability [9]. Schistosomes are
complex multicellular helminthes with different devel-
opmental stages in the human host. S. haematobium in
all developmental stages carries glycoconjugates that
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interact with innate immune recognition elements, such as
mannose-binding lectin (MBL) and ﬁcolins. Earlier studies
have demonstrated that Schistosoma organisms exhibit different
glycoproteins on their tegument [10], and carbohydrate moie-
ties remain a potential target for MBL [11]. Moreover, in vitro
studies have documented the complement-mediated killing of
Schistosoma mansoni in all life stages of the parasite [12]. In ad-
dition, our previous studies have demonstrated that MBL com-
petently binds to the sugar moieties of S. mansoni cercariae
and adult worms in vitro and, with MBL-associated serine pro-
tease 1 (MASP1) and MASP2, that it is capable of interacting
with the Schistosoma tegument, thereby activating the comple-
ment cascade [13].
MBL is a circulating innate immune recognition protein that
is involved in innate immune defense against pathogens [14,
15]. In humans, the MBL encoded by MBL2 is located on chro-
mosome 10. Three identiﬁed single-nucleotide polymor-
phisms (SNPs) in exon 1 of MBL2, at codons 52(MBL2*D),
54(MBL2*B), and 57(MBL2*C), interfere with the formation of
higher MBL oligomers, leading to alterations in functional ac-
tivity of the protein and their circulating levels [16, 17]. The
haplotype of variant alleles is designated as O, whereas the hap-
lotype of the common MBL2 allele is designated as A [18]. In
addition, 2 strongly linked SNPs in the proximal promoter (L/
H and X/Y), as well as a SNP in the 5′ untranslated region
(UTR; P/Q), together are linked to 3 independent nonsynony-
mous SNPs (ie, B, C, and D) to form “secretor haplotypes,”
which have been shown to partially account for alterations in
complement activation and for decreased circulating levels of
MBL [19]. In particular, a base substitution at −221 (G to C;
promoter allele X) is associated with a lower MBL concentra-
tion in serum [11]. Studies have documented that these SNPs
contribute to the circulating levels against the 7 common secre-
tor haplotypes (ie, HYPA, HYPD, LXPA, LYPA, LYPB, LYQA,
and LYQC) [11]. HYPA, LYQA, and LYPA are associated with
high expression of MBL, whereas LXPA, HYPD, LYPB, and
LYQC are associated with low expression of MBL [20]. These
secretor haplotypes modulate the MBL concentration in
healthy individuals, from levels that are undetectable to levels
that are several thousand times greater than the mean level [14,
21]. There is increasing evidence that MBL2 polymorphisms
are associated with infections in pediatric patients, severe acute
respiratory syndrome, Cryptosporidium infection, human im-
munodeﬁciency virus (HIV) infection in children, infections in
Polish neonates, visceral leishmaniasis, hepatitis B, malaria and
placental malaria, leprosy, and rheumatoid arthritis [22–37].
Despite the documented interaction of S. mansoni with the
MBL-MASP complex in vitro [38], there is no existing informa-
tion on the association between functional MBL2 variants and
serum MBL levels and schistosomiasis outcomes. We recently
demonstrated that certain FCN2 promoter variants and ﬁcolin-
2 serum levels protected against schistosomiasis. Both ﬁcolins
and MBL are similar immune recognition proteins that can
bind to carbohydrate sugars, such as N-acetylglucosamine, N-
acetylgalactosamine, and glucose, of adult worms and cercariae
[39]. Therefore, we hypothesized that MBL plays an analogous
role in S. haematobium infection. In this study, we investigated
the role of MBL2 polymorphisms and serum MBL levels in S.
haematobium infection. We examined the possible contribu-
tion of functionalMBL2 variants (2 strongly linked SNPs in the
proximal promoter, a 6-bp deletion in the promoter, 1 SNP in
the 5′ UTR, and 3 SNPs in exon 1) and investigated the rela-
tionship of genetic polymorphisms to circulating serum MBL
levels in a Nigerian cohort.
PATIENTS ANDMETHODS
Study Design and Sample Collection
We recruited 346 individuals blindly, irrespective of their infec-
tion status, from 2 communities in southwest Nigeria, Ilewo
Orile (Abeokuta North) and Ore (Osogbo), in which there was
a known history of S. haematobium infection. After parasito-
logical and serological testing (for total anti-schistosome im-
munoglobulin G [IgG] antibodies), the cohort was divided into
the following 3 groups: the case group (hereafter, the “SEP
group”), the ﬁrst control group (hereafter, the “SELP group”),
and the second control group (hereafter, the “SELN group”).
The SEP group was composed of 163 individuals who tested
positive for Schistosoma eggs. The ratio of males to females was
90 to 73; 99 (61%) were children, of whom 55 (34%) were
males, and 44 (27%) were females. The mean age (±SD) was
17.1 ± 12.4 years (range, 4–70 years). Hematuria was detected
in 90%, and the mean parasite count was 1595 parasites (range,
20–27 000 parasites).
The SELP group was composed of 119 individuals who
tested positive for Schistosoma antigens by enzyme-linked
immunosorbent assay (ELISA). The ratio of males to females
was 58 to 61; 23 (19%) were children, of whom 10 (8%) were
males, and 13 (11%) were females. The mean age (±SD) was
33.6 ± 18.8 years (range, 4–75 years). Hematuria was detected
in 2.4%.
The SELN group was composed of 64 individuals who tested
negative for Schistosoma antigens by ELISA and negative for
Schistosoma eggs. The ratio of males to females was 40 to 24; 31
(48%) were children, of whom 23 (36%) were males, and 8
(13%) were females. The mean age (±SD) was 20.2 ± 17.2 years
(range, 4–71 years). Hematuria was not detected in any subject.
All subjects were of Yoruba ethnicity. Additional parasitolog-
ical data, serological data, and characteristics of this cohort are
reported elsewhere [39].
About 10 mL of urine from all participants was collected
into a sterile, labeled container and examined for the presence
of S. haematobium eggs, and about 5 mL of blood was collected
for serological assays and DNA extraction. Details about the
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study were provided in the local language to potential partici-
pants, and informed consent was obtained before recruitment
into the study; for children, consent was obtained from parents
and/or guardians. Ethics approval was obtained from the
Ethical Committee of Ministry of Health, Abeokuta Ogun
State, Nigeria.
Serological Assays
Serological assays were performed using a modiﬁed ELISA pro-
tocol to detect total anti-schistosome IgG antibodies, as previ-
ously described [40]. Serum levels of MBL were measured in
patients and healthy control subjects, using an ELISA kit for
human MBL (Hycult Biotech, Uden, the Netherlands).
MBL2 Genotyping
Genomic DNA was extracted using the QIAamp DNA Blood
Mini Kit (Qiagen, Hilden, Germany). The MBL2 promoter
polymorphisms at −550G > C, −221G > C, and the 5′ UTR
+4C > T and the exon 1 polymorphisms at codons 52C > T,
54G > A, and 57G > A were ampliﬁed by polymerase chain re-
action (PCR), using primer pairs spanning from the promoter
region through exon 1. The primers used were as follows: pro-
moter, forward: 5′-GCCAGAAAGTAGAGAGGTATTTAG
CAC-3′; internal primer exon 1, forward: 5′-CAGGTGTCT
AGGCACAGATGAACC-3′; and exon 1, reverse: 5′-CCAA
CACGTACCTGGTTCCC-3′. In brief, 10 ng of genomic DNA
was ampliﬁed in a 20-µL volume of reaction mixture containing
1× PCR buffer (20 mM Tris-HCl [pH 8.4], 50 mM KCl, and
1.5 mM of MgCl2), 0.125 mM of dNTPs, 0.25 mM of each
primer, and 1 U Taq DNA polymerase (Qiagen, Hilden,
Germany) on a PTC-200 Thermal cycler (MJ Research, United
States). Thermal cycling parameters for ampliﬁcation of both
exon 1 and promoter regions were 94°C for 5 minutes (initial
denaturation); 35 cycles of 30 seconds at 94°C (for denatura-
tion), 30 seconds at 68°C (for annealing), 90 seconds at 72°C
(for extension); and 120 second at 72°C (for ﬁnal extension).
PCR products were cleaned up by use of Exo-SAP-IT (USB, Af-
fymetrix, United States), and 1 µL of the puriﬁed product was
directly used as a template for sequencing, using the BigDye
terminator v. 1.1 cycle sequencing kit (Applied Biosystems,
United States) on an ABI 3130XL DNA sequencer, according
to the manufacturers’ instructions. Polymorphisms were identi-
ﬁed by assembling the sequences with respective reference se-
quences (NG_008196.1), using CodonCode Aligner, version
4.0 (available at: http://www.codoncode.com/), and were recon-
ﬁrmed visually from their respective electropherograms.
Statistical Analysis
Data were analyzed using Intercooled Stata, version 9.1, and the
level of signiﬁcance was set as a P value of < .05. A Kruskal-
Wallis test was used to analyze the correlation of serum MBL
levels to MBL2 variants. A 2-tailed Fischer exact test was
performed to determine the differences in allele frequencies and
genotype distributions. The Benjamini-Hochberg procedure
was used for correction of P values involving multiple com-
parisons. Genotype or haplotype frequencies were analyzed by
simple gene counting and the expectation-maximum algorithm,
and the statistical signiﬁcance of deviations from Hardy-
Weinberg equilibriumwas tested using the random-permutation
procedure, as implemented in Arlequin software, version 3.5.1.2
(available at: http://cmpg.unibe.ch/software/arlequin3/). Linkage
disequilibrium analysis was performed using Haploview, version
3.2.
RESULTS
MBL2 Gene Polymorphisms and S. haematobium Infection
Both genotype and allele frequencies for all analyzed functional
MBL2 SNPs in each respective group were in Hardy-Weinberg
equilibrium. The distribution of MBL2 genotypes and allele(s)
in the cohort are shown in Table 1. Linkage disequilibrium
patterns of studied MBL2 variants, along with the observed
6-bp deletion in the SEP group, the SELP group, the SELN
group, and the SELP and SELN groups combined are shown
in Figure 1. The 6-bp deletion was in linkage disequilibrium
with the promoter variant +4C/T (P/Q) in all studied sub-
groups.
Signiﬁcant differences were observed either in genotypes or
allelic distributions between the SEP group and both the SELN
group alone and the SELP and SELN groups combined for the
−550G/C variant. The homozygous variant LL (−550CC) ge-
notype was observed more frequently in the SEP group, com-
pared with the SELN group alone (odds ratio [OR], 2.7; 95%
CI, 1.08–6.65; P = .02) and the SELP and SELN groups com-
bined (OR, 2.1; 95% CI, 1.06–4.59; P = .03), suggesting that it is
associated with an increased risk for S. haematobium infection
(Table 1). The heterozygous genotype HL (−550GC) was ob-
served less frequently in the SEP group, compared with the
SELN group alone (OR, 0.34; 95% CI, .13–.86; P = .01) and the
SELP and SELN groups combined (OR, 0.44; 95% CI, .20–.91;
P = .03), suggesting that it might be protective against S. hae-
matobium infection. The minor allele −550H was observed
more frequently in the SELN group alone (OR, 0.42; 95% CI,
.18–1.0; P = .048) and the SELP and SELN groups combined
(OR, 0.5; 95% CI, .24–.98; P = .03), compared with the SEP
group (Table 1). In exon 1, heterozygous genotype PQ (+4CT)
was observed more frequently in the SEP group, compared with
the SELN group (OR, 2.27; 95% CI, 1.2–4.31; P = .02). The ho-
mozygous genotype PP (+4CC) was observed less frequently in
the SEP group, compared with the SELN group (OR, 0.4; 95%
CI, .2–.9; P = .02). No signiﬁcant differences in any other geno-
type distribution were observed when the SEP group was com-
pared with the SELP group (data not shown). The heterozygous
6-bp deletion in the promoter region (−338 to −332) was more
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frequent in the SEP group, compared with the SELN group
(OR, 2.15; 95% CI, 1.1–4.09; P = .01).
No signiﬁcant differences were observed for other genotype
comparisons between the cases and both control groups. We
only observed variants at codon 57(MBL2*C), and no variants
were observed at codons 52(MBL2*D) and 54(MBL2*B) in
all the studied subgroups. When the combined genotypes
for variant −221G/C and exon 1 (at codons 52[MBL2*D],
54[MBL2*B], and 57[MBL2*C]) were investigated for their in-
ﬂuence in serum MBL levels (high MBL producers [YA/YA],
Table 1. Distribution ofMBL2 Genotypes and Alleles Among Cases and Controls
SNP Position Genotype
Subjects, No. (%), by Study Group(s) SEP vs SELN SEP vs (SELP + SELN)
SEP SELP SELN SELP+ SELN
OR (95% CI) Pa OR (95% CI) Pa(n = 163) (n = 119) (n = 64) (n = 183)
rs11003125 (−550G/C)
CC LL 149 (91.4) 101 (84.9) 51 (79.7) 152 (83.1) 2.7 (1.08–6.65) .02 2.1 (1.06–4.59) .03
GC HL 13 (8) 17 (14.3) 13 (20.3) 30 (16.4) 0.34 (.13–.86) .01 0.44 (.20–.91) .03
GG HH 1 (0.6) 1 (0.8) 0 1 (0.5) . . . NS . . .
C L 311 (95.4) 219 (92) 115 (89.8) 334 (91.3) . . . . . .
G H 15 (4.6) 19 (8) 13 (10.2) 32 (8.7) 0.42 (.18–1.0) .048 0.50 (.24–.98) .03
rs7096006 (−221G/C)
GG YY 126 (77.3) 98 (82.3) 46 (71.9) 144 (78.7) . . . . . .
GC YX 33 (20.2) 19 (16) 15 (23.4) 34 (18.6) . . . . . .
CC XX 4 (2.5) 2 (1.7) 3 (4.7) 5 (2.7) . . . NS . . .
G Y 285 (87.4) 215 (90.3) 107 (83.6) 322 (88) . . . . . .
C X 41 (12.6) 23 (9.7) 21 (16.4) 44 (12) . . . . . .
rs7095891 (+4C/T)
CC PP 23 (14.1) 15 (12.6) 18 (28.1) 33 (18.1) 0.4 (.2–.9) .02 . . .
CT PQ 94 (57.7) 61 (51.3) 24 (37.5) 85 (46.4) 2.27 (1.2–4.31) .02 . . .
TT QQ 46 (28.2) 43 (36.1) 22 (34.4) 65 (35.5) . . . NS . . .
C P 140 (42.9) 91 (38.2) 60 (46.9) 151 (41.3) . . . . . .
T Q 186 (57.1) 147 (61.8) 68 (53.1) 215 (58.7) . . . NS . . .
MBL2* exon 1 (codon 57)
GG AA 81 (49.7) 56 (46.2) 35 (54.7) 91 (49.7) . . . . . .
GA AO 71 (43.6) 50 (42.9) 27 (42.2) 77 (42.0) . . . . . .
AA OO 11 (6.7) 13 (10.9) 2 (3.1) 15 (8.3) . . . NS . . .
G A 233 (71.5) 162 (68.1) 97 (75.8) 259 (70.8) . . . . . .
A O 93 (28.5) 76 (31.9) 31 (24.2) 107 (29.2) . . . . . .
6-bp deletion (−338 to −332)
wt/wt 25 (15.3) 17 (14.3) 17 (26.6) 34 (18.6) . . . NS . . .
wt/del 92 (56.5) 56 (47) 24 (37.5) 80 (43.7) 2.15 (1.1–4.09) .03 . . .
del/del 46 (28.2) 46 (38.7) 23 (35.9) 69 (37.7) . . . NS . . .
wt 142 (43.5) 90 (37.8) 58 (45.5) 148 (40.4) . . . NS . . .
del 184 (56.5) 148 (62.2) 70 (54.5) 218 (59.6) . . . . . .
Promoter (−221) + exon 1
YA/YA 55 (33.7) 43 (36.1) 19 (29.7) 62 (33.9) . . . . . .
YA/YO 60 (36.8) 42 (35.4) 25 (39.1) 67 (36.6) . . . . . .
YO/YO 11 (6.7) 13 (10.9) 2 (3.1) 15 (8.2) . . . . . .
XA/YA 22 (13.5) 11 (9.2) 13 (20.3) 24 (13.1) . . . NS . . .
XA/YO 11 (6.7) 8 (6.7) 2 (3.1) 10 (5.5) . . . . . .
XA/XA 4 (2.4) 2 (1.7) 3 (4.7) 5 (2.7) . . . . . .
Percentages may not sum to 100%, because of rounding errors. Study groups were as follows: the SEP group (cases) was composed of individuals who tested
positive for Schistosoma eggs, the SELP group (controls) was composed of individuals who tested positive for Schistosoma antigens by enzyme-linked
immunosorbent assay (ELISA), and the SELN group (controls) was composed of individuals who tested negative for Schistosoma antigens by ELISA and negative
for Schistosoma eggs.
Abbreviations: CI, confidence interval; NS, not significant; OR, odds ratio.
a Adjusted by the Benjamini-Hochberg procedure.
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intermediate producers [YA/YO, XA/XA, and XA/YA], and low
producers [YO/YO, XA/YO, and XA/XO]), we observed no sig-
niﬁcant differences in comparisons between cases and controls
(Table 1).
The reconstructed MBL2 haplotypes and the observed distri-
bution in the Nigerian cohort are summarized in Table 2. We
observed only 5 secretor haplotypes in our study. The MBL2
haplotypes were divided into those associated with high expres-
sion (LYPA + LYQA +HYPA) and those associated with low ex-
pression (LYQC + LXPA) of MBL. No signiﬁcantly different
distributions were observed (Table 2). The reconstructed haplo-
types were marginally signiﬁcantly different in comparisons
between the SEP group and the SELN group alone (OR, 0.4;
95% CI, .18–1; P = .048) and the SELP and SELN groups com-
bined (OR, 0.5; 95% CI, .25–98; P = .03), providing genetic
clues about a possible factor of S. haematobium susceptibility
(Table 2). No signiﬁcant differences in haplotype distribution
were observed between the SEP group and the SELP group
(data not shown).
MBL Serum Levels and S. haematobium Infection
The serum MBL levels varied signiﬁcantly between the SEP and
SELP groups (P < .0001; Figure 2A). Also, the serumMBL levels
were signiﬁcantly higher in the SELP and SELN groups com-
bined, compared with the SEP group (P < .0001; Figure 2A). The
median MBL levels detected within groups were 27.6 ng/mL
Table 2. Distribution ofMBL2 Haplotypes in Cases and Controls
Haplotype
Haplotypes, No. (%), by Study Group(s) SEP vs SELN
SEP vs
(SELP + SELN)
SEP (n = 326) SELP (n = 238) SELN (n = 128) SELP + SELN (n = 366) OR (95% CI) Pa OR (95% CI) Pa
MBL2* LXPA 41 (12.6) 23 (9.7) 21 (16.4) 44 (12) . . . NS . . . NS
MBL2* LYQC 93 (28.5) 77 (32.3) 31 (24.2) 108 (29.5) . . . NS . . . NS
MBL2* LYQA 93 (28.5) 70 (29.4) 37 (28.9) 107 (29.3) . . . NS . . . NS
MBL2* HYPA 15 (4.6) 19 (8) 13 (10.2) 32 (8.7) 0.4 (.18–1) .048 0.5 (.25–.98) .03
MBL2* LYPA 84 (25.8) 49 (20.6) 26 (20.3) 75 (20.5) . . . NS . . . NS
Low expression ofMBL2*
LYQC+ LXPA 134 (41.1) 100 (42) 52 (40.6) 152 (41.5) . . . NS . . . NS
High expression ofMBL2*
HYPA+ LYQA+ LYPA 192 (58.9) 138 (58) 76 (59.4) 214 (58.5) . . . NS . . . NS
Percentages may not sum to 100%, because of rounding errors. Study groups were as follows: the SEP group (cases) was composed of individuals who tested
positive for Schistosoma eggs, the SELP group (controls) was composed of individuals who tested positive for Schistosoma antigens by enzyme-linked
immunosorbent assay (ELISA), and the SELN group (controls) was composed of individuals who tested negative for Schistosoma antigens by ELISA and negative
for Schistosoma eggs.
Abbreviations: CI, confidence interval; NS, not significant; OR, odds ratio.
a Adjusted by the Benjamini-Hochberg procedure.
Figure 1. Linkage disequilibrium pattern of MBL2 variants in individuals who tested positive for Schistosoma eggs (the SEP group [cases]; A), individu-
als who tested positive for Schistosoma antigens by enzyme-linked immunosorbent assay (ELISA; the SELP group [controls]; B), individuals who tested neg-
ative for Schistosoma antigens by ELISA and negative for Schistosoma eggs (the SELN group [controls]; C), and the SELP and SELN groups combined (D).
Empty squares indicate a high degree of linkage disequilibrium (D’ = 1). Numbers indicate the D’ value expressed as a percentile. The dense shading
indicates the r2 value. The haplotype block is outlined by a solid line.
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(range, 3.3–209 ng/mL) for the SEP group, 84.06 ng/mL (range,
6.13–13 122 ng/mL) for the SELP group, and 11.24 ng/mL
(range, 4.38–8936 ng/mL) for the SELN group. Similar results
from our recently published study demonstrated that higher
serum ﬁcolin-2 levels shield against schistosomiasis [39]. The
serum MBL level of the reconstructed MBL2*HYPA haplotype
for the SEP group was signiﬁcantly lower than that for the
SELP group alone (P < .0001) and the SELP and SELN groups
combined (P < .0001; Figure 2B). We observed a signiﬁcantly
different distribution of serum MBL levels both in the SEP
group and the SELP group among the investigated genotypes
that were associated with differential serum MBL levels
(Figure 3). In both observed distributions, the genotype YA/YA
(high MBL producers) had an increased MBL levels, compared
with the other genotypes in the studied population. No signiﬁ-
cant correlations were observed with the egg counts and serum
levels (data not shown).
DISCUSSION
To the best of our knowledge, this is the ﬁrst study that investi-
gated the role of MBL2 functional gene polymorphisms and
MBL serum levels in schistosomiasis susceptibility. In our
recent study, we demonstrated that FCN2 polymorphisms and
ﬁcolin-2 levels inﬂuence the outcome of schistosomiasis [39].
Similar to ﬁcolins, MBL is an innate immune recognition
protein that plays a vital role during the early phase of infection
and pathogen recognition. Additionally, our studies have
documented the involvement of MBL-activated complement in
the response to Schistosoma antigens in vitro [13]. Therefore, in
this study, we hypothesized that the sugar-rich surface of Schis-
tosoma organisms is a good target for MBL and that single-
locus substitutions in MBL2 resulting in variation in MBL
production would eventually affect the disease outcome. In this
study, we investigated the possible association of MBL serum
levels and MBL2 variants in a case-control study, using 2 inde-
pendent control groups. The classiﬁcation of the control group
is indispensable in Schistosoma-endemic areas, as it is difﬁcult to
differentiate individuals with and without a current infection.
MBL deﬁciency is associated with many diseases and protec-
tion against intracellular infections, such as tuberculosis,
leprosy, and leishmaniasis [27, 32, 37, 41]. In our study, we ob-
served that promoter genotypes (−550H/L) inﬂuence predis-
position to schistosomiasis. The heterozygous genotype
(−550HL) conferred protection against infection, whereas the
homozygous genotype (−550LL) contributed to increased sus-
ceptibility. The results remained consistent when egg-positive
patients (the SEP group) were compared to individuals in the
SELN group, with or without individuals in the SELP group.
The −550H minor allele in the studied population decreased
the risk of Schistosoma infection. Our results imply that indi-
viduals who are heterozygous at promoter position −550H/L
are less susceptible to infection. As observed in our study,
earlier studies have documented the inﬂuence of −550H/L vari-
ants on the risk of HIV infection and AIDS progression in
Italian children [34] and on prosthetic joint infection in Czech
Figure 2. A, Mannose-binding lectin (MBL) serum levels in individuals who tested positive for Schistosoma eggs (the SEP group [cases]), individuals
who tested positive for Schistosoma antigens by enzyme-linked immunosorbent assay (ELISA; the SELP group [controls]), individuals who tested negative
for Schistosoma antigens by ELISA and negative for Schistosoma eggs (the SELN group [controls]), and the SELP and SELN groups combined. B, MBL
serum levels in individuals with HYPA haplotype in cases and controls.
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patients [42]. However, another study, which investigated the
association of MBL2 variants with Bechet disease in a South
Korean population, demonstrated that the patients had lower
frequencies of the homozygous genotype (−550LL) [43]. This
variation emphasizes that the clinical signiﬁcance of the MBL2
variants may likely depend on the population and the disease
context. We also observed that a noncoding SNP located +4 bp
from the transcription start site (+4P/Q) was also observed to
inﬂuence the predisposition to schistosomiasis, as determined
by comparison of the SEP group to the SELN group. The indi-
viduals with major allele homozygous genotypes (+4PP) were
less susceptible to infection than those in the SELN group,
whereas the individuals with heterozygous genotypes (+4PQ)
had a higher risk of infection than those in the SELN group.
However, we did not observe signiﬁcant associations with
pooled values for the control groups.
In our studied population, we only observed theMBL2*C ge-
notype (codon 57). No signiﬁcant associations were observed
in the distribution of genotypes (MBL2*C independently and
with the combined promoter-220 + exon 1) that inﬂuences the
serum MBL levels. This observed MBL2*C genotype was docu-
mented to be the most frequent African MBL2 variant [31],
and studies have reported that theMBL2*C variant is associated
with placental malaria and malaria in African children [31, 44].
A heterozygous 6-bp deletion (wt/del) in the promoter region
was observed to confer increased risk to schistosomiasis in
comparisons between the SEP group and the SELN group.
These results are in accordance with those of another study,
which demonstrated that the 6-bp deletion at position −328
was correlated with HIV type 1 infection [34]. The reconstruc-
tion of haplotypes is important to revealing how different com-
binations of functional polymorphic alleles can interact to
modulate their individual effects. Moreover, many studies have
shown the effect of MBL2 haplotypes in disease association
studies [32, 35, 43]. Stratiﬁcation of our cohort on the basis of
MBL2 haplotype showed that the MBL2*HYPA haplotype was
signiﬁcantly lower in the case group than in controls, elucidat-
ing the fact that individuals with these haplotypes had a lower
risk of schistosomiasis. Similar results on the inﬂuence of
MBL2*HYPA haplotypes has been demonstrated in Bechet
disease, in pediatric patients with common infectious diseases,
and in patients with colon cancer [23, 43, 45].
Investigation of the MBL serum level further conﬁrms the
important role of MBL in schistosomiasis. MBL serum levels
Figure 3. Mannose-binding lectin (MBL) serum levels according to combined genotypes of the −221 promoter region and exon 1 of MBL2 in individuals
who tested positive for Schistosoma eggs (the SEP group) and individuals who tested positive for Schistosoma antigens by enzyme-linked immunosorbent
assay (the SELP group). Genotypes were divided into high MBL-producing genotypes (YA/YA), intermediate MBL-producing genotypes (YA/YO, XA/YA, and
XA/XA), and low MBL-producing genotypes (YO/YO and XA/YO).
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varied signiﬁcantly between cases and controls. A signiﬁcant
difference was found between the SEP group and both the
SELP group alone and the SELP and SELN groups combined.
MBL serum levels were signiﬁcantly higher in the control
groups, compared with the case group, showing that high levels
of MBL may have a protective role in reducing the susceptibility
to S. haematobium infection and adding further support the
view that MBL plays a role in ﬁrst-line defense against this
pathogen. The MBL2*HYPA haplotypes that contributed to a
decreased risk of schistosomiasis were also correlated signiﬁ-
cantly to MBL serum levels. The control groups (the SELP
group alone and the SELP and SELN groups combined) had
signiﬁcantly higher MBL serum levels, compared with the case
group. MBL2 polymorphisms related to higher MBL levels in
serum were associated with decreased susceptibility to respira-
tory tract infection in children [46] and to SARS coronavirus
infection, compared with controls [22]. The role of MBL as a
ﬁrst line of defense in infectious and noninfectious diseases has
been documented in many clinical settings. Comparable results
from our study were reported in individuals infected with the
intestinal protozoan parasite Cryptosporidium, in which MBL2
polymorphisms and haplotypes that were associated with deﬁ-
cient serum MBL levels increased the susceptibility to infection
[30]. On the contrary, MBL2 polymorphisms were also report-
ed to play a dual role in leprosy [32]: the wild-type haplotype
was shown to increase susceptibility to the disease per se, and
defective haplotypes were shown to confer protection against
lepromatous and borderline leprosy. Therefore, depending on
the type of disease, MBL deﬁciency may increase susceptibility
to intestinal parasite infections, as in cryptosporidium and
schistosomiasis, or may be protective against intracellular path-
ogens, such as Mycobacterium leprae [32]. In our study, a
normal MBL level was found to decrease the susceptibility to S.
haematobium infection.
In our earlier study, we observed that ﬁcolin-2 gene poly-
morphisms and ﬁcolin-2 serum level play an important role in
the susceptibility to S. haematobium infection [39]. Both MBL
and L-ﬁcolin have similar structural templates comprising col-
lagen-like and ligand binding domains that binds speciﬁcally
to pathogen-associated molecular patterns on the pathogen
surface. In association with the MBL-associated serine proteas-
es (MASP1 and MASP2), MBL and L-ﬁcolin initiate the com-
plement lectin cascade, leading to clearance of pathogens by
opsonization [47, 48]. A previous study showed that the surfac-
es of both S. mansoni cercariae and adult worms were recog-
nized speciﬁcally by the MBL-MASP complex, suggesting that
an interaction between MBL and the parasite results in activa-
tion of complement in vitro [13]. Lectin-binding studies of
Schistosoma organisms have revealed many different glycopro-
teins on the surface of the parasite, regardless of life cycle stage
and sex [38, 49], and it was shown MBL interacts with these
sugar residues on the parasite surface, triggering the host
immune response [13, 50]. We clearly observed in this study
that higher MBL levels and ﬁcolin-2 levels [39] were predictive
of protection from S. haematobium infection.
The study shows that there is still a high prevalence of S. hae-
matobium infection in Nigeria, with children bearing the
highest burden. Overall, we demonstrated that MBL2 variants
and serum MBL levels are associated with protection against S.
haematobium infection. This study, in line with our previous
study of ﬁcolins, may provide vital insights about the possible
role of MBL, a vital innate immune component of the comple-
ment system that regulates Schistosoma infection and may lay
the foundation for a testable immunological intervention to
control and contain the disease in human populations.
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Abstract
Background
Urinary Schistosomiasis is a neglected tropical disease endemic in many sub Saharan -Afri-
can countries. Collectin Kidney 1 (CL-K1, encoded by COLEC11 on chromosome 2p25.3),
a member of the vertebrate C-type lectin super family, has recently been identified as pat-
tern-recognition molecule (PRR) of the lectin complement pathway. CL-K1 is preferentially
expressed in the kidneys, but also in other organs and it is considered to play a role in host
defense to some infectious agents. Schistosome teguments are fucosylated and CL-K1
has, through its collagen-like domain, a high binding affinity to fucose.
Methodology/Principal Findings
We utilized a Nigerian study group consisting of 167 Schistosoma haematobium infected in-
dividuals and 186 matched healthy subjects, and investigated the contribution of CL-K1 de-
ficiency and of COLEC11 polymorphisms to infection phenotype. Higher CL-K1 serum
levels were associated with decreased risk of schistosome infection (Pcorr = 0.0004). CL-K1
serum levels were differentially distributed between the COLEC11 genotypes and haplo-
types observed. The non-synonymous variant p.R216H was associated with the occurrence
of schistosomiasis (OR = 0.44, 95%CI = 0.22–0.72, Pcorr = 0.0004). The reconstructed
COLEC11*TCCA haplotypes were associated with higher CL-K1 serum levels (P = 0.002)
and with decreased schistosomiasis (OR = 0.38, 95%CI = 0.23–0.63, Pcorr = 0.0001).
Conclusions
In agreement with findings from our earlier published study, our findings support the obser-
vation that CL-K1 and their functional variants may be host factors associated with protec-
tion in schistosomiasis and may be a useful marker for further investigations.
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Author Summary
Collectin Kidney 1 (CL-K1) was discovered in 2006. It is a pattern-recognition molecule
(PRR) of the lectin complement pathway and is mainly expressed in the kidneys. We in-
vestigated a possible functional role of CL-K1 during urinary schistosomiasis on the basis
of the rationale: i). Schistosome teguments are fucosylated and CL-K1 has high binding af-
finity to fucose ii). As CL-K1 is structurally similar to MBL, we hypothesize the involve-
ment of CL-K1 in immune modulation during urinary schistosomiasis. We investigated
the circulating CL-K1 serum levels in our study group. We initially screened the entire
promoter and the exons of the COLEC11 gene for population specific variants. We validat-
ed four promoter variants and one non-synonymous substitution in exon8 for possible as-
sociations with urinary schistosomiasis and circulating CL-K1 serum levels. The study was
conducted in Nigeria where the largest number of registered cases of schistosomiasis (29
million) for any sub-Saharan African country has been documented. Our findings support
the observation that CL-K1 and functional variants are host factors that may be associated
with protection in schistosomiasis and may be a useful marker for further investigations.
Introduction
Urogenital schistosomiasis, which is caused by infection with the trematode Schistosoma hae-
matobium, is a major public health problem in sub-Saharan Africa (SSA). Of the more than
200 million cases reported worldwide, 93% occur in SSA [1]. Up to two-thirds of S. haemato-
bium infections result in genital schistosomiasis [2]. The incidence of S. haematobium infec-
tions in SSA, however, is most likely underreported and might be much higher [3].
Schistosomiasis accounts for the loss of more than 70 million disability adjusted life years
(DALYs) [4,5]. A large proportion of infected individuals experience hematuria (70 million),
dysuria (32 million), bladder-wall pathology (18 million), and severe hydronephrosis (10 mil-
lion) [6]. Urinary schistosomiasis is endemic in Nigeria and approximately 25 million people
are currently infected, with an estimated 101 million at risk [7]. Schistosomiasis can also in-
crease the risk of urinary tract infections and bladder cancer [8–10]. Children and early adoles-
cents are at high risk of infection as their daily activities regularly include contact with water
infested with infectious cercariae [11]. Limited access to praziquantel treatment for schistoso-
miasis, repeated re-exposure, and rapid reinfections all contribute to the disease burden
[11,12].
Schistosomes are bisexual multicellular helminth parasites with six developmental stages in-
cluding, adult worms, eggs, miracidia, sporocysts, cercariae and schistosomulae [13]. Schisto-
somes have an outer syncytial cytoplasmic layer, the tegument [14]. Previous studies have
shown that the teguments consist of fucosylated carbohydrate epitopes (glycotopes) [15] and
glycoproteins [16] which are expressed at all developmental stages. These glycoconjugates act
as pathogen associated molecular patterns (PAMPs) that are recognized by pattern recognition
molecules (PRMs) such as the C-type lectins [17]. Earlier in vitro studies have demonstrated
successful complement-mediated tegument damage in the adult schistosomes [18]. We have
previously shown that the lectin proteins mannose binding lectin (MBL) and MBL-associated
serine protease 1 (MASP-1) and MASP-2 interact with schistosomal glycoconjugates, and sub-
sequently activate the lectin complement cascade [19].
Collectin kidney 1 (CL-K1 also known as Collectin 11), is a member of the group of C-type
lectins. The role of CL-K1 appears to be analogous to that of other C-type lectins [20]. To date,
many studies have concentrated on the complement proteins MBL [21–24] and ficolins [25–28]
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in disease. Far less is known about the mechanism of action of CL-K1. The human CL-K1 is en-
coded by COLEC11 (OMIM 612502) on chromosome 2 at position 2p25.3 [29]. CL-K1 is a cir-
culating serum protein and is expressed in many tissues. High mRNA expression is observed in
kidneys, liver and in the adrenal glands. Similar to MBL, CL-K1 has a collagen like domain and a
carbohydrate recognition domain (CRD) [20,30,31]. Six different genetic variants have been ob-
served in a homozygous state in individuals affected with the rare Carnevale, Mingarelli, Mal-
puech and Michels (also known as 3MC) syndrome [32]. Two affected individuals with the p.
Gly204Ser amino acid substitution in CRD of COLEC11 had undetectable amounts of CL-K1 in
their serum. Moreover, CL-K1 was shown to be a guidance cue for neural cell migration during
embryogenesis [32]. The COLEC11 variant rs10210631 is responsible for high IgE production in
children [33]. CL-K1 recognizes pathogens by interacting with parasites' glycoconjugates
[20,30]. A recent study has shown that CL-K1 can also deposit C4b upon binding with mannan
in the presence of MASP-2 [34]. In addition, interactions of CL-K1 with MASP-1/3 have been
well demonstrated [20,30].
We investigated the functional role of CL-K1 during urinary schistosomiasis on the basis of
the following rationale: i). Schistosome teguments are fucosylated and CL-K1 has a high bind-
ing affinity to fucose [35] ii). as CL-K1 is structurally similar to MBL, we hypothesized that
CL-K1 might be involved in immune modulation during urinary schistosomiasis. We therefore
investigated CL-K1 serum levels in a study group of Nigerian individuals of Yoruba ethnicity
as described in our previous studies [36,37]. Furthermore, we screened the entire COLEC11
gene for population specific functional variants. We then evaluated four promoter variants and
one non-synonymous substitution in COLEC11 exon8 for associations with urinary schistoso-
miasis and circulating CL-K1 serum levels.
Materials and Methods
Ethics statement
Informed oral consent in the local language was obtained from all participants; for those who
were children, informed consent was obtained from respective parents and/or guardians. The
consent was verbal because the study was conducted in rural communities where the level of
literacy was low. If the participants could not read or write, verbal consent was obtained after
explaining the purpose of the study to them. The consent was written in a note book and only
consenting individuals were recorded. The procedure was approved by the ethical committee
of the Ladoke Akintola University of Technology, Ogbomoso, Nigeria. Only those who provid-
ed their consent were recruited in the study. Ethical approval was also obtained from the ethical
committee of Ministry of Health, Abeokuta Ogun State, Nigeria.
Study design
Two villages known to be endemic for S. haematobium, Ilewo Orile (Abeokuta North) and Ore
(Osogbo), were chosen for the study. The communities lack sufficient clean water supply, safe
waste disposal and essential health centers. Members of the communities depend on rivers in
close proximity for their daily needs (collecting water, washing clothes, bathing). Fishing and
petty trading are the most common occupations. Based on responses to a questionnaire, over
93% of the participants had regular water contact (defined as at least four contacts to the in-
fected river in a week) for their daily needs. Most of the study participants had similar frequen-
cies of exposure with water infested with infectious cercariae. Epidemiological studies of
urinary schistosomiasis in Ogun state, Nigeria reported an infection rate of more than 80%
[38]. The current study is a cross-sectional study and individuals were recruited blindly irre-
spective of their infection status. Individuals from all age groups who gave their consent to
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participate in the study procedure were enrolled. Urine samples were collected from all individ-
uals and were microscopically examined. Based on the results of the microscopic examination,
the participants were divided into the case group positive for S. haematobium eggs in urine
(SEP) and the negative control group. The control group was further screened to determine
total anti-schistosoma IgG antibodies. Based on total IgG results, the control group was divided
into two subgroups. The first subgroup contained individuals positive for anti-Schistosoma
total IgG antibodies and negative for eggs in urine (SELP), and the second subgroup was nega-
tive for anti-Schistosoma total IgG antibodies and negative for eggs in urine (SELN). This clas-
sification is essential in endemic areas in order to differentiate individuals who were potentially
resistant from those with a previous or a current infection. Therefore, the detection of anti-
Schistosoma total IgG was employed as a marker of exposure.
Sample collection
Ten ml of urine were collected in a sterile container from all participants and the sample was
centrifuged at 5000 rpm for 5 minutes. The supernatant was discarded and the sediment was
transferred to a clean glass slide which was microscopically examined for the presence of S.
haematobium eggs. For negative individuals, urine samples were collected on three successive
days in order to confirm that they were true negatives. A Combur-Test reagent strip (Roche Di-
agnostics GmbHMannheim, Germany) was used according to the manufacturer's procedure
to estimate the degree of haematuria and proteinuria. About 5 ml of blood sample was collected
from all study participants for serological assays and subsequent DNA extraction. Those posi-
tive for urinary schistosomiasis were treated with a single dose of 40mg/kg praziquantel. Stool
samples were collected from all participants and processed using the Kato-Katz method in
order to exclude any individuals with S.mansoni infection.
Serological assays
Classification of the control group is essential in schistosoma endemic areas, as it is difficult to
differentiate individuals without a current infection (either individuals are less susceptible or not
been exposed to infection). Therefore detection of anti-schistosoma total IgG was employed as
diagnostic exposure marker. Serological assays were carried out to determine the level of anti-
Schistosoma total IgG antibodies in study participants’ sera by an in-house ELISA assay. In brief:
For each individual sample, eight wells were used. The Schistosoma mansoni adult antigen was
serially diluted from 0.02 to 2.5 μg per 200μl in carbonate buffer (NaHCO3 + Na2CO3 in water,
pH = 9.6) and were pre-coated in each well. Negative and positive control plasma samples, were
diluted 1:100 with milk buffer. 200μl of the test samples and controls were dispensed into the
wells and were incubated for one hour at room temperature. After incubation and subsequent
washing steps, each well was treated with 200μl of conjugate solution [goat anti-human IgG
bound to alkaline phosphatase, (Sigma-Aldrich, Munich, Germany)] at a concentration of
1:10,000 in 1%milk buffer and incubated for one hour at room temperature. After incubation
and subsequent washing steps (5x), 200μl of the substrate [pNPP: 4- Nitrophenyl phosphate di-
sodium salt hexahydrate (Sigma-Aldrich, Munich, Germany)] was added to each well and fur-
ther incubated for 15 minutes at room temperature. The optical density (OD) was measured at
405 nm. CL-K1 serum levels were determined in all study subjects in 1:5 diluted plasma by a
commercially available CL-K1 ELISA kit ELISA kit (EIAab Science, Taiwan) following the man-
ufacturer’s instruction. The lower detection limit of the assay was 7.8 ng/ml.
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COLEC11 genotyping
Genomic DNA was extracted from blood cells using the QIAamp DNAmini blood kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions. In a first step, the COLEC11
gene was screened by amplifying the promoter and the eight exons including intron-exon
boundaries in 65 healthy individuals. A total of nine genomic fragments of the entire COLEC11
promoter region, including the eight exons were amplified using 10 ng of genomic DNA. The
PCR mix consisted of 1x PCR buffer (20 mM Tris-HCl, pH 8.4; 50 mM KCl, 2 mMMgCl2),
0.125 mM of dNTPs, 2 μM of sequence-specific primer pairs and 1 U Taq DNA polymerase
(Qiagen, Hilden, Germany). A PTC-200 Thermal cycler (MJ Research, USA) was used. Primer
sequences and thermal cycling parameters for the nine PCR reactions are listed in the S1 Table.
Subsequently, PCR products were purified (Exo-SAP-IT; USB, Affymetrix, USA) and 1 μl of
the product was used as template for DNA-sequencing (BigDye terminator v.1.1 cycle sequenc-
ing kit, Applied Biosystems, USA) on an ABI 3130XL sequencer. Sequences were aligned with
the reference sequence of the COLEC11 gene (NCBI; NG_031954.1) using the CodonCode
Aligner 4.0 software (http://www.codoncode.com/) and confirmed visually from their
electropherograms.
Based on observed frequencies of 10% of COLEC11 variants and on variants with recog-
nized functional significance, the variants subjected to further investigation were selected. Four
promoter variants (−676T>C, −472T>C, −469C>G, −276C>T), and the non-synonymous
(ns) substitution p.R216H in exon8 were genotyped in the entire study group using the primer
pairs and PCR conditions as described in S2 Table.
Statistical analysis
Data were analyzed using the STATA software (STATA Corp., College Station, TX, USA) and
the level of significance was set to a p-value of<0.05. Kruskal Wallis rank sum tests following
Dunn’s multiple comparison post test were used to analyze the correlation of serum CL-K1 lev-
els with distinct COLEC11 variants using Graphpad Prism v6.0. Fisher’s exact test and logistic
regression analyses after adjustment for age and gender were performed to examine associa-
tions of CL-K1 variants with schistosomiasis. Correlation analyses were performed by non-
parametric Spearman´s rank coefficient tests as implemented in Graphpad Prism v.6.0. Geno-
type and haplotype frequencies were analyzed by gene counting and expectation-maximum
(EM) algorithms and the significance of deviation from Hardy-Weinberg equilibrium was test-
ed using the random-permutation procedure as implemented in the Arlequin v. 3.5.1.2 soft-
ware (http://lgb.unige.ch/arlequin). Linkage disequilibrium (LD) analysis was performed using
Haploview v. 3.2 (http://broadinstitute.org/haploview).
Results
Characteristics of the study groups
After parasitological and serological tests, our study group was divided into three groups. The
case group (SEP) was defined as being positive for Schistosoma haematobium eggs in urine
[(n = 167), 100(60%) children, 93(55%) males, 74(45%) females and the mean age 17.5 ±13.2].
The first control group is defined as negative for S. haematobium eggs in urine but positive for
anti-schistosoma total IgG antibodies (SELP) [(n = 119) 22(19%) children, 60(50%) males, 59
(50%) females and the mean age 34.3±19.1] and the second control group defined as negative
for S. haematobium egg in urine and also negative for anti-schistosoma total IgG antibodies
(SELN) [(n = 67), 33(49%) children, 41(61%) males, 26(39%) females and the mean age
20.4 ±17.1]. All of the study subjects belong to the Yoruba ethnicity of the Nigerian population.
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The epidemiological data for the case control groups were: Mean age (SEP = 17.5 [4–71],
SELP = 34[4–75], SELN = 20[4–71]) and hematuria (SEP = 90%, SELP = 2.4%, SELN = 0%),
respectively. The mean parasite count for individuals in the SEP group was 1595 (20–27000)
per 10 ml urine.
COLEC11 gene polymorphisms
A two step approach was followed to obtain population specific frequencies of COLEC11 vari-
ants in the investigated study group. First, the entire promoter region and the eight exons in-
cluding the intron-exon boundaries were screened in healthy controls (SELN n = 67). The
observed frequencies of variants was compared with available HapMap data (S2 Table). The
LD plot of observed variants in the entire COLEC11 gene is given in S1 Fig. In the second step,
all polymorphisms in the promoter region and the non-synonymous variant p.R216H in exon8
were chosen for further genotyping in the entire study group for investigation of genetic associ-
ations with infection phenotype.
COLEC11 gene polymorphisms and S. haematobium infection risk
The four gene variants in the promoter region, −676T>C, −472T>C, −469C>G, −276C>T,
and the non-synonymous substitution p.R216H in exon8 were genotyped. LDs of the five
COLEC11 variants in the case group and the two control subgroups are illustrated in Fig. 1.
The promoter variants rs1864480 (−676T/C) and rs4849953 (−472T/C) were observed to be in
strong LD in all groups. Genotype and allele frequencies in all groups were in Hardy-Weinberg
equilibrium, except for variant rs1864480 (−676T/C) in the egg positive (SEP) cases.
The non-synonymous COLEC11 variant rs7567833G/A (p.R216H) in exon8 was observed
more frequently among infected individuals (SEP) than egg and IgG-negative (SELN) healthy
controls. The COLEC11 homozygous genotype of the major allele rs7567833-GG was observed
significantly more often in the SEP group compared to SELN controls after adjusting for age and
gender (OR = 2.35, 95%CI = 1.26–4.37,Pcorr = 0.004), suggesting an association with increased
risk of infection. The COLEC11 homozygous genotype of the minor allele rs7567833-AA was
observed significantly less often in the SEP group than in the SELN group (OR = 0.2, 95%
CI = 0.08–0.90,Pcorr = 0.01), showing an association with decreased risk of urinary schistosomia-
sis. Similar effects were also observed in the allele distributions (allelic model: OR = 0.44, 95%
CI = 0.22–0.72, Pcorr = 0.0004; dominant model: OR = 0.42, 95%CI = 0.22–0.79, Pcorr = 0.0048;
and recessive model: OR = 0.2, 95%CI = 0.08–0.9, Pcorr = 0.01) (Table 1). The observations from
the different models indicate a significant contribution of the non-synonymous p.216H substi-
tution as a host genetic factor predisposing to schistosomiasis. Variant p.216H was not ob-
served in linkage with any other COLEC11 variant (Fig. 1). The other investigated COLEC11
variants −472T>C, −469C>G, −276C>T were not associated with urinary schistosomiasis.
The distribution of the reconstructed COLEC11 haplotypes including −472T>C,
−469C>G, −276C>T and +48912G>A are summarized in Table 2. Six haplotypes associated
with circulating levels of CL-K1 were observed. Among them, COLEC11TCCG,
COLEC11CCCG and COLEC11TCCA were observed at higher frequencies in the entire study
group. The COLEC11TCCG haplotype, representing all major alleles, was observed more fre-
quently in cases than in SELN controls (OR = 1.76, 95%CI = 1.15–2.70, Pcorr = 0.007).
COLEC11TCCA-p.R216H, was observed more frequently among SELN controls (SEP vs.
SELN: OR = 0.38, 95%CI = 0.23–0.63, Pcorr = 0.0001; SEP vs. SELP+SELN controls: OR = 0.66,
95%CI = 0.43–0.99, Pcorr = 0.04).
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Fig 1. Linkage disequilibrium (LD) pattern ofCOLEC11 variants in SEP cases group (A), in SELP control group (B), in SELN control group (C) and
in SELP+SELN combined control group (D).Open white squares indicate a high degree of LD (D’ = 1) between pairs of markers. Numbers indicate the D’
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CL-K1 serum levels and S. haematobium infection risk
Mean circulating CL-K1 serum levels among Nigerian individuals without schistosomiasis
were 246±155 ng/mL, largely similar to levels observed in Japanese (340±130 ng/mL), Danish
(284±*180 ng/mL) and American populations (265±177 ng/mL) [25, 26, 35]. The median cir-
culating CL-K1 serum levels in SEP, SELN and SELP+SELN were 161 ng/ml, 206 ng/ml and
175 ng/ml, respectively. Circulating CL-K1 serum levels were heterogeneously distributed
between our study subgroups (P = 0.0007) (SEP vs. SELN, P<0.001; SEP vs. SELP+SELN,
P>0.05) (Fig. 2).
Association of COLEC11 variants to circulating CL-K1 serum levels
Theminor allele of exon8 variant rs7567833A (p.R216H) was significantly associated with increased
CL-K1 serum levels (Fig. 3A and Fig. 3B). A gene dose-dependent effect on the distribution of
serum CL-K1 levels was observed. Individuals with the COLEC11TCCA haplotype had higher
CL-K1 serum levels in both control groups (SELN: P = 0.01 and SELP+SELN: P = 0.0004) (Fig. 4),
but such a trend was not observed in egg positive (SEP) individuals (S2 Fig). When only
COLEC11TCCA haplotypes were compared among the investigated groups, the SEP group had
lower CL-K1 serum levels than the groups (SELP, SELP+SELN) (P<0.0001) (Fig. 5). The COLEC11
haplotypes may further be classified as high expression (COLEC11CCCG + COLEC11TCCA) or
as low expression (COLEC11TCCG) haplotypes based on circulating serum CL-K1 levels observed
in the control subgroups (Table 2). The low secretor haplotype (COLEC11TCCG) was associated
value expressed as a percentile. The red square indicates pairs in strong LD with LOD scores 2; purple squares, D’ = 1 with LOD scores 1. The
haplotype block is outlined by a solid line.
doi:10.1371/journal.pntd.0003647.g001
Table 1. Distribution of COLEC11—rs7567833G/A (p.R216H) genotypes and allele(s).
Genotype SEPa n = 167
(%)
SELPb n = 119
(%)
SELNc n = 67
(%)
SELPb+SELNc n = 186
(%)
SEPa vs. SELNc OR
(95% CI)
p#value
Exon8 rs7567833 G/A (p.
R216H)
GG 114 (68.2) 81 (68) 32 (47.8) 113 (60.7) 2.35 (1.26–4.37) 0.004
GA 46 (27.5) 37 (31) 26 (38.8) 63 (33.9)
AA 7 (4.3) 1 (1) 9 (13.4) 10 (5.4) 0.2 (0.08–0.9) 0.01
Allele
G 274 (82) 199 (83.6) 90 (67.2) 289 (77.7) Reference
A 60 (18) 39 (16.4) 44 (32.8) 83 (22.3) 0.44 (0.27–0.72) 0.0008
Dominant
GG 114 (68.2) 81 (68) 32 (47.8) 113 (60.7) Reference
GA+AA 53(31.8) 38(32) 35(52.2) 73 (39.3) 0.42 (0.22–0.79) 0.004
Recessive
GG+GA 160 (95.7) 118 (99) 58 (86.4) 176 (94.6) Reference
AA 7 (4.3) 1 (1) 9 (13.4) 10 (5.4) 0.2 (0.08–0.9) 0.01
Note. CI, conﬁdence interval; OR, odds ratio.
Percentage may not add up to 100 due to rounding errors
# Adjusted P values for age and gender
a diagnosed with S. haematobium egg in urine [SEP]
b Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG [SELP]
c Negative for S. haematobium egg and anti-schistosoma total IgG [SELN]
doi:10.1371/journal.pntd.0003647.t001
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with S. haematobium infection (OR = 1.76, 95%CI = 1.15–2.70, Pcorr = 0.007) and the high secretor
haplotypes were associated with decreased risk of infection (OR = 0.52, 95%CI = 0.33–0.79, Pcorr =
0.002).
Discussion
Different immune strategies are employed by the host immune system to thwart an infection
and the innate immune system plays a critical role in the clearance of some pathogens. Immune
evasion from complement components is an important criterion for schistosomes to success-
fully establish an infection [14,39]. Lectin pathway proteins of the complement system are the
first components to recognize the pathogen. These proteins can initiate a complement attack
cascade independent of a specific antibody response [40]. Our previous studies have demon-
strated that lectin proteins Ficolin-2 [37] and MBL [36] are involved in S. haematobium
infections.
CL-K1 was first described in 2006 but relatively few studies only have looked at its role in in-
fectious diseases. This study investigated the association between serum CL-K1 level and func-
tional genetic variants in the COLEC11 gene in urinary schistosomiasis. Our study suggests
that a non-synonymous substitution p.R216H in the exon8 of COLEC11 contributes to suscep-
tibility to schistosomiasis. In particular, the major allele p.R216 increases the infection risk two-
fold compared to variant p.216H. Similar effects were also observed in different genetic models
for the contribution of the respective p.R216H genotypes. It has been hypothesized that the p.
R216H substitution increases the alpha helical propensity value that controls the protein stabil-
ity and protein folding properties [41]. The p.R216H substitution is located in the carbohydrate
recognition domain (CRD) of COLEC11, and therefore binding of the CRD with schistosome
elements may be impaired. In addition, this particular variant rs7567833G/A (p.R216H) was
reported to be under selective pressure [42] and was differentially distributed among a panel of
52 populations as described in HapMap and in the Human Genome Diversity Project–Centre
Table 2. Distribution of COLEC11 haplotypes in the investigated study groups
COLEC11* Haplotypes SEPa
(n = 334)
SELPb
(n = 238)
SELNc
(n = 134)
SELPb + SELNc
(n = 372)
SEPa vs SELNc OR (95%
CI)
p#
value
COLEC11*TCCG 184 (55) 142 (60) 55 (41) 197 (53) 1.76(1.15–2.70) 0.007
COLEC11*CCCG 83 (24.9) 45 (19) 33 (24.6) 78 (21) NS
COLEC11*TCCA 50 (15) 36 (15) 42 (31.4) 78 (21) 0.38(0.23–0.63) 0.0001
COLEC11*TGTG 7 (2) 12(5) 2 (1.5) 14 (3.5) NS
COLEC11*TGTA 6 (1.8) 0 (0) 0 (0) 0 (0) NS
COLEC11*CCCA 4 (1.3) 3(1) 2 (1.5) 5 (1.5) NS
Low Expression
COLEC11*TCCG 184 (55) 142 (60) 55 (41) 197 (53) 1.76(1.15–2.70) 0.007
High Expression
COLEC11*CCCG
+ COLEC11*TCCA
133 (39.8) 81 (34) 75 (56) 156 (42) 0.52(0.33–0.79) 0.002
Note. CI, conﬁdence interval; OR, odds ratio.
Percentage may not add up to 100 due to rounding errors
# Adjusted P values for age and gender
a diagnosed with S. haematobium egg in urine [SEP]
b Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG [SELP]
c Negative for S. haematobium egg and anti-schistosoma total IgG [SELN]
doi:10.1371/journal.pntd.0003647.t002
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d’Etude du Polymorphisme Humain (HGDP–CEPH) databases [43]. Also, the absence of LD
with other genetic variants in proximity indicates selection. None of the promoter polymor-
phisms contributed to schistosomiasis susceptibility. In addition, the regulatory polymor-
phisms in the promoter region does not appear to play a role in CL-K1 expression as reported
in another study [44].
Fig 2. Distribution of CL-K1 serum levels (median values) among the study groups (SEP: diagnosed with S. haematobium egg in urine; SELP:
Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG; SELN: Negative for S. haematobium egg and anti-
schistosoma total IgG). P = 0.007 illustrated in the figure is calculated by Kruskal-Wallis rank sum test. Study group comparison were calculated by Dunn’s
multiple comparison post test (SEP vs. SELN, P<0.001; SEP vs. SELP+SELN, P>0.05). Numbers in parentheses indicates absolute counts of sample size
in each group.
doi:10.1371/journal.pntd.0003647.g002
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Stratification of our study group based on reconstructed COLEC11 haplotypes revealed that
the frequency of the COLEC11TCCG haplotype was significantly more frequent in the infec-
tion group than in controls, suggesting that individuals with these haplotypes had a higher risk
of schistosomiasis. In addition, the COLEC11TCCA haplotype harboring the rs7567833-A
polymorphism occurred more frequently in healthy controls compared to the infection group,
suggesting that individuals with this haplotype were protected from S. haematobium infection.
Furthermore, when the SELP plus SELN controls were analyzed, significant differences were
observed with the same haplotype, supporting the suggestion that the COLEC11TCCA haplo-
type may help confer protection. The frequency of high CL-K1 expressing haplotypes was
higher in controls than in SEP cases.
This study demonstrates that CL-K1 serum levels were higher in the control group com-
pared with infected individuals, suggesting that high levels of CL-K1 might reduce the risk of S.
haematobium infection. Similar to MBL and ficolins, CL-K1 could recognize and bind to spe-
cific glycoproteins on the surface of the pathogens [7,13]. In line with our earlier studies on
Ficolin-2 [37] and MBL [36], we believe that CL-K1 serum levels may be down regulated dur-
ing S. haematobium infection. Recent investigations in patients with disseminated intravascular
coagulation (DIC) have shown that CL-K1 levels were significantly elevated [44]. The
COLEC11 rs7567833G/A (p.R216H) variant was observed to correlate with increased CL-K1
serum levels. In addition, the COLEC11TCCA haplotype with the allele p.216H was associated
with higher CL-K1 serum levels in healthy individuals. Inversely, COLEC11TCCG with allele
p.R216 was associated with lower CL-K1 serum levels. These results substantiate that the vari-
ant in exon8 is a host genetic factor that may help protect against schistosomiasis. When the in-
dividuals with COLEC11TCCA were analyzed for CL-K1 serum levels in the different patient
Fig 3. Distribution of CL-K1 serum levels (median values) with investigated rs7567833G/A (p.R216H) variant. (Left) SELN group (Right): SELP+SELN
group. P = 0.03 and P = 0.001 illustrated in the figures are calculated by Kruskal-Wallis rank sum test. Study group comparison were calculated by Dunn’s multiple
comparison post test (SELN-GG vs. SELN-AA, P<0.05; SELN-GA vs. SELN-AA, P>0.05); (SELN+SELP-GG vs. SELN+SELP-AA, P<0.01; SELN+SELP-GA vs.
SELN+SELP-AA, P<0.05). Numbers in parentheses indicates absolute counts of sample size in each group. (SEP: diagnosed with S. haematobium egg in urine;
SELP: Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG; SELN: Negative for S. haematobium egg and anti-schistosoma total
IgG).
doi:10.1371/journal.pntd.0003647.g003
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Fig 4. Distribution of CL-K1 serum levels (median values) with investigatedCOLEC11 haplotypes (Left)
SELN controls (Right): SELP+SELN combined controls. P = 0.03 and P = 0.0004 illustrated in the figures
are calculated by Kruskal-Wallis rank sum test. Study group comparison were calculated by Dunn’s multiple
comparison post test (COLEC11*TCCG-SELN vs.COLEC11*TCCA-SELN, P<0.05;COLEC11*CCCG-SELN
vs.COLEC11*TCCA-SELN, P>0.05;COLEC11*TCCG-SELN+SELP vs.COLEC11*TCCA-SELN+SELP,
P<0.001;COLEC11*TCCG-SELN+SELP vs.COLEC11*CCCG-SELN+SELP, P>0.05). Numbers in
parentheses indicate absolute counts of sample size in each group.SEP: diagnosed with S. haematobium egg
in urine;SELP: Negative for S. haematobium egg in urine but positive for anti-schistosoma total IgG;SELN:
Negative for S. haematobium egg and anti-schistosoma total IgG).
doi:10.1371/journal.pntd.0003647.g004
Fig 5. Distribution of CL-K1 serum levels (median values) with investigatedCOLEC11*TCCA haplotype
in all study groups. P<0.0001 illustrated in the figure is calculated by Kruskal-Wallis rank sum test. Study
group comparison were calculated by Dunn’s multiple comparison post test (COLEC11*TCCA-SEP vs.
COLEC11*TCCA-SELN, P<0.001;COLEC11*TCCA-SEP vs.COLEC11*TCCA-SELP+SELN, P<0.01).
Numbers in parentheses indicates absolute counts of sample size in each group.SEP: diagnosed with S.
haematobium egg in urine;SELP: Negative for S. haematobium egg in urine but positive for anti-schistosoma
total IgG; SELN: Negative for S. haematobium egg and anti-schistosoma total IgG.
doi:10.1371/journal.pntd.0003647.g005
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groups, SEP individuals had lower levels than egg negatives, indicating that CL-K1 serum levels
were modulated by infection.
CL-K1 has a collagen and a ligand binding domains, similar to MBL and ficolins. These
structural domains bind specifically to pathogen-associated molecular patterns (PAMPs) on
the surface of infectious agents [45]. We postulate that CL-K1, along with the MBL-associated
serine proteases MASP-1/3 and MASP-2 initiate the complement lectin cascade to reduce S.
haematobium infection. [20,30,34].
We have shown that allelic variants associated with increased CL-K1 levels may be a con-
tributing protective host factor in schistosomiasis caused by S. haematobium. Furthermore, the
variant in p.R216H in exon8 of the COLEC11 gene is a host genetic factor associated with uri-
nary schistosomiasis. Taken together, both COLEC11 variants and CL-K1 serum levels are as-
sociated with the phenotype occurring after S. haematobium infection.
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a b s t r a c t
Urogenital schistosomiasis caused by Schistosoma haematobium induces a Th2 immune response,
including expression of Interleukin-6. IL-6 confers protection from experimental Schistosoma-induced
pulmonary hypertension and modulates production of mannose-binding lectin (MBL) and other lectins.
We studied IL-6 levels in schistosomiasis and its effect on lectins production. Elevated IL-6 levels
occurred in cases, compared to controls. IL-6 correlated with the lectins MBL, ﬁcolin-2 and Collectin
Kidney-1 (CL-K1) in cases, but correlated inversely in controls. The study shows that IL-6 levels are ele-
vated in individuals infected with urogenital schistosomiasis. IL-6 was also found to be correlated with
the production of lectins in S. haematobium infection. A similar correlation between IL-6 and MBL was
observed during visceral leishmaniasis.
 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Schistosomiasis is a chronic parasitic disease due to infection
with different species of trematode worms of the genus
Schistosoma. Infection with Schistosoma haematobium is the main
cause of urogenital schistosomiasis. The clinical presentation
includes hematuria, hydronephrosis, anemia and predisposition
to HIV and other infections of the urogenital tract.
Schistosomiasis accounts for more than 70 million disability
adjusted life years (DALYs) lost and with more than 240 million
individuals currently infected it is the second most common devas-
tating parasitic disease after malaria in sub-Saharan Africa [1].
Schistosomes induce strong Th2 immune response during infec-
tion by down-regulation of the Th1 immune response through
increased production of Interleukin-6 (IL-6) [2]. IL-6 is an
immunoregulatory cytokine [3], secreted by T cells and macropha-
ges to stimulate non-speciﬁc immune responses, including fever -
and acute phase responses in parasitic diseases [4]. The larvae of
schistosomes are recognized by host macrophages, which induce
the secretion of IL-6 [5]. Subsequently, IL-6 stimulates the expres-
sion of acute phase proteins in the liver by binding to
IL-6-responsive elements of the promoter of respective genes [6].
IL6 has been found to be involved in protection against
Schistosoma-induced pulmonary hypertension in an animal model
[7].
Mannose-binding Lectin (MBL) is an acute-phase plasma pro-
tein (APP) with circulating serum levels increasing 1.5–3.0-fold
during distinct infections [8]. MBL is an initiation molecule of the
complement-lectin pathway and MBL deﬁciency is associated with
a variety of diseases [9]. In the course of many infectious diseases,
MBL modulates IL-6 production at the mRNA and protein level by
signaling to human peripheral blood mononuclear cells to suppress
the production of the pro-inﬂammatory cytokines IL-1a and IL-1b,
and enhances the secretion of anti-inﬂammatory cytokines, includ-
ing IL-6 [10]. Several type 1 and type 2 IL-6-responsive sequences
observed in the human MBL2 promoter region point to possible
interactions of IL-6 and MBL in the pathogenesis of many disease
[11].
We have previously shown that MBL, ﬁcolin-2 and CL-K1 deﬁ-
ciency constitutes a risk factor for urogenital schistosomiasis
[12–14]. Based on the rationale that IL-6 is involved in the patho-
genesis of schistosomiasis as well as in the induction of MBL [11],
we aimed to explore the role of IL-6 and its relation with MBL
http://dx.doi.org/10.1016/j.cyto.2015.04.019
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during S. haematobium infection. As ﬁcolin-2 and CL-K1 share sim-
ilarities in both their structure and function with MBL [15], we
studied the correlation of IL-6 in the expression of these proteins
during urogenital schistosomiasis. We also investigated the corre-
lation of IL-6 with lectins to visceral leishmaniasis (VL).
2. Materials and methods
2.1. Study design
The study included a total of 359 individuals from the two vil-
lages Ilewo Orile, Ogun State and Ore, Osun State, southwest
Nigeria. The area is highly endemic for S. haematobium infections.
The study was designed as a cross-sectional study with individuals
recruited blindly, irrespective of their infection status. Ten ml of
urine were collected and screened for schistosomal eggs using a ﬁl-
tration technique and subsequent microscopic examination. In
addition, ﬁve ml of whole venous blood were collected from all
individuals for the serological assessment of anti-Schistosoma total
IgG as an exposure marker using Schistosoma adult worm antigen.
For individuals negative for eggs of S. haematobium at the ﬁrst
examination, urine samples were collected on two successive days
to avoid biases in the ﬂuctuation of egg shedding. Based on results
of the microscopic examination of urine ﬁltrates and the
anti-Schistosoma total IgG antibodies tests, the study participants
were assigned to three groups. Individuals of the case group were
positive for S. haematobium eggs in urine [SEP; n = 167, 93 (56%)
males, 74 (44%) females (P = 0.048); age range 2–70 years, mean
egg count per 10 ml urine 1595 eggs (20-27000)]. Participants of
the control subgroup 1 were negative for S. haematobium eggs in
urine, but positive for anti-Schistosoma total IgG antibodies [SELP
n = 123, 61 (50%) males, 62 (50%) females (P = 1.0); age range
4–80 years]. The control group 2 consisted of individuals negative
for both S. haematobium eggs in urine and anti-Schistosoma total
IgG antibodies [SELN n = 69, 43 (62%) males, 26 (38%) females (P
= 0.006); age range 4–70]. Cases were treated with a single dose
of 40 mg/kg of praziquantel. Stool samples were collected from
all participants and processed using the Kato-Katz method in order
to exclude Schistosoma mansoni infections. Cases with other infec-
tions including HIV were excluded from the study. The Ethical
Committee of the Ministry of Health, Abeokuta Ogun State,
Nigeria approved the study design. Informed consent in the local
language Yoruba was obtained from all participants. For children,
consent was sought for from their parents and/or guardians.
2.2. Measurement of IL-6
IL-6 serum levels were measured in 1:4 diluted sera of urinary
schistosomiasis cases (n = 167) and controls (n = 192) using the
commercially available Human IL-6 High Sensitivity ELISA
(eBiosciences, San Diego, USA) following the manufacturer‘s
instructions. The detection limit of the assay was 0.08 pg/mL. We
used our previously reported serum level determination of MBL,
ﬁcolin-2 and CL-K1 [12–14] of the same samples. IL-6 levels were
assessed by calculating unknown values from standard curves
using the Michaelis–Menten model in the Graphpad Prism v.6.0d
software (www.graphpad.com).
2.3. Statistical analysis
Kruskal–Wallis rank sum tests were applied to analyze differ-
ences of serum IL-6 levels between the study subgroups.
Multivariate regression analysis was performed to adjust the con-
founding effects of age and gender in IL-6 serum levels (Intercooled
STATA, STATA Corp., College Station, TX, USA). The correlation
analyses of IL-6 were performed with MBL, ﬁcolin-2 and CL-K1
by non-parametric Spearman´s rank coefﬁcient tested as imple-
mented in Graphpad Prism v.6.0d.
3. Results
IL-6 serum levels among combined (SELP + SELN) controls var-
ied from 0.2 to 18.9 pg/ml with a median of 1.8 pg/mL. IL-6 serum
levels were signiﬁcantly elevated in S. haematobium egg-positive
(SEP) cases (mean 8.7 pg/ml) when compared to the both control
subgroups separated or merged. (SELP: mean 4.9 pg/ml, SELN:
mean 5.9 pg/ml, SELP + SELN: mean 5.3 pg/ml) (P < 0.0001;
Fig. 1A). The gender distribution was observed to be signiﬁcant,
with more male individuals in both SEP and SELN subgroups.
This was a cross sectional study and both male and female individ-
uals were recruited blind irrespective of their prior infection status,
hence this observation was likely. However, multivariate analysis
of gender and also age with IL-6 did not reveal any relevant contri-
bution of these confounders to circulating IL-6 serum levels. We
further correlated IL-6 serum levels with those of the previously
reported lectins (MBL, ﬁcolin-2, CL-K1) in both SEP cases and con-
trol subgroups. IL-6 serum levels were positively correlated with
MBL (Spearman’s rho coefﬁcient: q = 0.189, P = 0.01), ﬁcolin-2
(q = 0.192, P = 0.01) and CL-K1 (q = 0.292, P = 0.0002) in cases
(Fig. 1B). Notably, IL-6 was inversely correlated with MBL
(q = 0.239, P = 0.001) and ﬁcolin-2 (q = 0.239, P = 0.001) in the
pooled control subgroups (Fig. 1C). CL-K1 did not show any signif-
icant correlation with IL-6 in controls. We observed a similar cor-
relation when the control subgroups were analyzed separately
(data not shown).
In order to verify the association of IL-6 with lectins production
in other parasitic disease, we measured the IL-6 levels in the sera
from Indian VL cases (n = 58) and controls (n = 30) using the same
ELISA kit and correlated with lectins MBL, ﬁcolin-2 levels. Detailed
information on the study group and the study design is provided
elsewhere [16]. We observed that IL-6 levels were elevated in VL
cases (mean 7.07 pg/mL) compared to controls (mean 3.1 pg/mL)
(P = 0.003; Fig. 2A). In VL cases, the MBL levels were positively cor-
related with IL-6 (Spearman’s rho coefﬁcient: q = 0.3, P = 0.01;
Fig. 2B) while ﬁcolin-2 did not show any signiﬁcant correlation
with IL-6. No correlation was observed between IL-6 and lectins
in control subjects (Fig. 2C).
4. Discussion
The pathogenesis of urogenital schistosomiasis is complex [17].
Cytokines are released in response to infection and they are,
directly or indirectly, involved in many pathophysiological events
[18]. Here, we studied the role of IL-6 in urogenital schistosomiasis.
Our ﬁndings indicate that IL-6 serum levels were higher among S.
haematobium egg-positive individuals compared to the S. haemato-
bium sero-positive and sero-negative control subgroups. This is in
line with reports where IL-6 was observed to be elevated in both
natural and experimental Schistosoma infection [2,19,20]. IL-6
serum levels have previously been shown to be also elevated in
patients with bladder cancer associated with S. haematobium infec-
tion, correlating with advanced tumor grade and exhibiting an
independent functional role as a disease modiﬁer [21]. Our ﬁndings
emphasize the potential role of IL-6 in the pathogenesis of urogen-
ital schistosomiasis. Likewise, IL-6 levels were elevated in investi-
gated VL cases compared to controls suggesting the role of this
cytokine in VL pathogenesis [22].
In the present study we hypothesized that IL-6 might exert syn-
ergistic effects with MBL and other lectins during S. haematobium
infection [10]. We observed a positive correlation of the lectins
MBL, ﬁcolin-2 and CL-K1 with IL-6 in urogenital schistosomiasis.
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Similar observations of interaction of IL-6 and the C-reactive pro-
tein (CRP) were made in HIV patients with the immune reconstitu-
tion inﬂammatory syndrome (IRIS), where IL-6 and CRP levels were
positively correlated [23]. It is clear that MBL and other functional
analogues may be modulated by IL-6 stimuli. TNF-a, IL-1, and IL-6
essentially regulate the acute phase response proteins (APP),
including MBL, which responds to IL-6 and glucocorticoids [24]
by up-regulating the APP genes. However, in spite of the
up-regulation by IL-6 of APP genes, our observations indicate that
S. haematobium parasite factors contribute to lower circulating
serum levels of MBL, ﬁcolin-2 and CL-K1 by consumption of com-
plement [12–14,25,26]. Corresponding observations of MBL and
IL-6 have been described in meningococcal infection [27]. A similar
correlation between IL-6 and MBL was observed in VL while no
association between ﬁcolin-2 and IL-6 was observed. A larger sam-
ple size and functional studies may help to better understand the
contribution of IL-6 with other investigated lectins such as
ﬁcolin-2.
Schistosomiasis is a strong inducer of a Th2 immune response
with IL-6 expression. During the infection, IL-6 enhances IL-10
Fig. 1. (A) Distribution of IL-6 serum levels in individuals positive for Schistosoma haematobium eggs in urine (SEP cases), individuals negative for S. haematobium eggs in
urine, but total IgG positive (adult S. haematobium antigen; SELP control subgroup 1) and individuals negative for both S. haematobium eggs in urine and negative for anti-
Schistosoma antibodies (SELN control subgroup 2) along with the combined control subgroups. Box-plots illustrate medians with 25 and 75 percentiles with whiskers to 10
and 90 percentiles. P < 0.0001 illustrated in the ﬁgure is calculated by Kruskal–Wallis rank sum test. (B) Correlation analysis of IL-6 serum levels with MBL, ﬁcolin-2 and CL-K1
in cases, (C) combined control subgroups. For proper scaling ﬁcolin-2 serum values, these were divided by the factor of 10.
Fig. 2. Distribution of IL-6 serum levels in visceral leishmaniasis cases and healthy controls. Box-plots illustrate medians with 25 and 75 percentiles with whiskers to 10 and
90 percentiles. P = 0.003 illustrated in the ﬁgure is calculated by Wilcoxon–Mann–Whitney rank sum test. Numbers in parenthesis represent the number of samples (A).
Correlation analysis of IL-6 serum levels with MBL and ﬁcolin-2 in VL cases (B) and controls (C). For proper scaling ﬁcolin-2 serum values, these were divided by the factor of
10.
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production and inhibits IL-12 and IFN-c, thus directing immunity
towards a Th2 response through negative regulation of the type
1 response [2]. MBL serum levels were observed to be inversely
correlated with IL-6 and CRP levels in a cystic ﬁbrosis patient
who underwent partially successful MBL therapy [28]. In that case,
treatment with MBL could modulate the inﬂammatory reaction
regulated by IL-6. IL-6 was also observed to interact with mono-
cytes and platelets in killing of S. mansoni parasites.
Notably, we observed an inverse correlation of IL-6 with MBL
and ﬁcolin-2, but not with CL-K1 serum levels, both in seropositive
and seronegative controls. As healthy individuals are not exposed
to inﬂammatory stimuli, the negative correlation of IL-6 levels with
the lectins MBL and ﬁcolin-2 may be explained [29]. However, the
exact mechanism responsible for the inverse correlation of MBL
and ﬁcolin-2 with IL-6 and the absence of any correlation of IL-6
with CL-K1 in healthy individuals needs to be explored further.
5. Conclusion
This study aimed at exploring the role of IL-6 in urogenital
schistosomiasis caused by S. haematobium. We have shown that
IL-6 levels are elevated in infected individuals and that IL-6 levels
correlate with the production of lectins during the schistosomiasis.
We observed similar correlation of IL-6 with lectin MBL during VL.
These ﬁndings warrant further investigation of other Th2 speciﬁc
cytokines and their roles in schistosomiasis or other diseases in
general and the lectin pathway in particular.
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Abstract
Background
Visceral leishmaniasis (VL), one of the neglected tropical diseases, is endemic in the Indian
subcontinent. Ficolins are circulating serum proteins of the lectin complement system and
involved in innate immunity.
Methods
We have estimated ficolin-2 serum levels and analyzed the functional variants of the encod-
ing gene FCN2 in 218 cases of VL and in 225 controls from an endemic region of India.
Results
Elevated levels of serum ficolin-2 were observed in VL cases compared to the controls (ad-
justed P<0.0001). The genetic analysis revealed that the FCN2structural variant +6359
C>T (p.T236M) was associated with VL (OR=2.2, 95% CI=1.23-7.25, P=0.008) and with
high ficolin-2 serum levels. We also found that the FCN2*AAAC haplotype occurred more
frequently among healthy controls when compared to cases (OR=0.59, 95%CI=0.37-0.94,
P=0.023).
Conclusions
Our findings indicate that the FCN2 variant +6359C>T is associated with the occurrence of
VL and that ficolin-2 serum levels are elevated in Leishmania infections.
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Introduction
Visceral leishmaniasis (VL; Kala-Azar), a neglected tropical disease strongly associated with
poverty, claims 400.000 new cases and 40.000 deaths annually [1]. VL leads to a loss of about
2 million disability adjusted life years (DALYs) every year [2]. The vector-borne infection oc-
curs in the four distinct clinical manifestations as cutaneous leishmaniasis, muco-cutaneous
leishmaniasis, VL and post-kala-azar dermal leishmaniasis [3]. VL is the severest form and se-
verely affects visceral organs including the spleen, liver and lymph nodes [4]. Although trans-
mission of VL has been reported in 66 countries, more than 90% of the disease burden are
observed in six countries only, viz. Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil [3].
Among these countries, the Indian sub-continent (India, Nepal and Bangladesh) harbours 67%
of the global VL disease burden [5]. In particular, the Bihar state of India shares 50% of VL and
is considered a “hot spot” of VL [6]. Inadequate vector control practice and disease manage-
ment have been claimed to be responsible for the increased incidence of VL and associated
mortality in India [7].
Leishmania donovani is the causative agent of VL in India. The organism is transmitted to
mammalian hosts by infective bites of the sandfly Phlebotomus argentipes. L. donovani is a uni-
cellular trypanosomatid protozoan parasite with a dimorphic life cycle between the sandfly vec-
tor (extracellular promastigotes) and the human host (intracellular amastigotes) [8]. Both
developmental stages of L. donovani are coated with various secreted and membrane bound
phosphoglycans. During the promastigote stage, abundant lipohosphoglycan (LPG) and gp63
are expressed, which aid immune evasion of the parasite by inhibiting the phagolysosome bio-
genesis in phagocytes [9]. Further, these glycoconjugates facilitate the parasite´s survival in the
hostile macrophage environment [10]. However, LPG and gp36 may also serve as pathogen-as-
sociated molecular patterns (PAMPs) which are recognized by pattern recognition molecules
(PRMs) of the innate system such as complement serum proteins, mannose-binding lectin
(MBL), ficolins (FCN), other soluble C-type lectins and toll-like receptors [11]. Serum comple-
ment activating pattern recognition molecules act in a first-line innate defense against promas-
tigotes inoculated by the sandfly bite. Leishmania parasites have developed various evasion
strategies to avoid the lytic action of the complement system. The parasites use host comple-
ment proteins to escape the immune attack by entering into macrophages [12]. Mannose-
binding lectin (MBL), a circulating serum protein, recognizes the carbohydrate domain of L.
major, L.mexicana, and L. braziliensis. MBL binds to the surface of Leishmania promastigotes
to opsonize the parasites. Upon binding to parasites, MBL initiates the complement cascade
and provides an additional uptake mechanism of parasites by enhancing opsonophagocytosis
and protects them from the immune attack [13,14] and, thus, modulates the clinical outcome
of VL [15].
Ficolins are serum complement lectins that are structurally and functionally analogous to
MBL [16] and, hence, expected to modify the clinical outcome of VL due to their involvement
in innate immunity. Interestingly, a significant association of a distinct FCN2 haplotype with
cutaneous leishmaniasis has been reported from a Syrian population [17]. Ficolins are a group
of complement activating pattern recognition molecules consisting of a collagen-like tail region
and a fibrinogen-like domain (FBG) [18]. Three types of ficolins (Ficolin-1, -2, -3) of similar
structure exist in humans. These types have differential tissue expression patterns and func-
tions [19]. The role of ficolin-2, as an innate immunity component, has been studied in several
infectious diseases including Hepatitis B, schistosomiasis, Chagas disease and others [16,20–
22]. Ficolin-2 recognizes superficial acetylated compounds of invading pathogens by their FBG
domain and initiates the lectin complement cascade [23]. The FCN2 gene localizes to chromo-
some 9q34.3 (OMIM 601624) and hepatic cells predominantly express the corresponding
Ficolin-2 and FCN2 Variants and Visceral Leishmaniasis
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protein. The variants in the promoter region of FCN2 gene at positions -986A>G, -602G>A
and -4A>G have been observed to modulate the circulating ficolin-2 concentration in a dose-
dependent manner. The non-synonymous exon-8 variant alleles at positions +6359C>T and
+6424G>T were shown to exhibit differential binding affinities to acetylated compounds when
compared to the wildtype reference alleles [24]. Studies have shown that inter-individual varia-
tion of circulating ficolin-2 concentration are correlated with polymorphisms in the promoter
and exon-8 regions [25].
Although it has been showed that FCN2 gene polymorphisms and haplotypes are associated
with cutaneous leishmaniasis [17], no investigations of ficolins have so far focused on VL.
Moreover, we recently observed that functionalMBL2 polymorphisms and lower MBL levels
confer relative protection against VL (unpublished). As ficolin-2 shares similarities both in
structure and function with MBL [26], we aimed to explore the role of potentially important
FCN2 gene variants and circulating ficolin-2 levels in VL in our Indian study group. Three pro-
moter SNPs (-986A>G, -602G>A and -4A>G) and two structural SNPs in exon 8 (+-
6359C>T and +6424G>T) were genotyped and studied.
Materials and Methods
Ethics statement
Informed written consent was obtained either from the participating individual or from the pa-
rents/guardians if an individual was less than 18 years old. The study was approved by the In-
stitutional Ethical Committee (IEC) of the CSIR-Centre for Cellular and Molecular Biology
(CCMB), Hyderabad, India. Permission was also sought for and obtained from district
government hospitals.
Study design and sample collection
This is a case-control study matched for ethnicity, sex and geographical location. All cases and
controls were recruited through multiple field visits from villages located within a radius of
~120 km from the city of Muzaffarpur in the Bihar state of India. Previous epidemiological
studies of VL have indicated that the Bihar state is a hot spot for VL with an average annual in-
cidence of 2.49/1000 individuals [6]. The sample size was calculated prior to recruitment using
the Open Epi platform (http://www.openepi.com/) based on the incidence rate and the risk of
VL in the study area. A total of 443 unrelated subjects (218 cases and 225 healthy controls)
were recruited. The mean age of VL cases was 28.7±16.7 and 35.3±16.2 in healthy controls
(P = 0.001). No significant difference in the male/female ratio was observed in cases (125:95)
and controls (122:93). The cases were determined based on the clinical features of VL in medi-
cal records issued by government hospitals in the study region. Typical clinical features of the
cases included fever with rigors and chills and significant splenomegaly. Cases were tested with
the rk39 leishmanin antigen by nitrocellulose dipstick tests (InBios International, Seattle,
USA). The control subjects were free of any relevant infectious disease. Pregnant women, cases
with other infections, healthy controls with a family history of VL and relatives of cases were
excluded from the study. About 5.0 mls of full venous blood were collected from study subjects
for serological and genetic studies. The samples were immediately transported to the lab and
the serum samples were separated from whole blood and stored in the same type of tubes at
-20°C until further use.
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DNA isolation and FCN2 genotyping
Genomic DNA was extracted from peripheral blood leukocytes using the protocol described
previously [27]. The reference genomic sequence was retrieved from the Ensembl database
(www.ensembl.org). The five FCN2 variants studied were PCR amplified from two genomic re-
gions. The three promoter variants -986A>G, -602G>A and -4A>G were amplified by the
primer pairs PromF-5'-ATTGAAGGAAAATCCGATGGG-3' and PromR-5'-GAAGCCACC
AATCACGAAG-3', and the two exon-8 variants +6359 C>T and +6424 G>T were amplified
using the primer pairs Exon8F-5'-CCAGCTCCCATGTCTAAAGG-3' and Exon8R-5'-
TTACAAACCGTAGGGCCAAG-3'. Primers were designed by Primer-BLAST (http://www.
ncbi.nlm.nih.gov/tools/primer-blast) and synthesized commercially (Eurofins, Bangalore,
India). The target regions were amplified using an Emerald PCR master mix (TaKaRa, Shiga,
Japan) and reactions were carried out in the ABI GeneAmp PCR system 9700. The thermal cy-
cling parameters for both amplicons were: initial denaturation at 95°C for 5 minutes, followed
by 35 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 30 seconds and elonga-
tion at 72°C for 1 minute. PCR products were purified using Exo-SAP-IT (USB-Affymetrix,
Santa Clara, USA) and 1.0 μl of the products were directly used as templates for sequencing
using the BigDye terminator (v.3.1) cycle sequencing kit (Applied Biosystems, Texas, USA) on
an ABI 3730XL DNA Analyzer. Variations were identified by assembling DNA sequences with
the reference sequence using AutoAssembler software (Applied Biosystems, Texas, USA) and
were reconfirmed visually from their electropherograms.
Ficolin-2 serological assay
Ficolin-2 levels were measured in the sera of VL cases (n = 166) and healthy controls (n = 85)
using the human Ficolin-2 ELISA kit following manufacturer’s instructions (Hycult Biotech,
Uden, The Netherlands). The detection limit of the assay was 16 ng/mL.
Statistical analysis
Data were analyzed using the STATA software (Intercooled STATA, STATA Corp., College
Station, TX, USA) and the level of significance was set to a P value of<0.05. Genotype or hap-
lotype frequencies were calculated by simple gene counting and by expectation-maximum
(EM) algorithm and the deviations from Hardy-Weinberg equilibrium were tested using the
random-permutation procedure as implemented in the Arlequin v.3.5.1.2 software (http://lgb.
unige.ch/arlequin). The linkage disequilibrium (LD) analysis was performed using Haploview
v.3.2 (http://broadinstitute.org/haploview). Multivariate analysis was performed after adjust-
ment with the confounding factors such as age, ethnicity and gender using the STATA soft-
ware. In all comparisons, P values<0.05 were considered significant. Kruskal-Wallis or
Wilcoxon-Mann-Whitney rank sum tests were applied wherever appropriate to analyze the
correlation of serum ficolin-2 levels with FCN2 variants and haplotypes by using the Kaleida-
graph software (www.synergy.com).
Results
Association of FCN2 variants with the risk of VL
The genotype and allele frequencies for the variants -986G>A, -602A>G, -4A>G and +-
6359C>T) in VL cases and controls were in Hardy-Weinberg equilibrium (P>0.05). This did
not apply to the variant +6424G>T in VL cases. This variant was excluded from further analy-
ses. The LD patterns of the FCN2 variants are given in Fig 1. The LD plot indicates that the pro-
moter variants -986G>A, -4A>G and the exon 8 variant +6359C>T were in strong LD with
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each other both in cases and controls. The variant -602A>G was in LD with +6359C>T only
in controls. Significant differences were observed both in genotype and allele distributions be-
tween cases and controls for the non-synonymous variant +6359C>T (p.Thr236Met). The ho-
mozygous genotype +6359TT occurred more frequently among VL cases compared to controls
after adjusting for age, sex and ethnicity (OR = 2.2, 95%CI = 1.23–7.25, P = 0.008), indicating
that this variant was associated with an increased risk for L. donovani infection (Table 1). We
observed a similar effect of the +6359T variant, when different genetic models are employed
[Allelic: OR = 1.4, 95%CI = 1.02–1.94, P = 0.03; Recessive: OR = 2.2, 95%CI = 1.23–7.25,
P = 0.008] (Table 1). The different genetic models indicate that the +6359Tminor allele in-
creases the susceptibility of L. donovani infection. The other investigated FCN2 variants were
not significantly associated with VL.
The distribution of reconstructed FCN2 haplotypes including variants -986G>A,
-602A>G, -4A>G and +6359C>T are summarized in Table 2. Fifteen secretor haplotypes
were observed. The four haplotypes FCN2GGAC, AGGT, AAAC and GGAT occurred at
frequencies >10%. The reconstructed haplotype FCN2AAAC was found more frequently in
healthy controls compared to VL cases (OR = 0.59, 95%CI = 0.37–0.94, P = 0.023).
Fig 1. Linkage disequilibrium (LD) pattern of SNPs studied. (A): LD pattern of FCN2 variants in visceral leishmaniasis cases and (B): LD pattern of FCN2
variants in healthy controls. Numbers indicate the D’ value expressed as percentile. Open squares indicate the high degree of LD (LD coefficient D’ = 1)
between pairs of variants. The red squares indicate pairs in strong LD with LOD scores.
doi:10.1371/journal.pone.0125940.g001
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Ficolin-2 serum levels and risk of VL
Ficolin-2 serum levels were significantly higher in VL cases (mean 2.77 μg/ml) compared to
healthy controls (mean 1.94 μg/ml) (adjusted P<0.0001 for age, sex and ethnicity; Fig 2). Fico-
lin-2 levels are significantly distributed across different +6359 genotypes in controls (P = 0.03;
Fig 3). Serum ficolin-2 levels in cases with the reconstructed FCN2AAAC haplotypes were sig-
nificantly higher than those measured in individuals of the control group (P = 0.01; Fig 4).
Table 1. Distribution of FCN2 genotypes and alleles among visceral leishmaniasis cases and healthy controls.
rs17549193 (+6359C>T) (p.T236M) VL Cases n = 204 (%) Controls n = 223 (%) OR (95% CI) P# value
Genotype
CC 110 (53.9) 134 (60.1) 1 Reference
CT 72 (35.2) 80 (35.8) NA NS
TT 22 (10.7) 9 (4.1) 2.2 (1.23–7.25) 0.008
Allele
C 292 (71.5) 348 (78) 1 Reference
T 116 (28.5) 98 (22) 1.4 (1.02–1.94) 0.03
Dominant
CC 110 (53.9) 134 (60.1) 1 Reference
CT+TT 94 (46.1) 89 (39.9) NA NS
Recessive
CC+CT 182 (89.3) 214 (95.9) 1 Reference
TT 22 (10.7) 9 (4.1) 2.2 (1.23–7.25) 0.008
Note: CI, conﬁdence interval; OR, odds ratio; NS, not signiﬁcant; NA, not applicable. Percentage may not add up to 100 due to rounding errors
# Adjusted P values for age, gender and ethnicity
doi:10.1371/journal.pone.0125940.t001
Table 2. Association of functional FCN2 haplotypes and visceral leishmaniasis.
FCN2 Haplotypes (-986/-602/ -4/+6359) VL Cases n = 408(%) Controls n = 446(%) OR (95% CI) P# value
GGAC 225 (55.1) 236 (52.9) NA NS
AGGT 54 (13.2) 53 (11.8) NA NS
AAAC 36 (8.8) 62 (13.9) 0.59 (0.37–0.94) 0.023
GGAT 24 (5.8) 20 (4.4) NA NS
AAAT 16 (3.9) 12 (2.6) NA NS
AGAC 14 (3.4) 24 (5.3) NA NS
AGGC 9 (2.2) 13 (2.9) NA NS
AAGT 8 (1.9) 0 NA NA
AGAT 8 (1.9) 0 NA NA
GAAC 7 (1.7) 10 (2.2) NA NS
GGGT 4 (0.9) 12 (2.6) NA NA
GAAT 2 (0.5) 0 NA NA
AAGC 1 (0.2) 0 NA NA
GGGC 0 3 (0.6) NA NA
GAGT 0 1 (0.2) NA NA
Note: CI, conﬁdence interval; OR, odds ratio; NS, not signiﬁcant; NA, not applicable. Percentage may not add up to 100 due to rounding errors
#Adjusted P values for age, gender and ethnicity
doi:10.1371/journal.pone.0125940.t002
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Discussion
Visceral leishmaniasis develops when L. donovani parasites are successfully inoculated and sur-
vive the first-line attack of innate immune components such as phagocytes and the comple-
ment system. Indeed, these innate immune components play a major role both in the control
and establishment of L. donovani infections [28]. Complement components including lectins
are the primary molecules of the innate immune system to encounter inoculated metacyclic
promastigotes. The early activation of the complement system during pathogen invasion oc-
curs predominantly by the lectin pathway, as it is independent of a specific antibody response.
Moreover, it prompts the activation of the alternative pathway [29]. The lectin pathway protein
MBL induces opsonophagocytosis by depositing C3b on the surface of Leishmania which is
crucial for parasite survival and multiplication [13,14]. We assume that, as ficolins are func-
tionally similar to MBL, they equally influence the outcome of VL. No study so far, however,
Fig 2. Distribution of ficolin-2 serum levels in visceral leishmaniasis cases and healthy controls. Box-plots illustrate medians with 25 and 75
percentiles with whiskers to 10 and 90 percentiles. *P values were calculated by multivariate analysis adjusted for age, gender and ethnicity. Numbers in
parenthesis represent the number of samples.
doi:10.1371/journal.pone.0125940.g002
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has focused on the role of ficolin-2 in VL. We studied the contribution of ficolin-2 serum levels
and of FCN2 functional variants in VL.
The structural variant +6359C>T (p.T236M) in the fibrinogen-like domain of the FCN2
gene confers relative susceptibility to VL. The finding remains consistent in recessive and allelic
genetic models. The computational prediction revealed that the T236M substitution has a
major impact on the physiochemical property of ficolin-2 [30]. In addition, the +6359T allele
was found associated with higher ficolin-2 serum levels [31] and the observation was recon-
firmed in a cohort of neonates [32]. We also observed a similar effect of the +6359T allele in
controls, but not in cases. Our results inferred that ficolin-2 serum levels were modulated sig-
nificantly by the infection in VL cases rather than by FCN2 variants. Moreover, the ficolin-2
protein with T236M substitution had a markedly decreased binding capacity to acetylated aga-
rose beads. Therefore, this structural variant is believed to alter the binding properties of the
protein to recognize invading pathogens [24,33,34]. These reports indicate that individuals
with higher ficolin-2 serum levels and altered binding capacities might favor L. donovani
Fig 3. Distribution of ficolin-2 serum levels with +6359C>T variant in controls. Box-plots illustrate medians with 25 and 75 percentiles with whiskers to
10 and 90 percentiles. Ficolin-2 serum levels were measured and separated based on different genotypes of FCN2 variant +6359C>T. P = 0.03 illustrated in
the figure is calculated by Kruskal-Wallis rank sum test.
doi:10.1371/journal.pone.0125940.g003
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invasion into macrophages and the development of VL. Previous studies have also reported
that +6359C>T in the FCN2 gene is a risk factor for staphylococcal peritonitis in continuous
ambulatory peritoneal dialysis cases [35] and for bloodstream infections in kidney transplant
recipients [36].
In FCN2 gene-association studies, haplotype analyses should be taken into account as they
may influence disease susceptibility [37]. Our FCN2 haplotypes revealed that the FCN2AAAC
haplotype frequency was higher among controls than in VL cases, indicating that individuals
with this haplotype had a diminished probability to develop VL. The FCN2AAAC haplotype
harbors the +6359Cmajor allele, which accounts for reduced ficolin-2 levels [31,32]. In light of
Fig 4. Distribution of ficolin-2 serum levels with FCN2*AAAC in VL cases and control. Box-plots illustrate medians with 25 and 75 percentiles with
whiskers to 10 and 90 percentiles. P = 0.01 illustrated in the figure is calculated byWilcoxon-Mann-Whitney rank sum test.
doi:10.1371/journal.pone.0125940.g004
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these observations, it is evident that the FCN2 genetic factors that contribute to low ficolin-2
level decrease the risk of VL. FCN2 promoter haplotypes did not show any differences among
groups, suggesting the relative contribution of the +6359C>T genotype in Indian VL.
Ficolin-2 serum levels were elevated in VL cases compared to controls, indicating that fico-
lin-2 is a susceptibility factor. The result is in accordance with a study published previously
[15]. Corresponding results were also observed in infections withMycobacterium spp., where
higher MBL serum levels increased the risk of infection [38–40]. The proposed mechanism
may be that intracellular parasites abuse C3 opsonization and enhance opsonaophagocytosis
by monocytes/macrophages to avoid complement attacks. Any increase in the MBL and ficolin
levels in turn may enhance complement activation and, thus, the probability of parasitization
by depositing C3b on parasite surfaces [41]. Our observation supports this notion as cases with
VL had higher ficolin-2 levels than uninfected controls. Nevertheless, discordant results were
reported for ficolin-2 in tuberculosis and Chagas disease, where cases presented lower ficolin-2
plasma levels than did controls [22,42]. No clear mechanism is proposed to address the conflic-
tive observations of functionally similar proteins in intracellular habitant infections. In addi-
tion, the recognition and interaction of mannose binding lectin (MBL) with Leishmania
parasites are well established [13,14] and ficolins were shown to be functional analogous to
MBL [16]. However, a limitation of our study is that there is a lack of data showing the interac-
tion of ficolin-2 with L. donovani. Nevertheless, our earlier study demonstrated the genetic as-
sociation of FCN2 polymorphism with cutaneous leishmaniasis in Syrian population [17].
In conclusion, our results show that the FCN2 +6359C>T variant is associated with in-
creased susceptibility to VL and that the FCN2AAAC haplotype is associated with relative pro-
tection. Higher serum ficolin-2 levels were observed in cases with VL than among controls.
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Low MBL-associated serine protease 2 (MASP-2) levels
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Abstract objectives The human mannose-binding lectin (MBL) and ficolins (FCN) are involved in pathogen
recognition in the first line of defence. They support activation of the complement lectin cascade in
the presence of MBL-associated serine protease 2 (MASP-2), a protein that cleaves the C4 and C2
complement components. Recent studies found that distinct MBL2 and FCN2 promoter variants and
their corresponding serum levels are associated with relative protection from urogenital
schistosomiasis.
methods We investigated the contribution of MASP-2 levels andMASP2 polymorphisms in a Nigerian
study group, of 163 individuals infected with Schistosoma haematobium and 183 healthy subjects.
results MASP-2 serum levels varied between younger children (≤12 years) and older children
(>12 years) and adults (P = 0.0001). Younger children with a patent infection had significantly lower
MASP-2 serum levels than uninfected children (P = 0.0074). Older children and adults (>12 years)
with a current infection had higher serum MASP-2 levels than controls (P = 0.032). MBL serum
levels correlated positively with MASP-2 serum levels (P = 0.01). MASP2 secretor haplotypes were
associated with MASP-2 serum levels in healthy subjects. The heterozygous MASP2 p.P126L variant
was associated with reduced serum MASP-2 levels (P = 0.01).
conclusions The findings indicate that higher MASP-2 serum levels are associated with relative
protection from urogenital schistosomiasis in Nigerian children.
keywords MASP-2, MBL, complement, genotypes, haplotypes, Schistosomiasis
Introduction
Schistosomiasis is caused by several trematode species of
the genus Schistosoma and is one of the major neglected
tropical diseases targeted for elimination by WHO [1].
Schistosomiasis is a considerable public health problem in
sub-Saharan Africa, and Nigeria shares 14% of the global
schistosomiasis burden [2]. The most widely distributed
species in many parts of Nigeria is S. haematobium. The
parasite causes immense morbidity as assessed by disabil-
ity-adjusted life-years. An enormous prevalence of schis-
tosomiasis occurs among school children who are
frequently in contact with water infested by the infectious
form of schistosoma, the cercariae [1, 3]. The disease
may lead to severe pathological conditions such as hae-
maturia, hydronephrosis and bladder cancer [1, 4]. The
limited availability of praziquantel [5], the drug of choice
in schistosomiasis treatment, rapid and frequent reinfec-
tions and failure of the immune system to clear infections
adds to the schistosomiasis burden [6].
Schistosomes are multicellular helminth parasites bear-
ing an outer syncytial cytoplasmic layer, the tegument
[7]. Schistosomal teguments consist of fucosylated carbo-
hydrate epitopes [8] and glycoproteins [9] which are
expressed at all developmental stages. These glycoconju-
gates serve as pathogen-associated molecular patterns
(PAMPs) in immune recognition and subsequent comple-
ment-mediated lysis [10, 11]. Previous in vitro studies
have shown that mannose-binding lectin (MBL) binds to
the sugar moieties of S. mansoni cercariae and adult
worms together with the MBL-associated serine protease
1 (MASP-1) and MASP-2 and subsequently activates the
complement cascade [12].
†Contributed equally to the work.
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MBL and ficolins (ficolin-1, ficolin-2 and ficolin-3) are
pattern recognition molecules (PRMs). Variants of the
genes encoding these molecules are associated with several
infectious diseases [13–17]. The PRMs bind to the surface
glycoconjugates and form a complex with MASPs (MASP-
1, MASP-2 and MASP-3) to proteolytically cleave the cir-
culating complement components C4 and C2 to form C3
convertase (C4b2a) [18]. The C3 convertase subsequently
activates the lectin complement cascade, which eventually
results in the membrane attack complex and lysis of the
pathogen [19]. Currently, the precise role of MASP-3 in the
lectin complement pathway is not well established [20].
However, MASP-1 and MASP2 have been proven to be
functional in the cleavage of C4 and C2. MASP-2 is there-
fore a vital protein in the lectin complement cascade [21].
The gene-encoding MASP-2 (MASP2) is located on
chromosome 1p31.23-31 (OMIM: 605102) and com-
prises 12 exons. MASP-2 is composed of six domains
including C1r/C1s, Uegf and bone morphogenetic protein
1 domain (CUB1), epidermal growth factor, CUB2, con-
tiguous complement control proteins 1 and 2 and a serine
protease domain [22]. It was shown that single nucleotide
polymorphisms (SNPs) of MASP2 are associated with cir-
culating MASP-2 serum levels [23, 24]. The non-synony-
mous variant of MASP2 (rs72550870; p.D120G) located
in the CUB1 domain prevents formation of the ficolin/
MASP-2 complex, causing the complement cascade to
fail. In addition, the non-synonymous MASP2 substitu-
tions p.P126L (rs56392418) and p.R99Q (rs61735600)
in the CUB1 domain were reported to be associated with
altered MASP-2 levels [25]. Ten MASP2 haplotypes have
so far been identified and shown to modulate circulating
MASP-2 levels. The nomenclature of the haplotypes
accounts for the variable capability of MASP-2 secretion,
classifying them as high secretor (MASP-2*1A, *1B1-h,
*1B2-h), intermediate secretor (MASP-2*2B1-i, *2B2A-i)
and low MASP-2 secretor haplotypes (MASP-2*1C1-l,
*1C2-l,*2A1,*2A2-l and *2B2B-l) [23].
The functional role of MASP2 variants and/or MASP-2
levels has been addressed in a few disease association
studies only, namely in Chagas disease, leprosy, placental
malaria, rheumatic fever and hepatitis C virus infection
[26–30]. Recent studies have indicated that distinct
MBL2 and FCN2 promoter variants and their corre-
sponding serum levels are associated with relative protec-
tion from urogenital schistosomiasis [31, 32]. MASP-2 is
a protein that occurs downstream lectin complement
pathway and the generation of C3 convertase, and it is
crucial for the complement lectin cascade. Therefore, we
investigated circulating MASP-2 serum levels and previ-
ously reported MASP2 genetic variants in the promoter
region (1), exon 3 (3), intron 9 (1), exon 10 (2) and exon
11 (2) for associations with clinically patent urogenital
schistosomiasis [26, 27, 33].
Materials and methods
Study design and sample collection
We recruited 346 individuals, irrespective of their infec-
tion status from two communities of south-west Nigeria
where S. haematobium infection is endemic (Ilewo Orile,
Abeokuta North and Ore, Osogbo). All participants were
of Yoruba ethnicity. About ten mL of urine was collected
from all participants for microscopic examination of
S. haematobium eggs. In brief, urine samples were centri-
fuged and the sediment was examined microscopically for
the presence of S. haematobium eggs. For negative indi-
viduals, urine samples were collected on three successive
days to ensure negativity. A Combur-Test reagent strip
(Roche Diagnostics, Mannheim, Germany) was used to
estimate the haematuria and proteinuria. About 5 mL of
full venous blood was collected from all study partici-
pants for DNA extraction and serological assays. Persons
positive for urogenital schistosomiasis were treated with
a single dose of 40 mg/kg praziquantel. Stool samples
were collected from all participants and processed using
the Kato-Katz method to exclude S. mansoni infection.
Detailed information on the study group and the study
design is provided elsewhere [31, 32].
After parasitological and serological testing (anti-Schis-
tosoma total IgG antibodies as marker of exposure), the
study group was divided into three groups. The case group,
defined as positive for S. haematobium eggs in urine
(Schistosoma egg positive (SEP); n = 163), consisted of 99
(61%) children, 90 (55%) of them males and 73 (45%)
females. The mean age was 17 (12.4), and 90% of them
had haematuria. The first control group was defined as
being negative for S. haematobium eggs in urine, but posi-
tive for Schistosoma total IgG antibodies (Schistosoma
ELISA positive (SELP); n = 118). Of these, 58 (50%) were
males and 60 (50%) were females; 23 (19%) were children
under 12. The mean age in this group was 34.3 (19.1).
The second control group was defined as being negative
for S. haematobium eggs in urine and negative for anti-
Schistosoma total IgG antibodies (Schistosoma ELISA neg-
ative, (SELN); n = 65). A total of 31 (48%) individuals
were children, 40 (62%) were males and 25 (38%) were
females; the mean age was 20.2 (17.2).
Serological assays
Serological assays applying an in-house ELISA system
[34] were carried out to detect total anti-Schistosoma IgG
1312 © 2015 John Wiley & Sons Ltd
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antibodies. The technique has been described previously
in detail [32]. MASP-2 serum levels were measured in all
study subjects using the commercially available human
MASP-2 ELISA kit (Hycult Biotech, Uden, the Nether-
lands) following the manufacturer’s instructions. The
lower detection limit of the assay was 1.6 ng/ml.
MASP2 genotyping
Genomic DNA was extracted from peripheral blood cells
using the QIAamp DNA mini blood kit (Qiagen, Hilden,
Germany). The fragment containing nine studiedMASP2
variants was PCR-amplified from three genomic regions.
The promoter and exon 3 were amplified by primer pairs
PromF: 50-TGAAGCCGGGGCAACAGAACA-30 and
Exon3R: 50-ACAGAGTTACCCCCACAGCCAG-30, while
intron 9 and exon 10 were amplified by primers Int9F: 50-
TGTTAGCCAGGATGGTCTCC-30 and Exon10R: 50-
GGGGGCTCAAGTTCCAAGTA-30 and the exon 12 was
amplified by primers Exon12F: 50-TCAGGTGTTT-
GAACTGTGATGTT-30 and Exon12R: 50-
GGCAGACAAATAGGCGTGAT-30. In brief, 10 ng of
genomic DNA was amplified in a 20 ll volume of reaction
mixture containing 1x PCR buffer (20 mM Tris-HCl pH
8.4, 50 mM KCl, 1.5 mM of MgCl2), 0.125 mM of dNTPs,
0.25 mM of each primer and 1U Taq DNA polymerase
(Qiagen, Hilden, Germany) on a PTC-200 Thermal cycler
(MJ Research, Waltham, USA). Thermal cycling parame-
ters for amplification of all fragments were as follows: ini-
tial denaturation at 94 °C for 5 min, followed by 35 cycles
of 45 sec at 94 °C denaturation, 45 s annealing at 68 °C
for the promoter and exon 3, 66 °C for the intron 9 and
exon 10 and 61.5 °C for the exon 12. Extension was
1 min 30 s at 72 °C, followed by a final extension step of
2 min at 72 °C. Subsequently, PCR products were purified
using Exo-SAP-IT (USB Affymetrix, Santa Clara, USA),
and 1 ll of the purified product was directly used as tem-
plate for sequencing (BigDye terminator v. 1.1 cycle
sequencing kit; Applied Biosystems, Foster City, CA, USA)
on an ABI 3130XL DNA sequencer. For amplicons gener-
ated from the promoter and exon 3 regions, internal prim-
ers were used for sequencing. The internal reverse primer
50-CTACGCTGGTCTCACCTTTGAT-30 was used for the
-154C>A (rs7548659) variant and an additional internal
exon 1 forward primer 50-CGCCTCTACTTCACC-
CACTTCG-30 was used for sequencing variants in the co-
dons p.R99Q, p.D120G and p.P126L. Polymorphisms
were identified by assembling the sequences with respective
reference sequences of theMASP2 gene (NG_007289.1)
using Codoncode Aligner 4.0 software (http://www.codon-
code.com/) and were reconfirmed visually from their
electropherograms.
Statistical analysis
Data were analysed using the STATA software (Inter-
cooled STATA; STATA Corp., College Station, TX,
USA), and the level of significance was set to a P-value of
<0.05. Two-sided Fisher exact tests were computed to
determine the distribution of the genotypes and alleles
between cases and control groups. Bonferroni corrections
applied. Multivariate analysis was performed to adjust
the confounding effects of age and gender in estimations
of the contribution of MASP2 variant and MASP-2 serum
levels to schistosomiasis susceptibility. Kruskal–Wallis or
Wilcoxon–Mann–Whitney rank sum tests were applied to
analyse associations of serum MASP-2 levels with
MASP2 variants, haplotypes and phenotypes using the
KaleidaGraph software (www.synergy.com). Genotype
and haplotype frequencies were calculated by simple gene
counting and by expectation-maximum (EM) algorithm.
Possible deviations from Hardy–Weinberg equilibrium
were tested using the random permutation procedure as
implemented in the Arlequin v.3.5.1.2 software (http://
lgb.unige.ch/arlequin). Linkage disequilibrium (LD)
analyses were performed using Haploview v.3.2 (http://
broadinstitute.org/haploview). The correlation between
serum MBL and ficolin-2 levels with serum MASP-2 lev-
els was analysed by nonparametric Spearman’s rank coef-
ficient using the SPSS statistical package. The MBL and
ficolin-2 data have been described previously [31, 32].
Ethics statement
Informed consent was obtained from all participants; for
children, consent was obtained from their parents and/or
guardians. Ethical approval was sought for and obtained
from the Ethical Committee of the Ministry of Health,
Abeokuta Ogun State, Nigeria.
Results
MASP2 gene polymorphisms and urogenital
schistosomiasis
Both genotype and allele frequencies for all analysed
functional MASP2 variants in each subgroup were in
Hardy–Weinberg equilibrium, except for the variant
rs2273346 (p.V377A) in SEP cases, which was excluded
from further analyses. LD patterns of the nine MASP2
variants studied in the case (SEP) group, the previously
exposed (SELP) group, the non-exposed (SELN group)
and the combined controls (SELP and SELN) are shown
in Figure 1. The distribution of MASP2 alleles and geno-
types in the entire study group is given in Table 1. No
© 2015 John Wiley & Sons Ltd 1313
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significant contribution of alleles or genotypes was
observed. Although a marginal contribution of the
rs56392418 (p.P126L) variant was seen (SEP cases vs.
SELP+SELN controls OR 6.9; 95% CI 0.8–321.5;
P = 0.04), the observation was not significant after test-
ing for multiple comparisons. The exon 3 variant
rs72550870 (p.D120G) was monomorphic in the popula-
tion under study.
MASP2 haplotypes and urogenital schistosomiasis
A total of twelve haplotypes were observed at frequencies
>2% in our study population (data not shown). The fre-
quencies of the secretor haplotypes observed did not dif-
fer between subgroups (SEP cases vs. SELP, SELN
controls; SEP cases vs. SELP+SELN controls).
MASP-2 serum levels and urogenital schistosomiasis
MASP-2 serum levels varied from 1.8 to 1073 ng/ml with
a median of 106.9 ng/ml. The serum levels were equally
distributed among our study subgroups (P > 0.05). The
multivariate analysis, however, revealed a significant con-
tribution of age to MASP-2 serum levels (P = 0.0001).
We therefore grouped our study participants according to
age and to the rationale that younger children might be
rather at risk, as they have frequent contacts with water
infested by the infectious form of schistosoma the cerca-
riae. Younger children below the puberty age are more
susceptible to schistosomiasis than older children and
adults [35]. Based on an average puberty age of 12 years
in the population studied [36], the subjects were sepa-
rated into the groups of ≤12 years and >12 years of age.
We observed that MASP-2 serum levels were significantly
lower in children ≤12 years with a patent infection (SEP)
than in those with previous infections (SELP)
(P = 0.0074; Figure 2a). MASP-2 serum levels were sig-
nificantly higher in infected (SEP) older children and
adults (>12 years) than in those who were exposed previ-
ously (SELP) (P = 0.032; Figure 2b). We also correlated
the MBL and ficolin-2 serum levels described previously
for the same study group [31, 32] with the circulating
MASP-2 serum levels assessed here. Only MBL serum
levels were positively correlated with MASP-2 serum lev-
els (r = 0.39, P = 0.01; Figure 3a).
MASP2 gene polymorphism and MASP-2 serum levels
MASP-2 serum levels did not differ with regard to high,
intermediate or low secretor haplotypes, neither in active
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(c) (d) Figure 1 (a) Linkage disequilibriumpatterns of studied SNPs in cases who
tested positive for Schistosoma eggs, the
SEP group; (b) individuals who tested
positive for Schistosoma antigens by
ELISA, the SELP group (control group 1);
(c) individuals who tested negative for
Schistosoma antigens by ELISA and
negative for Schistosoma eggs, the SELN
group (control group 2); and (d) the SELP
and SELN groups combined. Empty
squares indicate a high degree of linkage
disequilibrium (D’ = 1). Numbers indicate
the D0 value expressed as a percentile.
The dense shading indicates the r2 value.
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Table 1 Distribution of MASP2 genotypes and allele(s) among cases and controls
SNP
position Genotype
SEP
n = 163
(%)
SELP
n = 118
(%)
SELN
n = 65
(%)
SELP+SELN
n = 183 (%)
SEP vs. SELP
SEP vs.
(SELP+SELN)
OR
(95% CI)
P-
value (95% CI)
P-
value
Prom (C>A) rs7548659 CC 126 (77.3) 92 (78) 52 (80) 144 (78.7)
CA 36 (22.1) 23 (19.5) 13 (20) 36 (19.7) NS NS
AA 1 (0.6) 3 (2.5) 0 3 (1.6)
C 288 (88.3) 207 (87.7) 117 (90) 324 (88.5)
A 38 (11.7) 29 (12.3) 13 (10) 42 (11.5)
Exon3(G>A) rs61735600
(R99Q)
GG 133 (81.6) 101 (85.6) 51 (78.5) 152 (83.1)
GA 30 (18.4) 17 (14.4) 14 (21.5) 31 (16.9) NS NS
AA 0 0 0 0
G 296 (90.8) 219 (92.8) 116 (89.2) 335 (91.5)
A 30 (9.2) 17 (7.2) 14 (10.8) 31 (8.5)
Exon3(A>G) rs72550870
(D120G)
AA 163 (100) 118 (100) 65 (100) 183 (100)
AG 0 0 0 0 NS NS
GG 0 0 0 0
A 326 (100) 236 (100) 130 (100) 366 (100)
G 0 0 0 0
Exon 3(C>T) rs56392418
(P126L)
CC 106 (65) 76 (64.4) 48 (73.8) 124 (67.8) NS NS
CT 51 (31.3) 42 (35.6) 16 (24.6) 58 (31.7) NS NS
TT 6 (3.7) 0 1 (1.5) 1 (0.5) NS NS NS
C 263 (80.7) 194 (82.2) 112 (86.2) 306 (83.6)
T 63 (19.3) 42 (17.8) 18 (13.8) 60 (16.4)
Intron9(C>T) rs1961795 CC 106 (65) 78 (66.1) 38 (58.5) 116 (63.4)
CT 51 (31.3) 38 (32.2) 23 (35.4) 61 (33.3) NS NS
TT 6 (3.7) 2 (1.7) 4 (6.2) 6 (3.3)
C 263 (80.7) 194 (82.2) 99 (76.2) 293 (80.1)
T 63 (19.3) 42 (17.8) 31 (23.8) 73 (19.9)
Exon 10(G>T) rs12711521
(D371Y)
GG 126 (77.3) 94 (79.7) 50 (76.9) 144 (78.7)
GT 36 (22.1) 19 (16.1) 14 (21.5) 33 (18) NS NS
TT 1 (0.6) 5 (4.2) 1 (1.5) 6 (3.3)
G 288 (88.3) 207 (87.7) 114 (87.7) 321 (87.7)
T 38 (11.7) 29 (12.3) 16 (12.3) 45 (13.1)
Exon 10(T>C) rs2273346
(V377A)
TT 127 (77.9) 87 (73.7) 49 (75.4) 136 (74.3)
TC 30 (18.4) 30 (25.4) 16 (24.6) 46 (25.1) NA NA
CC 6 (3.7) 1 (0.8) 0 1 (0.5)
T 284 (87.1) 204 (86.4) 114 (87.7) 318 (86.9)
C 42 (12.9) 32 (13.6) 16 (12.3) 48 (13.1)
Exon 11(G/A) rs12085877
(R439H)
GG 122 (74.8) 99 (83.9) 50 (76.9) 149 (81.4)
GA 41 (25.2) 19 (16.1) 15 (23.1) 34 (18.6) NS NS
AA 0 0 0 0
G 285 (87.4) 217 (91.9) 115 (88.5) 332 (90.7)
A 41 (12.6) 19 (8.1) 15 (11.5) 34 (9.3)
Exon 11(C/T) rs1782455 CC 107 (65.6) 74 (62.7) 41 (63.1) 115 (62.8)
CT 54 (33.1) 39 (33.1) 22 (33.8) 61 (33.3) NS NS
TT 2 (1.2) 5 (4.2) 2 (3.1) 7 (3.8)
C 268 (82.2) 187 (79.2) 104 (80) 291 (79.5)
T 58 (17.8) 49 (20.8) 26 (20) 75 (20.5)
NS, non-significant; NA, not applicable. Percentages may not sum to 100%, because of rounding errors. Study groups were as follows:
the SEP group (cases) was composed of individuals who tested positive for Schistosoma eggs, the SELP group (controls) was composed
of individuals who tested positive for Schistosoma antigens by enzyme-linked immunosorbent assay (ELISA), and the SELN group (con-
trols) was composed of individuals who tested negative for Schistosoma antigens by ELISA and negative for Schistosoma eggs. CI, con-
fidence interval; NS, not significant; OR, odds ratio.
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(SEP) cases nor in exposed (SELP) controls. However, in
SELN controls, a significant difference in MASP-2 levels
was observed in accordance with secretor haplotypes as
MASP-2 serum levels differed with regard to the individ-
uals with high, intermediate or low secretor haplotypes
(high [MASP2*1A, *1B1-h, *1B2-h] vs. low
[MASP2*1C1-l,*1C2-l,*2A1,*2A2-l and *2A23-l]
MASP2 secretor haplotypes P = 0.0001; intermediate
[MASP2*2B1-i, *2B2A-i] vs. low MASP2 secretor haplo-
types; P = 0.023; Figure 3b). In SEP cases, the heterozy-
gous genotype p.P126L (rs56392418CT) was observed to
be associated with reduced circulating MASP-2 serum
levels compared to the reference genotype (P = 0.01; Fig-
ure 4). MASP-2 serum levels were analysed for a possible
association with the MBL2 variants described previously
[31]. Neither the MBL2 alleles nor the MBL2* secretor
haplotypes or genotypes revealed any significant contribu-
tion to MASP-2 serum levels.
Discussion
This study investigated the role of functional MASP2
gene polymorphisms and MASP-2 serum levels in schisto-
somiasis. The lectin complement pathway acts in the first
line of defence that, to a certain degree, can recognise
and eliminate many pathogens encountered. Our recent
studies have demonstrated that the lectin complement
components, namely ficolin-2 [32] and MBL [31], con-
tribute to S. haematobium susceptibility.
Despite antigen recognition in the first line of defence,
a multitude of factors such as host genetics, worm burden
and coinfections with other pathogens contribute to
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Figure 2 Serum MASP-2 levels (a): in children <12 years of age and (b): in adolescents and adults >12 years of age. Study groups were
as follows: the SEP group (cases) was composed of individuals who tested positive for Schistosoma eggs, the SELP group (controls) was
composed of individuals who tested positive for Schistosoma antigens by enzyme-linked immunosorbent assay (ELISA), and the SELN
group (controls) was composed of individuals who tested negative for Schistosoma antigens by ELISA and negative for Schistosoma
eggs.
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Figure 3 (a). Correlation of serum MBL
levels with serum MASP-2 levels. A
positive correlation was observed, and
P-values are given. (b). Distribution of
secretor haplotypes in the SELN group
(controls). The SELN controls were
composed of individuals who tested
negative for Schistosoma antigens by
ELISA and negative for Schistosoma eggs.
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S. haematobium survival in human hosts [37, 38]. To
establish an active infection, schistosomes need to effi-
ciently evade complement-mediated responses. Schisto-
somes bind complement proteins on their surfaces to
avoid lysis or opsonisation [39, 40]. In vitro studies have
also confirmed that the complement proteins C1, C4 and
C2 are utilised at a larger extent in the presence of
S. mansoni schistosomula [41], signifying that the high
utilisation or strong inhibition of complement proteins is
essential for their survival [12]. We hypothesised that the
MASP-2 complement protein is equally consumed by
S. haematobium as is MBL and ficolin-2, providing the
opportunity to schistosomes to evade host immune
responses. In contrast to our earlier observations of
genetic variants in the genes encoding ficolin-2 and MBL,
no significant contribution was observed for the func-
tional MASP2 variants studied. A trend of significance
towards an increased risk of schistosomiasis was observed
for the homozygous genotype rs56392418TT (exon 3,
p.P126L). An earlier study has shown that MASP2 in
individuals with the homozygous genotype of
rs56392418TT in exon 3 (p.126L) was non-functional
and unable to cleave C4 and C2 components [25]. Of
interest is that, in infected individuals, we observed a sig-
nificant contribution of the heterozygous genotype
p.P126L (rs56392418CT) to lower MASP-2 serum levels
compared to levels in individuals carrying the reference
allele (p.P126, rs56392418C). This suggests that the vari-
ant p.P126L accounts for the impaired complement activ-
ity and lower MASP-2 serum levels.
As shown previously [23, 25], serum MASP-2 levels
were associated with distinct MASP2 genotypes and hapl-
otypes. Our results revealed no significant associations
either with genotypes or with haplotypes in the case and
the first control subgroup (SELP). Nevertheless, we
observed genotype-/haplotype-specific secretor patterns of
serum MASP-2 levels in the second control subgroup
(SELN), in line with previous findings on the contribution
of MASP-2 serum levels associated with distinct secretor
haplotypes [23]. No differing distributions were observed
of MASP-2 serum levels among the subgroups. Age, how-
ever, was a confounding factor. We therefore grouped
the study participants based on the common puberty age
in the studied population [36]. Differential distributions
of MASP-2 serum levels were observed when comparing
younger and older children and adults. Younger children
(≤12 years) had, during active infection, lower serum
MASP-2 levels compared to SELP controls of the same
age group, whereas older children and adults (>12 years)
with active infections had higher serum MASP-2 levels
than individuals of the control group. These results indi-
cate an age-related pattern in the distribution of MASP-2
levels in individuals exposed to and infected with S. hae-
matobium and suggest that serum MASP-2 levels may be
modified during ongoing infections in an age-dependent
manner. Similar age-related patterns in urogenital schisto-
somiasis have also been identified in studies on other
immune components such as myeloid dendritic cells
(mDCs) and distinct cytokines, including IL-5 [42–44].
Moreover, the experimental infection of Schistosoma
mansoni in mice either before or after puberty showed
that prepuberty infected mice had a higher number of
adult worms, more severe granulomas, higher mortality
rates and higher proliferative responses than in post-pub-
erty infected mice [45]. Together, these observations indi-
cate age-related patterns and effects of pubertal
development with infection status as observed in our
results. In schistosomiasis-endemic areas, a clear associa-
tion between age and intensity of infection has been well
documented. Younger children below the puberty age are
generally more heavily infected than older children and
adults and are more susceptible to reinfection
[35, 45, 46]. In the present study, we observed that
MASP-2 might also contribute to the differential immune
response in younger children and adults during urogenital
schistosomiasis. Based on our observations, we agree
with the hypothesis of ‘Puberty and Resistance to Schisto-
somiasis’ proposed by Fulford et al., as it suggests that
host age needs to be considered to achieve elimination of
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Figure 4 Association of the p.P126L (rs56392418C/T) MASP2
variant with circulating MASP-2 serum levels in individuals who
tested positive for Schistosoma eggs (SEP).
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schistosomiasis [46]. However, this hypothesis has not
received much attention as no specific mechanisms have
been proposed.
There are several limitations in our study: A larger
sample size would corroborate the understanding of the
contribution of the P126L variant in the studied popula-
tion. So far, we cannot explain the exact mechanism
lying behind our key finding, that is age-related pattern
of MASP-2 levels in patent infections. It appears, how-
ever, that complement utilisation and low MASP-2 levels
are indispensable for S. haematobium in establishing a
chronic and/or recurrent infection in children. In conclu-
sion, our findings show that high MASP-2 serum levels
are associated with relative protection from urogenital
schistosomiasis in Nigerian children.
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Visceral Leishmaniasis (VL), caused by Leishmania donovani is endemic in the Indian sub-continent. Mannose-
binding Lectin (MBL) is a complement lectin protein that binds to the surface of Leishmania promastigotes and
results in activation of the complement lectin cascade. We utilized samples of 218 VL patients and 215 healthy
controls from an Indian population.MBL2 functional variants were genotyped and the circulating MBL serum
levels were measured. MBL serum levels were elevated in patients compared to the healthy controls (adjusted
P=0.007). TheMBL2 promoter variants−78C/T and+4P/Q were signiﬁcantly associated with relative protec-
tion to VL (−78C/T, OR= 0.7, 95% CI= 0.5–0.96, adjusted P=0.026 and+4P/Q, OR= 0.66, 95% CI= 0.48–0.9,
adjusted P=0.012).MBL2*LYQA haplotypes occurred frequently among controls (OR=0.69, 95% CI= 0.5–0.97,
adjusted P=0.034).MBL recognizes Leishmania and plays a relative role in establishing L. donovani infection and
subsequent disease progression. In conclusion,MBL2 functional variants were associated with VL.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Leishmaniasis is a neglected tropical disease, caused by parasites of
the genus Leishmania that inhabits hostmacrophages. Leishmania infec-
tion is transmitted by an infective bite of a female phlebotomine sand
ﬂy. Leishmaniasis is endemic in tropical regions including the Indian
sub-continent, Africa and in South America and accounts for approxi-
mately 1.3 million new cases every year [1]. Four distinct clinical
features of Leishmaniasis include, Cutaneous Leishmaniasis (CL),
Muco-cutaneous Leishmaniasis (MCL), Visceral Leishmaniasis (VL or
Kala-azar) and Post-Kala-azar Dermal Leishmaniasis (PKDL) [2]. Viscer-
al Leishmaniasis (VL) is the severest form, caused by an intracellular
pathogen Leishmania donovani and is fatal if left untreated [3]. VL still re-
mains a global health burdenwith400,000new cases and 40,000deaths
reported annually [4,5]. VL accounts for more than 2 million disability-
adjusted life years (DALYs) lost [6] and approx. 90% of these cases
occur in Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil [2]. VL is
considered as a major health problem in the Indian sub-continent
with an estimated 150 million people living at risk and patients from
this region share 67% of the global disease burden [7]. In India, VL is en-
demic in Central-East India (Bihar, West Bengal and Eastern part of
Uttar Pradesh) and accounts for more than 90% of all Indian VL [8].
Leishmania is a Trypanosomatid protozoan parasite, with two
different developmental stages namely the promastigotes and
amastigotes [9]. In both developmental stages, the parasites are
enveloped with mannose-containing lipophosphoglycan (LPG) and
mannose glycoinositol-phospholipids [10]. These glycoconjugates act
as pathogen associated molecular patterns (PAMPs) and are recognized
by the lectin complement components such as the Mannose-binding
Lectin (MBL). Earlier studies have shown that, Leishmania major, Leish-
mania mexicana, Leishmania chagasi and Leishmania braziliensis were
recognized by the carbohydrate recognition domain (CRD) of the MBL
protein [10–12]. MBL binds to the surface of the promastigotes and ac-
tivates complement lectin cascade, thereby promastigotes are phagocy-
tosed by the macrophages.
MBL is a circulating serum protein and a pathogen recognition re-
ceptor (PRR) which binds to PAMPs, leading to the activation of the lec-
tin complement cascade [13]. The humanMBL encoded byMBL2 gene is
located on chromosomes 10q11.2–q21. MBL has higher afﬁnity to mi-
crobial polysaccharides and/or their glycoconjugates, which are rich in
mannose and fucose sugars. MBLwas shown earlier to bind cell surfaces
of bacteria, fungi, protozoa and viruses and acts as an acute-phase plas-
ma protein (APP) during infection and inﬂammation [14,15]. When in-
fection progresses, MBL serum levels increase to 1.5–3.0 folds [16] and
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act as a pro-inﬂammatory marker [17]. The carbohydrate recognition
domain (CRD) of the MBL recognizes the parasite epitopes [18].
Functional MBL2 variants in the promoter region and in exon 1
were shown to modulate the expression and oligomerization of
the protein, respectively [19]. Three MBL2 promoter variants at
positions −550(H/L), −221(X/Y) and +4(P/Q) modulate the MBL
transcriptional activity [20,21]. In addition, three non-synonymous sub-
stitutions in exon 1 at codons 52 (MBL2*D), 54 (MBL2*B) and 57
(MBL2*C) disrupt the oligomerization of the MBL protein to the patho-
gen, and thus impede activation of the lectin complement cascade.
Seven common secretor MBL2 haplotypes were reported. The haplo-
typesMBL2*HYPA, LYPA and LYQA are associated with high expression
ofMBL,while thehaplotypesMBL2*LYQC, LXPA,HYPD and LYPB are asso-
ciated with low expression of MBL [18]. Lectin complement proteins
have been associated with many infectious diseases including intra-
and extracellular infections [22–25]. Our earlier study has shown that,
another analogous lectin complement protein ﬁcolin-2 was associated
with occurrence of VL [26].
Earlier studies on Brazilian patients have shown that MBL plays a
signiﬁcant role in VL caused by L. chagasi [11,27]. In this study, we aim
to investigate the possible association of circulating MBL levels and
MBL2 functional variants duringVL caused by the intracellular pathogen
L. donovani.
2. Material and methods
2.1. Ethical approval
Informed written consent was provided either by the participating
individual or from the parents, if patient was less than 18 years of age.
The study was approved by the Institutional Ethical Committee (IEC)
of Center for Cellular and Molecular Biology (CSIR), Hyderabad, India
and prior permission was obtained from the district government
hospitals.
2.2. Study design and sample collection
This cross-sectional, case–control study was conducted in an endemic
region with high incidence of VL. All patients and controls were recruited
through multiple ﬁeld visits from villages located within a radius of
approx. 120 km from the city of Muzaffarpur in the Bihar state. Previous
epidemiological studies have indicated that, Bihar state is a hot spot for
VL with an average annual incidence of 2.49/1000 individuals [28,29].
The sample size was calculated prior to recruitment using the Open Epi
platform (http://www.openepi.com/) based on the incidence rate and
the risk of VL in the study area. A total of 443 unrelated subjects (218
cases and 225 healthy controls) were recruited. The mean age of VL pa-
tients and healthy controls was 28.7± 16.7 and 35.3± 16.2, respectively
(P= 0.001). No signiﬁcant difference in male/female ratio was observed
between cases (125:95) and controls (122:93). The cases were deter-
mined based on the clinical features of VL in medical records issued by
government hospitals in the study region. Typical clinical features of the
patients included fever with rigors and chills and splenomegaly. Patients
and controls were tested with the rk39 leishmanin antigen by nitrocellu-
lose dipstick tests (InBios International, Seattle, USA). The control subjects
were free of any relevant infectious disease. Pregnant women, patients
with other infections, healthy controls with a family history of VL and rel-
atives of cases were excluded from the study. Approximately 5 ml of ve-
nous blood was collected from each study participant who presented at
the time of diagnosis at a referral center The samples were immediately
transported to the lab and were stored at−20 °C until use.
2.3. MBL serum level measurement
MBL serum levels were measured in VL patients (n = 101) and
healthy controls (n = 60) using a human MBL ELISA kit following the
manufacturer's instructions (Hycult Biotech, Uden, The Netherlands).
The detection limit of the assay was 0.4 ng/ml.
2.4. MBL2 genotyping
Genomic DNAwas extracted from peripheral blood leucocytes using
a QIAamp DNA mini blood kit (Qiagen, Hilden, Germany). MBL2 pro-
moter polymorphisms at −550G/C, −6 bp deletion −338 to −332,
−221G/C and 5′UTR +4C/T and exon 1 polymorphisms at codons
52C/T, 54G/A and 57G/A were ampliﬁed by polymerase chain reaction
using primer pairs spanning the promoter region to exon 1. The primers
employed were: PromF: 5′-GCCAGAAAGTAGAGAGGTATTTAGCAC-3′,
internal primer Exon1F: 5′-CAGGTGTCTAGGCACAGATGAACC-3′ and
Exon1R: 5′-CCAACACGTACCTGGTTCCC-3′. In brief: 20 ng of genomic
DNA was ampliﬁed in a 10 μl volume of reaction mixture containing
1× PCR buffer (20 mM Tris–HCl pH 8.4, 50 mM KCl, 1.5 mM of
MgCl2), 0.125 mM of dNTPs, 0.25 mM of each primer and 1 U Taq
DNA polymerase (TaKaRa, Shiga, Japan). Thermal cycling parameters
for ampliﬁcation of both exon 1 and promoter regions were: initial de-
naturation at 94 °C for 5 min, followed by 35 cycles of 30 s at 94 °C de-
naturation, 30 s at 68 °C annealing temperature, 1 min 30 s at 72 °C
extension, followed by a ﬁnal extension of 2 min at 72 °C. The ampliﬁed
PCR fragmentswere run on a 1.5% agarose gel andwere visualized using
a UV transilluminator. PCR products were cleaned up using Exo-SAP-IT
(USB-Affymetrix, Santa Clara, USA) and 1 μl of the puriﬁed product was
directly used as templates for sequencing using a BigDye® Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA)
in an automated sequencer (ABI Prism 3730XL Genetic Analyzer, Ap-
plied Biosystems). The resulting DNA sequences were aligned using
AutoAssembler software (Applied Biosystems, Foster City, CA, USA)
and were reconﬁrmed visually from their electropherograms.
2.5. Statistical analysis
Data were analyzed using the STATA software (Intercooled STATA,
STATA Corp., College Station, TX, USA) and the level of signiﬁcance
was set to a P value of b0.05 in all comparisons. Allele, genotype and
haplotype frequencies were calculated by simple gene counting and
by expectation–maximum (EM) algorithm and the deviations from
the Hardy–Weinberg equilibrium were tested using the random-
permutation procedure as implemented in the Arlequin v.3.5.1.2 soft-
ware (http://lgb.unige.ch/arlequin). The linkage disequilibrium (LD)
analysis was performed using Haploview v.3.2 (http://broadinstitute.
org/haploview). Binary logistic regression was performed to adjust for
the confounding effects such as the age, ethnicity and gender. Multivar-
iate analysis was performed to analyze the differences in serum MBL
levels between cases and controls adjusted for age, ethnicity and gen-
der. Kruskal–Wallis or Wilcoxon Mann–Whitney rank sum tests were
applied to analyze the association of serum MBL levels withMBL2 vari-
ants and haplotypes by using the SPSS v.19 software (IBM Corp. USA).
3. Results
3.1. MBL serum levels and Visceral Leishmaniasis
TheMBL serum levels in the studied healthy individuals varied from
0.49 to 911 ng/ml with a median of 78.6 ng/ml while the MBL serum
levels in theVL cases varied from0.47 to 833.3 ng/mlwithmedian levels
of 155.1 ng/ml.We observed increasedMBL serum levels in the VL cases
compared to those in the healthy controls (adjusted P=0.007) (Fig. 1).
3.2. MBL2 variants and Visceral Leishmaniasis
The genotype frequencies for all the analyzedMBL2 functional SNPs
in each respective group were in the Hardy–Weinberg equilibrium ex-
cept for variant rs10556764 (−338 to −332 6 bp deletion) in VL
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cases therefore this variant was excluded from further association anal-
ysis. Linkage disequilibriumpattern of studiedMBL2 variants in VL cases
and controls are shown in Fig. 2. The Linkage Disequilibrium (LD) pat-
tern revealed that the promoter variants −78C/T and +4P/Q are in
strong LD both in VL cases and controls. TheMBL2 minor allele−78T
in the promoter region was observed to be signiﬁcantly higher in
healthy controls compared to that in the VL cases after adjusting for
age, sex and ethnicity (OR = 0.7, 95% CI = 0.5–0.96, adjusted P =
0.026). The frequency of minor allele +4Q at the transcription start
site was observed to be signiﬁcantly higher in healthy controls than
that of patients after adjusting for age, sex and ethnicity (OR = 0.66,
95% CI = 0.48–0.9, adjusted P = 0.012). These results suggest that
MBL2 variants −78C/T and +4P/Q were signiﬁcantly associated
with relative protection against VL (Table 1). A similar effect was also
observed with the dominant genetic model. In addition, other investi-
gated MBL2 functional variants in the promoter region [(−550H/L),
(−221X/Y)] and exon 1 region [codons 52 (MBL2*D), 54 (MBL2*B)
and 57 (MBL2*C)] were not signiﬁcantly associated with VL (data not
shown).
3.3. MBL2 haplotype and Visceral Leishmaniasis
The distribution of reconstructedMBL2 haplotypes is summarized in
Table 2. In total, sixteen secretor haplotypes were observed in this
study. Five main haplotypes MBL2*LYPA, MBL2*HYPA, MBL2*LXPA,
MBL2*LYQA andMBL2*LYPB were found at higher frequencies (N10%).
However, only theMBL2*LYQA haplotype was observed more frequent-
ly in healthy controls than that in VL patients after adjusting for age, sex
and ethnicity (OR = 0.69, 95% CI = 0.5–0.97, adjusted P= 0.034). The
other haplotypes remained insigniﬁcant when compared between VL
cases and control group (Table 2). The contribution of either high secre-
tor (LYPA+LYQA+HYPA) or low secretor (LYQC+LXPA+HYPD+LYPB)
haplotypes revealed no signiﬁcance (Table 2). In addition, investigation
ofMBL2 diplotypes (YA/YA, YA/YO, XA/YA, XA/YO, YO/YO and XA/XA) also
revealed no signiﬁcant association with VL (data not shown).
3.4. Association of MBL2 variants with MBL serum levels
The association of−78C/T and+4P/Q variants with circulatingMBL
serum levels was analyzed. MBL serum levels were segregated accord-
ing to different genotypes of−78C/T and +4P/Q variants in VL cases
and healthy controls. The results indicated that the minor alleles−78T
and +4Q contribute to increased MBL serum levels, whereas the
major alleles−78C and +4P contribute to decreased MBL serum levels
in healthy controls (P = 0.024 and 0.033, respectively) (Fig. 3). Also a
gene dose dependent effect on the distribution of serum MBL levels
was observed. However, the −78C/T and +4P/Q variants did not
show any signiﬁcant contribution to MBL serum levels in VL patients.
4. Discussion
The clinical progression of VL is modulated by multitude of factors
such as host genetics, immunological factors and pathogenesis of Leish-
mania spp. [30]. Geographical heterogeneity and host genetic variations
in HLA-DRB1, HLA-DQA1, HLA class II region, SLC11A1 and DLL1 were
shown to modulate VL susceptibility in Indian patients [31–33].
Human and animal models have shown that host genetic factors play
Fig. 1. Distribution of MBL serum levels in Visceral Leishmaniasis patients and healthy
controls. P values were calculated by using multivariate analysis adjusted for age, sex
and ethnicity.
Fig. 2. Linkage disequilibrium pattern of studied SNPs. (A): Linkage disequilibrium pattern of studiedMBL2 variants in Visceral Leishmaniasis patients and (B): Linkage disequilibrium pat-
tern of studiedMBL2 variants in healthy controls. Numbers indicate theD′ value expressed as percentile. Open squares indicate the high degree of LD (D′=1). The dense shading indicates
the r2 value.
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a vital part in determining the severity of VL and subsequent progres-
sion [34]. The MBL is one such protein that can recognize the invaded
metacyclic promastigotes and VL outcome [35]. In this study, we inves-
tigated theMBL2 functional polymorphisms and respective MBL serum
levels with VL susceptibility in an Indian population and MBL serum
levels andMBL2 variants (−78C/T and+4P/Q)were signiﬁcantly asso-
ciated with VL.
The MBL serum levels were observed to be high in the VL patients
than those in the controls. These results support previous ﬁndings
showing high MBL levels during L. donovani infection [11,27]. The ele-
vated MBL levels may be due to the acute-phase reactions during dis-
tinct infections [16]. Moreover, the MBL serum levels observed in this
study were in accordance with another study on pulmonary tuberculo-
sis, which conﬁrmed higher MBL levels during intracellular infections
[36]. Congenital MBL deﬁciency per se increases the susceptibility to
many infections [37]. In addition, a recent study has shown that, com-
plement receptor type 1, expressed on macrophages binds to MBL and
enhances the phagocytosis of intra-cellular pathogens [38]. Therefore,
highMBL levelsmay aid in establishing intra-cellular infections. Howev-
er, decreasedMBL proteinswill result in fewer parasites being phagocy-
tosed bymacrophages, their preferred environment and thus result in a
balanced immune response [36].
In our investigations, we observed a promoter polymorphism
−78C/T as a possible locus associatedwith VL occurrence. Theminor al-
lele−78T was signiﬁcantly associated with decreased susceptibility to
VL. The contribution of this studiedMBL2−78C/T with other diseases
is limited. This particular MBL2 −78C/T variant has been reported in
Han Chinese and Gabonese populations [39,40]. In the HapMap data-
base, the investigated variant −78C/T was widely distributed across
all ethnicities and was observed to be in high LD with another variant
+4P/Q in the 5′UTR region of exon 1 especially in the Han Chinese pop-
ulation. However, no signiﬁcant associations with leprosy were report-
ed in the Han Chinese population [39]. Also in this study, the
investigated variants +4P/Q and −78C/T were in strong LD. The re-
cruited individuals are from the Bihar state, a geographical location en-
demic for VL with different ethnicities. The inﬂuence of confounding
factors such as age, ethnicity and gender was considered in the analyses
in order to identify independent effects ofMBL2 variants onVL outcome.
The minor allele +4Q was earlier reported to be associated with
high MBL expression in different geographically isolated populations
[41,42]. An earlier study has reported that, the heterozygous genotypes
(+4PQ), is a risk factor for schistosomiasis in anAfrican population [43].
In our investigations, no signiﬁcant associations were observed for the
promoter variant −221X/Y. However, the heterozygous genotype −
221XY conferred a protective role against VL in a studied Morocco pop-
ulation [44]. This particular study onMoroccan VL patients has analyzed
−221X/Y genotypes fromanasymptomatic group, and the analyzed ge-
notypes were not in the Hardy–Weinberg equilibrium therefore these
results are void. The studied exon 1 variants at codons 52, 54 and 57
were not associated with the VL. MBL2 haplotype analysis revealed
that theMBL2*LYQA haplotype was signiﬁcantly higher in healthy con-
trols compared to that in the VL patients indicating that individuals
with this haplotype have reduced risk for VL. TheMBL2*LYQA haplotype
is associatedwith higherMBL expression and reduced risk in severema-
laria patients [24]. TheMBL2*LYPA haplotypewas a risk factor in a study
on Brazilian patients with leprosy caused by another intracellular
pathogen [45]. These results indicate that the role of MBL2 variants
in different intracellular infections likely depends on different
geographical settings. The MBL2 genotypes and haplotypes were as-
sociated with MBL protein expression in different world populations
[14,43,46].
In the current study, theMBL2+4P/Q genotypes were also associat-
ed with serumMBL levels in healthy individuals, but not in VL patients.
The infection phenotype may possibly contribute to higher MBL levels
in VL patients. The Leishmania spp. promastigotes have a signiﬁcant
role both in classical [47,48] and alternative pathways [49], as lysis of
promastigotes is mediated via an antibody-independent mechanism
[47–49]. Yet another study has shown that the binding of MBL to the
Leishmania surface activates the alternative pathway [12]. In addition,
MBL-opsonized L. chagasi promastigotes can induce TNF-α and IL6 pro-
duction by monocytes. These observations support the mechanism that
MBL modulates inﬂammatory cytokine production, such as TNF-α and
IL6 [11].
Table 1
Distribution ofMBL2 genotypes and alleles in Visceral Leishmaniasis patients and healthy
controls.
SNP position Cases Controls Cases vs. controls
n = 218 (%) n = 215 (%) OR (95% CI) P valuea
rs11003123 (−78C/T)
CC 131 (60.1) 108 (50.2)
CT 73 (33.5) 85 (39.6)
TT 14 (6.4) 22 (10.2)
Allele
C 335 (76.8) 301 (70) 1 Reference
T 101 (23.2) 129 (30) 0.7 (0.5–0.96) 0.026
Dominant
CC 131 (60.1) 108 (50.2) 1 Reference
CT+TT 78 (39.9) 107 (49.8) 0.66 (0.45–0.99) 0.044
Recessive
CC+CT 104 (93.6) 193 (89.8) 1 Reference
TT 14 (6.4) 22 (10.2) NA NS
rs7095891 (+4C/T)
CC (PP) 134 (61.5) 110 (51.2)
CT (PQ) 72 (33.0) 83 (38.6)
TT (QQ) 12 (5.5) 22 (10.2)
Allele
C (P) 340 (78) 303 (70.5) 1 Reference
T (Q) 96 (22) 127 (29.5) 0.66 (0.48–0.9) 0.012
Dominant
CC (PP) 134 (61.5) 110 (51.2) 1 Reference
CT(PQ)+TT(QQ) 84 (38.5) 105 (48.8) 0.65 (0.44–0.97) 0.037
Recessive
CC(PP)+CT(PQ) 206 (94.5) 193 (89.8) 1 Reference
TT (QQ) 12 (5.5) 22 (10.2) NA NS
Genotype frequencies ofMBL2 SNPs were tested for the Hardy–Weinberg equilibrium in
each group using Arlequin. No signiﬁcant SNP-speciﬁc deviation was observed (P N 0.05).
NS: Not signiﬁcant; NA: not applicable.
a P values were calculated by logistic regression adjusted for age, gender and ethnicity.
Table 2
Distribution ofMBL2 haplotypes in Visceral Leishmaniasis patients and healthy controls.
MBL2 haplotype Cases Controls Cases vs. controls
n = 436
(%)
n = 430
(%)
OR (95% CI) P valuea
LYPA 101 (23.2) 78 (18.1) NS
HYPA 87 (20) 79 (18.4) NS
LXPA 81 (18.6) 82 (19.1) NS
LYQA 77 (17.7) 99 (23) 0.69 (0.5–0.97) 0.034
LYPB 57 (13.1) 51 (11.9) NS
LYQC 14 (3.2) 17 (4) NS
HYPD 7 (1.6) 7 (1.6) NS
HYQA 4 (0.9) 6 (1.4) NS
LYPD 3 (0.7) 3 (0.7) NS
HYPB 1 (0.2) 1 (0.2) NS
LYPC 3 (0.7) 0 NA
HXQA 1 (0.2) 0 NA
LYQB 0 3 (0.7) NA
HXPA 0 2 (0.5) NA
LXQA 0 1 (0.2) NA
HYQC 0 1 (0.2) NA
High expression of MBL
LYPA+LYQA+HYPA 265 (60.8) 256 (59.5) Reference
Low expression of MBL
LYQC+LXPA+HYPD+LYPB 159 (36.5) 157 (36.5) NS
NS: not signiﬁcant; NA: not applicable.
a P values were calculated by logistic regression adjusted for age, gender and ethnicity.
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In conclusion, MBL2 promoter variants are signiﬁcantly associated
with VL caused by L. donovani. MBL serum levelswere elevated in VL pa-
tients and increased MBL levels aid in establishing intra-cellular infec-
tions and thus modulated the VL outcome.
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